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ABSTRACT OF DISSERTATION

INVESTIGATING THE PHYSICAL STABILITY OF AMORPHOUS
PHARMACEUTICAL FORMULATIONS
Amorphous formulations, including amorphous solid dispersions (ASDs),
consisting of the active pharmaceutical ingredient (API) intimately mixed in a polymeric
matrix, are an attractive formulation approach to improve drug delivery, dissolution, and
solubility. However, an amorphous API in an ASD is in a higher energy state compared to
the crystalline drug and results in most ASDs being inherently unstable. The polymer helps
to stabilize the amorphous drug against crystallization such that the resulting homogenous
mixture maintains its solubility advantage relative to the crystalline form. One challenge
of ASDs is that the presence of impurities including crystals or residual solvent, variations
in the ingredients, or changes in storage conditions can all affect physical stability and
bioavailability. There is a clear need for advanced analytical techniques that can both
detect, characterize, and quantify the components of amorphous formulations, especially
ASDs. This research focuses on methods to detect and quantify crystallinity, ensure
consistency between manufactured lots of amorphous formulations, and predict shelf life
and drug substance properties. Poorly soluble model drug compounds such as nifedipine,
indomethacin, and patiromer were studied using multiple analytical techniques including
solid-state nuclear magnetic resonance (SSNMR) spectroscopy. First, SSNMR was used
to develop a method to quantify the monomeric makeup of an insoluble polymeric API
which can be used to demonstrate API sameness during generic drug development. Second,
crystallinity was detected, quantified, and compared using a variety of analytical
techniques with SSNMR and powder X-ray diffraction being used to predict drug-polymer
solubility form the first time. Third, an extensive investigation into the effect of hydrogen
bonding, drug loading, and storage temperature on crystallization tendency was conducted
around the glass transition temperature (Tg) and found that hydrogen bonding plays a
particularly important role in stability near Tg. Lastly, the impact of multiple absorbed
solvents on the physicochemical properties of pharmaceutical polymers was investigated
using dynamic vapor sorption. In conclusion, this research proposes new methods and new
applications of existing analytical techniques for the advanced characterization of
pharmaceutical amorphous formulations. The results provide an improved understanding
of the factors affecting the physical stability of ASDs and should aid in their successful
formulation.

KEYWORDS: Amorphous solid dispersion, solid-state nuclear magnetic resonance
spectroscopy, crystallinity, physical stability, glass transition temperature, hydrogen
bonding
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CHAPTER 1: INTRODUCTION
1.1

Pharmaceutical Development
The vast majority of drugs are formulated as an oral solid dosage form, typically a

tablet or capsule. As of 2017, 62% of marketed drugs were taken orally (1). There are many
reasons why oral dosage forms dominate the pharmaceutical landscape. From a patient
compliance point of view, taking a tablet is often preferable to an injection especially as
tablets are easy to store and transport. Similarly, tablets are often much easier and cheaper
to product from a manufacturing standpoint. Despite the simplicity of a tablet, the route it
takes to deliver the drug to the site of action is often extremely difficult. Once swallowed,
the drug typically must survive the stomach’s acidic environment before disintegrating and
dissolving in the gastrointestinal fluid of the small intestine. Even then, a sufficient amount
of drug must remain soluble long enough to be absorbed across the intestinal membrane
and survive hepatic clearance in the liver before reaching systemic circulation to reach the
site of action. Each of the aforementioned steps contribute to the oral bioavailability.
Perhaps most importantly, the success or failure of an oral solid dosage form is dependent
on two properties: solubility and permeability, from which the biopharmaceutical
classification system (BCS) is based (2).
The BCS system, shown in Figure 1.1, divides drugs into four categories based on
their solubility and permeability. Ideally, drugs are BCS class I (high solubility and
permeability) and easily deliver efficacious amounts of drug. More commonly, however,
many drugs suffer from poor solubility and fall under BCS classes II (low solubility/ high
permeability) or IV (low solubility and permeability). A recent survey by Di et al. found
that 40% of marketed drugs are poorly soluble while at least 75% of drug candidates in the
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development pipeline suffer from poor solubility (3, 4). This is likely a result of the
hydrophobic interactions which mediate drug-receptor binding as well as an increased use
of high throughput screening in non-aqueous or mixed solvent media (5). These findings
are particularly striking for two reasons. First, they demonstrate that low solubility is a
current problem broadly impacting the pharmaceutical industry. Second, and more
importantly, poorly soluble compounds will continue to plague the drug development
process for years to come. Each highlights the need for new and improved formulation
strategies that will be required to solubilize and deliever the majority of new drugs in the
near future.

Figure 1.1. Biopharmaceutical Classification System (BCS) and typical formulation
approaches. Adapted from refs. (2) and (6).
Figure 1.1 highlights some of the typical formulation approaches based on the BCS
class of the drug. For the purposes of this dissertation, most drugs of interest fall into BCS
class II or IV indicating the main challenge for a successful formulation is overcoming a
slow dissolution rate and low solubility (7). There are many ways to improve the
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dissolution rate and apparent solubility of a drug including many which have already
received FDA approval. This includes the use of co-solvents, salts, surfactants,
cyclodextrin complexation, particle size reduction, polymorphic changes, lipid-based
systems, co-crystals, prodrugs, and amorphous solid dispersions. Without a formulation to
deliver therapeutic amounts of drug, all of the prior work in discovering, synthesizing, and
characterizing the drug candidate is wasted.

1.2

Pharmaceutical Solids
Pharmaceutical solids can be broadly classified into two categories: crystalline and

amorphous. The two states vary broadly in both their physicochemical properties, stability,
prevalence, and application in drug development.
1.2.1

The Crystalline State
The crystalline state has a defined rigid structure in which molecules are highly

ordered resulting in both short- and long-range order. The molecules are held together
though non-covalent interactions including hydrogen bonding, ionic bonding, and pistacking. The rigid order and intramolecular bonds result in the crystal being the most
thermodynamically stable solid form of a given molecule (5). The thermodynamic stability
of crystalline solids often comes at the cost of aqueous solubility. The increased prevalence
of poorly solubility drugs has led to the need for alternative formulation strategies other
than standard crystalline solids (5).
1.2.1.1 Polymorphism
The same compound can exist in more than one crystalline structure, a phenomenon
known as polymorphism. For instance, diamond and graphite are both polymorphs of
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carbon. Diamond forms a cubic crystal structure whereas graphite is hexagonal (8, 9). In
addition, pseudopolymorphs can exist, typically as hydrates or solvates where one or more
water or solvent molecules are incorporated into the crystal structure, respectively.
As a rule of thumb, “the number of known polymorphic forms for a given
compound is proportional to the time and energy spent in research on that compound” (10).
However, over half of molecules in the Cambridge Structural Database have only a single
known

crystal

structure,

while

5-methyl-2-((2-nitrophenyl)amino)3-3

thiophenecarbonitrile (ROY) has at least eleven confirmed polymorphic forms (11, 12).
Different packing arrangements in polymorphs may result in varying physicochemical
properties including solubility, hardness, density, and crystal shape (13). A metastable
polymorph may be chosen during the formulation process to exploit its unique
physicochemical properties and improve drug product performance (i.e., bioavailability).
For example, equivalent doses of chloramphenicol palmitate polymorphs resulted in a
seven-fold increase in maximum blood serum concentration for form B relative to form A
(14). Provided that the polymorph of interest can remain stable over the shelf-life of the
drug, varying the polymorphic form drug product may be a viable formulation approach.
However, at a particular temperature and pressure, only one polymorph is the most stable
(i.e., it has the lowest free energy). All other polymorphs at those conditions are metastable
polymorphs and have the potential to convert to the stable form. Thus, there is always
significant risk when using a metastable polymorphic form. Perhaps most notably is the
example of ritonavir. Ritonavir was marketed as an anti-HIV drug in the late 1990’s. The
crystalline form of ritonavir used in the formulation (Form I) was assumed to be
thermodynamically stable but after two years of production, a previously unknown,
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thermodynamically more stable form appeared during the manufacturing process (Form
II). Form I was up to 5.6x more soluble than Form II leading to the repeated failing of
dissolution testing (15). Ritonavir was eventually pulled from the market until a process
was developed to control the formation of Forms I and II. Hence, the ritonavir example
underscores the importance for controlling polymorphism during production and its
potential impacts on product performance.
The relative stability of polymorphs at constant pressure can vary as a function of
temperature. A pair of polymorphs which have the same relative stability across all
temperatures below each melting point are known as monotropic. On the other hand, the
relative stability of enantiotropic polymorphs varies as a function of temperature with a
transition occurring somewhere below the melting point of each form. Burger and
Ramberger developed various rules which help to predict the stability-temperature
relationship of different polymorphs including the heat of fusion rule, heat of transition
rule, density rule, and the infrared rule (16). Figure 1.2 illustrates the temperature
relationship for monotropic and enantiotropic polymorphs.
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Figure 1.2. Energy-temperature diagrams for two hypothetical polymorphs (forms I and
II) showing a (A) monotropic and (B) enantiotropic relationship. Adapted from ref. (16).
GI, GII, and Gliq are the Gibbs free energy of polymorphs I, II, and the liquid, respectively
while HI, HII, and Hliq are the enthalpy of polymorphs I, II, and the liquid, respectively.
∆Hfus,I and ∆Hfus,II are the heat of fusion for forms I and II which occur at their respective
melting points Tm,I and Tm,II. ∆HIàII is the enthalpy change of the polymorphic transition
from form I to form II occurring at the transition temperature, TIàII.
1.2.1.2 The Amorphous State
It is easiest to describe the amorphous state relative to the crystalline state. Contrary
to the crystalline state, the amorphous state lacks long-range order but still may possess
short-range molecular ordering with immediately adjacent molecules (i.e., on the order of
a few angstroms) (17). The amorphous state is also thermodynamically unstable and wants
to revert back to the stable crystalline state. Despite its inherent instability, amorphous
solids are widely used in the pharmaceutical industry. Many compounds including
peptides, proteins, and some polymers are naturally occurring amorphous forms.
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Additionally, the fact that amorphous drugs are more soluble than their crystalline
counterparts make amorphous formulations a desirable approach for improving the
bioavailability of poorly soluble drug candidates.
The amorphous state is often defined by the glass transition temperature (Tg). The
glass transition is a pseudo second order phase transition characterized by a dramatic
increase in viscosity and decrease in molecular mobility (18). Depending on the
temperature relative to Tg, the amorphous state takes on different forms and has different
properties. Above Tg, the amorphous solid can be viewed as an extension of the liquid
phase. More specifically, the amorphous solid is a supercooled liquid or rubber. Below Tg,
the amorphous state is classified as a glass and behaves more like a solid. A detailed
illustration of the thermodynamic relationship of crystalline and amorphous compounds is
shown in Figure 1.3.
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Figure 1.3. Illustration of the enthalpy and volume relationship with temperature in
amorphous and crystalline solids.
When a crystalline or amorphous drug is heated above the melting point (Tm), the
liquid is at equilibrium and the original state cannot be discerned. Crystallization typically
occurs upon cooling below Tm as the molecules have sufficient time to reorganize into a
thermodynamically stable point in a crystal lattice (19). This is a first order phase transition
leading to a step decrease in H and V as the ordering of molecules into a defined crystal
lattice results in densification and a decrease the system energetics. However, if upon
cooling below Tm, crystallization does not occur, the drug enters the supercooled liquid
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state and no discontinuity in H or V is observed. At this point, the system is still in
equilibrium and is also referred to as the rubbery state. The molecular mobility further
decreases, and viscosity increases with continued cooling. Eventually, molecular mobility
decreases to the point where molecules are no longer able to sufficiently rearrange on the
experimental timescale and the system falls out of equilibrium. The temperature at which
this pseudo second order phase transition occurs is the Tg and results in a change in slope
of the H or V as a function of temperature. It is important to note that the glass transition
is a kinetic phenomenon and the exact temperature (Tg) at which it occurs is heavily
influenced by many factors including heating/ cooling rate, moisture content, thermal
history, etc.
Further cooling through Tg enters the non-equilibrium glassy state. At this point,
viscosity has increased (> 1012 Pa·s) to the point where molecular mobility occurs on > 100
s timescales and the drug is kinetically stabilized against crystallization (20). Molecular
mobility continues to decrease with decreasing temperature to the point at which it becomes
insignificant. This is known as the Kauzmann temperature (TK) and hypothetically occurs
at the temperature where the supercooled liquid line intersects with the crystalline line. At
this point, configurational entropy (the difference in entropy between the crystalline and
amorphous phase) would become negative and violate the third law of thermodynamics
(21). Thus, this point cannot be reached before the system falls out of equilibrium.
However, it is estimated that TK ≈ Tg – 50°C is sufficient for molecular motions to become
negligible (20).
The amorphous drug will relax towards the equilibrium supercooled liquid state
upon storage below Tg. This relaxation is structural in nature, resulting in a lower energy,
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densified glass. The enthalpy lost to relaxation is recovered upon heating through Tg and
is observed as an enthalpic recovery endotherm.
Various types of relaxation contribute to the reduction in free energy of a glassy
API. a-relaxation is the cooperative motion of multiple molecules and mainly contributes
to the glass transition and crystallization above Tg (22). This cooperative motion results in
a large activation energy. Below Tg, the timescales of alpha-relaxations become increasing
long and cooperative or diffusive motions are quickly inaccessible. At this point, secondary

β or Johari-Goldstein (βJG) relaxations occurring on much shorter timescales become
increasingly important. βJG relaxations correspond to noncooperative single molecule
motions with lower activation energies than a-relaxations (23). These βJG motions are
thought to occur in ‘islands of mobility’ where hindered rotational motions of the whole
molecule are possible (24). βJG motions often serve as the precursors to cooperative amotion and therefore contribute to the physical stability of glassy solids. Additional
secondary relaxations (gamma, delta, etc.) exist in the glassy state including side-chain
rotations or bond vibrations (25). However, secondary motions aside from βJG are not
thought to contribute to the instability of amorphous solids (26).

1.3

Amorphous Drug Instability
The greater free energy and molecular mobility in amorphous drugs often leads to

improved dissolution and solubility relative to the crystalline form. However, this comes
at the cost of chemical and physical instability and is the biggest issue with the use of
amorphous formulations. This disadvantage must be accounted for during the formulation,
manufacture, and storage of the drug to inhibit any instability that is detrimental to
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bioavailability (25). Just as tablets containing crystalline API are formulated with a variety
of excipients, amorphous drug substances are also formulated with other molecules
including polymers and surfactants to help stabilize the API from physicochemical
degradation. Chemical stability is defined as changes in chemical composition that occur
as a result of chemical reactions within the drug substance or drug product. Regarding
amorphous solid dispersions, physical stability is defined as the ability of the drug to
remain amorphous and prevent crystallization.
1.3.1

Chemical Instability
Chemical stability is the main concern of crystalline drug products since they are

the most physically stable form. However, chemical stability is often overlooked in the
amorphous state yet is still critically important and will briefly be considered. Chemical
degradation may simply cause changes in physical appearance such as discoloration. Often,
however, the results of chemical degradation are more severe and may include the loss of
therapeutic potency or the production of toxic degradation byproducts (25).
Reactions in the solid state are proposed to follow a four-step process (27). 1)
Loosening of molecules at the reaction site; 2) molecular change; 3) solid solution
formation; and 4) separation of the product phase. In particular, the first step requires
sufficient molecular mobility to occur. For example, chemical degradations in crystalline
solids occur preferentially at crystalline defects where molecular mobility is increased
relative to the bulk crystal. Since the amorphous state has enhanced molecular mobility
relative to the crystalline state, it follows that chemical reactions may be especially
prevalent in amorphous solids.
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The most common chemical degradation reactions in the solid state include thermal
decomposition, photodegradation, hydrolysis, oxidation, or rearrangement reactions
(cyclization, isomerization, etc.) (28, 29). The enhanced mobility in amorphous solids often
results in increased degradation rates relative to the same crystalline drug. For instance, the
rate of spirapril HCl cyclization was over 25-fold faster in the amorphous solid than its
crystalline form (30).
Chemical reactivity can be minimized or prevented entirely over the shelf life of an
amorphous drug product by storage below the Tg where molecular mobility is restricted.
Solid-state reactions typically do not follow Arrhenius reaction kinetics as in the solution
state which complicates the extrapolation of accelerated stability or stress testing to
relevant storage temperatures (25). Instead, more complex models are needed to predict
the chemical stability of amorphous solids (31, 32). Clearly, the chemical stability of
amorphous drugs is very important and must be considered during the design, production,
and storage of an amorphous drug product. However, the work of this dissertation focuses
on the physical stability of amorphous pharmaceuticals and will be discussed in more
detail.
1.3.2

Physical Instability
Physical instability is a concern in the formulation of any drug product however, it

is particularly important any time a metastable phase is used such as a metastable crystal
polymorph or an amorphous solid. While the focus of this dissertation is on the physical
instability of small molecule APIs (namely, crystallization), it is important to note another
source of physical instability in the amorphous state. Lyophilization is often used to
stabilize peptides, proteins, or other large molecules in the amorphous state. Specifically,
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rather than preventing protein crystallization, it is important to sufficiently stabilize
proteins in their native state to prevent aggregation and preserve their activity upon
reconstitution and administration.
Recrystallization represents one of the biggest hurdles to the widespread use of
amorphous pharmaceuticals to overcome the poor solubility of many drug candidates (17).
The higher free energy of the amorphous state makes it metastable relative to the crystal
form which is the most stable state at any temperature. The free energy difference between
the amorphous and crystalline form represents a thermodynamic driving force to revert to
the stable crystalline form through crystallization. Figure 1.4 illustrates the different
energetics of the crystalline and amorphous states.

Figure 1.4. Energy diagram for various solid-state forms. Adapted from ref. (33).
1.3.2.1 Crystallization from the Amorphous State
Crystallization is a two-step process involving nucleation and crystal growth. The
rate and extent of crystallization is dependent on temperature and governed by two
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competing processes: thermodynamic driving force (supersaturation or supercooling) and
molecular mobility. Supercooling is defined as the difference in temperature between the
melting point, Tm, and the temperature, T, of the amorphous system. Decreasing
temperature (increasing supercooling) increases the thermodynamic driving force for
crystallization. At the same time, decreasing temperature also reduces the molecular
mobility as the thermal barrier to translational/ diffusional motion decrease. The decrease
in mobility is observed as a decrease in diffusivity or an increase in viscosity. Figure 1.5
illustrates the competing forces of supercooling and molecular mobility and their effect on
the overall crystallization rate.
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Figure 1.5. Overall crystallization rate from the amorphous state as a function of
temperature and the relative importance of thermodynamic and kinetic factors. Adapted
from ref. (34).
The maximum rate of crystallization is expected to occur at a temperature
intermediate to the glass transition and melting point. The specific temperature of
maximum crystallization rate is dependent on the molecule as well as the polymorphic
form (35, 36). Note that while the effects of supercooling reach zero at Tm, molecular
mobility still contributes to crystallization below Tg. Although translational mobility is
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significantly inhibited in the glassy state, molecules still possess rotational and vibrational
motion which can spur nucleation and crystal growth (25).
While Figure 1.5 provides a good picture of crystallization from the amorphous
state, the reality is more complex. As noted earlier, crystallization consists of nucleation
followed by crystal growth. The rate of each process varies with temperature and may
operate in different temperature regimes. The temperature dependence of the rates of
crystal nucleation and growth are illustrated in Figure 1.6.

Figure 1.6. Nucleation and temperature growth regimes as a function of supercooling.
Adapted from refs. (37) and (38).
The exact temperature range, shape, and relative magnitude of each rate may
change based on the amorphous molecule observed. It is also important to note that the
presence of excipients, such as in polymeric ASDs, does not change the maximum
temperatures during isothermal crystallization (39). Rather, the magnitude of each regime
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will likely change if the polymer functions to slow nucleation and/ or crystal growth. A
thorough understanding of the API-specific crystallization kinetics displayed in Figures 1.5
and 1.6 is required to avoid temperature regimes during the manufacture and storage that
are conducive to crystallization.
The relative position of each regime has also been related to the glass forming
ability (GFA) of the drug molecules (40). Drugs with significant overlap of the two zones
are typically poor glass formers as the rate of each process is relatively high at the same
temperature. Crystal nuclei that form are then able to immediately grow to measurable
sizes. On the other hand, compounds with well-resolved nucleation and crystal growth
temperature ranges are typically better glass formers as amorphous molecules do not have
sufficient mobility to diffuse to the nuclei formed at lower temperatures and thus hinder
crystal growth. Figure 1.6 also helps to explain the observation that crystallization is more
likely to occur in freshly prepared amorphous materials during reheating rather than during
cooling (40). Despite first traversing the temperature range favoring growth upon cooling,
it is unlikely that any nuclei have formed. Reheating the same sample from the glassy state
traverses the nucleation zone and the likelihood of crystal nuclei existing is now greater
and serves as a starting point for crystal growth upon heating.
It is important to note that crystallization from the amorphous state is slightly
different than crystallization from the liquid or in the presence of solvent. Nonetheless,
classical nucleation and crystal growth theory can be used to provide a general
understanding of the factors affecting crystallization.

17

1.3.2.1.1 Classic Nucleation Theory
Nucleation can be divided into two broad categories: primary and secondary
nucleation. Secondary nucleation occurs on preexisting crystal surfaces which act as
nucleation sites for further crystal growth. Primary nucleation occurs without preexisting
crystal surfaces and can be subdivided into heterogeneous nucleation, which is induced by
dissolved impurities, and homogenous nucleation. Heterogeneous nucleation is nearly
always observed in practice as it is nearly impossible to eliminate all impurities and
surfaces which may act as nucleation sites. Therefore, homogeneous nucleation is
extremely rare in practice, yet it forms the basis of classical nucleation theory (41). A more
detailed discussion of homogeneous and heterogeneous nucleation follows as well was the
impact of each on amorphous drug stability.
Homogeneous nucleation results from local solute concentration fluctuations in a
supersaturated solution. Increased local concentrations can create ordered clusters which
form by an additive mechanism (42, 43). Nucleation is a balance of competing energetic
forces which determine whether a stable nucleus forms or redissolves. The free energy
change of forming a new phase, ∆G(r), is shown in Equation 1.1 where ∆Gv and ∆Gs are
the bulk free energy difference between the crystalline and amorphous/ liquid state, and
the free energy required to create a new surface, respectively.
∆𝐺𝐺(𝑟𝑟) = ∆𝐺𝐺! + ∆𝐺𝐺"

(1.1)

The liquid or amorphous state is metastable relative to the crystalline state so
crystallization is exothermic and ∆Gv is negative. Surface tension (g) opposes the creation
of new surfaces so ∆Gs is positive. Equation 1.2 shows the balance between the energy
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gain associated with forming a solid phase and the energy penalty of creating a new crystal
surface.
#

∆𝐺𝐺(𝑟𝑟) = − 𝜋𝜋𝑟𝑟 $ ∆𝐺𝐺! + 4𝜋𝜋𝑟𝑟 % 𝛾𝛾
$

(1.2)

Initially, the radius of a molecular clusters is very small and high surface tension
makes nucleation unfavorable. Eventually, the growing cluster reaches a critical size (r*)
where the additional volume of forming crystal nucleus outweighs the effects of surface
tension and nucleation becomes energetically favorable. The nucleus now continues to
grow into an observable crystal. Figure 1.7 illustrates the competition between ∆Gv and
∆Gs during nucleation as a function of radius where the critical nucleus (r*) the
corresponding energy barrier it must overcome (∆G*) are calculated in Equations 1.3 and
1.4.
𝑟𝑟 ∗ =
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(1.3)
(1.4)

Figure 1.7. Free energy as a function of crystal nucleus radius. Adapted from ref. (37).
∆Gv, or the free energy difference between the crystalline and amorphous state, can
be estimated by the Hoffman equation (Equation 1.5) which uses the degree of
supercooling (Tm – T) and the heat of fusion (∆Hfus) of pure drug to estimate the free energy
change during crystallization (44).
∆𝐺𝐺! = ∆𝐻𝐻-."

(0$ 10)0
#
0$

(1.5)

This relationship assumes that enthalpy varies linearly with temperature for both
the supercooled liquid and crystal (44). Therefore, it can only be applied to supercooled
liquids between Tg and Tm. The growth of the critically sized clusters is governed by the
Gibbs-Thompson equation where S is the supersaturation ratio, v is the molecular volume,
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and k is the Boltzmann constant (Equation 1.6) (25). Combining Equations 1.6 and 1.4
when r = r* to yield energy barrier in terms of supersaturation and temperature (Equation
1.7).
ln 𝑆𝑆 =

%'!

(1.6)
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Equation 1.8 shows that the nucleation rate (I) follows an Arrhenius type expression
where A is a preexponential constant. Substituting Equation 1.7 into Equation 1.8 provides
a more detailed picture of the various parameters that affect nucleation (Equation 1.9).
∆) ∗

(1.8)
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Temperature and the supersaturation ratio have the largest effects on nucleation
rate. Increasing concentration and/ or supercooling in the amorphous state should
exponentially increase nuclei formation. While this is true for increasing concentration,
nucleation rate increases then decreases with decreasing temperature. Clearly, there is an
additional factor affecting nucleation that is not accounted for in Equation 1.9. Decreasing
temperature results in a reduction in molecular motion which is observed as an increase in
viscosity (45). This was shown above in Figure 1.5. The viscous free energy, ∆Gvisc, was
therefore incorporated as Equation 1.10 and better predicts the nucleation behavior from
the amorphous state (46).
*+,' " ! #
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The equations above represent the ideal case of homogeneous primary nucleation.
In reality, homogeneous nucleation is rarely observed, and heterogeneous nucleation is
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more common. The presence of foreign materials or surfaces is typically found to reduce
the free energy of nucleation which poses a particular challenge for stabilizing amorphous
drugs (41). Similarly, secondary nucleation is also a particular concern in amorphous
formulations as preexisting ‘parent crystals’ catalyze further nucleation and subsequent
crystal growth (41).
Furthermore, measuring nucleation rate is rarely done by measuring the time at
which at which a nucleus forms because nuclei are extremely small and difficult to detect
until they grow into larger crystals. Rather, nucleation rates are estimated by measuring the
induction time, tind, which is defined as the elapsed time between creation of
supersaturation and the formation of a new phase (41). The new crystalline phase can be
detected visibly or through a change in a property of the solution. Therefore, the induction
time contains both the time for nucleation to occur as well as the time for the nucleus to
grow to a detectible size (Equation 1.11).
(1.11)

𝑡𝑡;6< = 𝑡𝑡6 + 𝑡𝑡=

Here, tn is the steady-state nucleation time and tg is the time to grow to a detectible size.
1.3.2.1.2 Crystal Growth
The second step in crystallization is crystal growth whereby additional molecules
add to a stable nucleus and grow to an observable size. Crystal growth can occur either in
the bulk or on the surface of amorphous solids. Surface crystallization is observed to be
faster due to enhanced molecular mobility at the surface, however both must be inhibited
to fully physically stabilize an amorphous formulation (47).The normal crystal growth rate
(u) from the amorphous state can be described by Equation 1.12 (48).
3

𝑢𝑢 = 71 − 𝑒𝑒𝑒𝑒𝑒𝑒 5−
>
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Here, k is a constant, η is the supercooled liquid viscosity, ∆Gc is the free energy difference
between the amorphous and crystalline states, and R is the ideal gas constant. Similar to
Equation 1.10 that described nucleation rate, Equation 1.12 also describes the competing
contributions of thermodynamics and molecular mobility. [1 – exp(-∆Gc/RT)] describes
the thermodynamic driving force where increased supercooling also increases ∆Gc and the
crystal growth rate. Conversely, the molecular mobility contribution, 1/ η, shows that
increasing viscosity slows the growth rate. Other factors including intermolecular
interactions, polymeric additives, and humidity can also impact the crystal growth rate of
amorphous pharmaceuticals (37, 49).
Crystal growth is normally diffusion-controlled whereby the rate of molecular
addition to the growing crystal surface is limited by the rate at which molecules diffuse to
the crystal-liquid (amorphous) interface. The crystal growth rate is directly proportional to
diffusivity and is observed over a wide range of supercoolings (50). However, this
relationship breaks down in some molecular systems near Tg and an abrupt increase in
growth rate is observed relative the predicted diffusion-controlled rate (51-53). The
positive deviation from diffusion-controlled crystal growth rate near Tg is termed
diffusionless or glass-crystal (GC) crystal growth. Diffusionless crystal growth is not
observed in all systems leading to potential issues modeling the stability of amorphous
pharmaceuticals. The origin of this anomaly is debated in the literature and will be
discussed further in chapter 5 (52, 54, 55).
1.3.2.1.3 Factors Affecting Crystallization Tendency
Configurational properties are a measure of the difference between the
thermodynamic properties of the crystalline and amorphous state and have been used to
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explain the thermodynamic driving force for crystallization from the amorphous state.
Configurational properties are typically measured using differential scanning calorimetry
(DSC) and rely on an accurate measurement of the difference in heat capacity (CP,config)
between the pure amorphous (CP,amorph) and crystalline (CP,crystal) phases. Figure 1.8 shows
the reversing heat capacity of indomethacin and the corresponding configurational heat
capacity.

Figure 1.8. Crystalline, amorphous, and configurational heat capacity of indomethacin.
The change in CP,config with temperature (T) is used to measure configurational
enthalpy, entropy, and free energy (Hconfig, Sconfig, and Gconfig, respectively). Equations 1.13
– 1.16 show how each configurational property is calculated from heat capacity data.
𝐶𝐶@,BC6-;= = 𝐶𝐶@,DEC4FG − 𝐶𝐶@,B4H"ID5
0

𝐻𝐻BC6-;= = ∆𝐻𝐻E − ∫0 $ 𝐶𝐶@,BC6-;= 𝑑𝑑𝑑𝑑
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(1.13)
(1.14)
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(1.16)

Here, ∆Hm is the heat of fusion, Tm is melting temperature, and ∆Sm (= ∆Hm/Tm) is the
entropy of fusion. Configurational free energy is the same value used in Equations 1.5 and
1.12.
The importance of configurational properties has been discussed previously by
Zhou et al. (56). Briefly, the thermodynamic driving force for crystallization can be
enthalpic or entropic based. Since the crystal form is more stable than the amorphous state,
crystallization is expected to be exothermic. Larger values for the heat of fusion or
configurational heat capacity are directly related to the energy dissipated to the
surroundings during crystallization. Conversely, there is an entropic energy penalty during
crystallization as the crystal packs in a well-defined lattice whereas the amorphous form
lacks long-range order. The configurational entropy can be thought of the degree of
different configurations that molecules can exist in between the amorphous and crystalline
states (57). The number of configurations in the crystal state is well defined by the crystal
state of a particular polymorph. However, the lack of long-range order in the amorphous
state allows molecules to orient in more configurations which may be dissimilar to the
crystal structure. Therefore, configurational entropy is inversely related to the probability
that molecules in the amorphous state are properly oriented for nucleation and crystal
growth (56). Configurational entropy has been used to predict physical stability as
compounds with greater configurational entropy values are generally found to possess
superior physical stability however certain exceptions have been observed (56-58). While
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the configurational entropy has predicted relative physical stability rather well,
configurational enthalpy and free energy generally do not correlate well with stability (56).

1.4

Amorphous Solid Dispersions
The enhanced dissolution and greater solubility of the amorphous state relative to

the crystalline state provide an opportunity to overcome the poor solubility of many drug
candidates. However, it was shown above that the main drawback to an amorphous
formulation is its inherent physical instability and propensity to recrystallize. The
amorphous form must be stabilized during manufacturing and storage and, ideally, should
also resist crystallization during dissolution in vivo.
In order to better stabilize the drug in the amorphous state it can be intimately mixed
with an excipient, typically a polymer. The resulting molecular mixture is known as an
amorphous solid dispersion (ASD) and helps maintain a solubility advantage relative to the
crystalline state while having enhanced physical stability relative to the pure amorphous
drug (Figure 1.4). While the focus of this dissertation is on the physical stability of ASDs
during shelf life, their stability and performance during dissolution must briefly be
considered.
Dissolution of a crystalline compound must overcome the crystal packing energy
by disrupting the crystal lattice and removing individual molecules into solution (59). This
is an energy intensive process and often limits the solubility of crystalline drugs. However,
amorphous drugs do not have to break the crystalline lattice which often results in their
rapid dissolution and high aqueous solubility. Ideally, an amorphous formulation provides
a “spring and parachute” effect where a supersaturated solution is quickly generated and
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the concentration is maintained for longer periods of time to maximize exposure to the drug
(Figure 1.9). The spring is a result of the increased free energy of the amorphous state and
its rapid dissolution. Since the resulting solution is supersaturated, the dissolved
amorphous drug is thermodynamically unstable must be stabilized by the polymeric
component of the ASD. If the parachute fails, the solubility advantage of the ASD is not
realized, and the concentration dissolved equals the crystalline solubility (Cx).

Figure 1.9. Spring and parachute dissolution profile where CX is the crystalline solubility.
Adapted from ref. (59).
BCS class II and IV are ideal candidates for formulation as an ASD. The choice of
polymer is dependent on the physicochemical properties of the API. However, only a few
classes of polymers are used in most marketed formulations. This includes
vinylpyrrolidone-based (PVP, PVPVA), cellulose-based (HPC, HPMC, HPMCAS),
polyethylene glycol, and methacrylate/ methacrylic acid (Eudragit) (60, 61). The polymer
usually acts to physically stabilize the amorphous drug and/ or improve dissolution.
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Ternary ASDs may also be formulated with a surfactant or multiple polymers to better
control the dissolution rate and stability.
In order to take advantage of the combined drug-polymer properties relative to the
individual components on an ASD, the drug and polymer must be intimately mixed to form
a miscible single-phase system (25). Miscibility is determined both by the drug-polymer
combination their relative ratio. Miscibility is expected when the free energy change upon
mixing is negative (∆Gmix < 0), as expressed by the Gibbs-Helmholtz equation (Equation
1.17).
∆𝐺𝐺E;K = ∆𝐻𝐻E;K − 𝑇𝑇∆𝑆𝑆E;K

(1.17)

The free energy change is controlled by either the enthalpy (∆Hmix) or entropy
(∆Smix) of mixing at a given temperature, T. There is greater disorder in a mixture relative
to the individual components so entropic changes are typically favorable to mixing (∆Smix
> 0). Higher temperatures further favor mixing when ∆Smix is negative such that the
magnitude of the entropic contribution is greater.
There is no enthalpy change in an ideal mixture (i.e., ∆Hmix = 0) and miscibility is
determined by entropy. However, real mixtures often have enthalpic contributions due to
specific interactions between the drug and polymer. The enthalpy of mixing is determined
by the number and strength of interactions between the drug and polymer. Exothermic
mixing occurs when adhesive drug-polymer interactions are more favorable than the
cohesive drug-drug and polymer-polymer interactions (∆Hmix < 0). Conversely, mixing is
endothermic when ∆Hmix > 0.
The thermodynamics of mixing in solid systems are usually described by the FloryHuggins (FH) lattice theory (62). FH theory was developed to calculate the change in free
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energy upon mixing two polymers in the absence of any specific interactions and takes the
difference in size of the polymeric units into account by using volume fractions of drug
and polymer rather than mole fractions. Despite hydrogen bonding in many drug-polymer
systems, FH lattice theory is often sufficient for modeling the mixing of a small molecule
API with a relatively large polymer (Equation 1.18).
∆𝐺𝐺E;K = 𝑅𝑅𝑅𝑅(𝑛𝑛* 𝑙𝑙𝑙𝑙𝜙𝜙* + 𝑛𝑛% 𝑙𝑙𝑙𝑙𝜙𝜙% + 𝑛𝑛* 𝜙𝜙% 𝜒𝜒)

(1.18)

Here, R is the ideal gas constant, n1 and n2 are the moles of drug and polymer, respectively.
Φ1 and Φ2, are the volume fractions of drug and polymer, respectively, and χ is the FloryHuggins drug-polymer interaction parameter. The left-hand portion of the FH equation
describes the entropic contributions to mixing (Equation 1.19) whereas the enthalpic
contribution is described by the right-hand portion of the FH equation (Equation 1.20) (63).
∆𝑆𝑆E;K = −𝑅𝑅(𝑛𝑛* 𝑙𝑙𝑙𝑙𝜙𝜙* + 𝑛𝑛% 𝑙𝑙𝑙𝑙𝜙𝜙% )
∆𝐻𝐻E;K = 𝑅𝑅𝑅𝑅𝑛𝑛* 𝜙𝜙% 𝜒𝜒

(1.19)
(1.20)

χ provides a numerical measure of miscibility where negative values indicate
miscibility and positive values suggest immiscibility. χ can be determined by Hildebrand
solubility parameters, melting point depression, or drug-polymer dissolution/
crystallization data (64-66). Chapter 4 demonstrates the use of recrystallization data to
determine χ in a nifedipine-polyvinylpyrrolidone ASD.
1.4.1

Causes of Instability
Amorphous solid dispersions are still plagued by many of the problems facing a

pure amorphous drug in addition to new issues that arise by the addition of a polymeric
excipient. Most notably, the polymers used are often hygroscopic and may absorb
significant amounts of water which can lead to phase separation and/ or drug crystallization
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(67). The possibility also exists for chemical interactions or degradation between the drug
and polymer including hydrolysis, oxidation, acid-base reactions, or Maillard reactions
(25). However, despite the issues mentioned above and the stabilizing effects of the
polymeric excipient, the biggest stability concern to ASDs is recrystallization or phase
separation. Most pharmaceutically relevant drug loadings result in formulations which are
still metastable relative to the crystalline form. Formulation of low drug loadings and
storage at low temperatures (below Tg) are the most common ways in which ASDs can be
further stabilized against recrystallization.
1.4.1.1 Drug-in-Polymer Solubility
The physical stability of an amorphous drug in an ASD is ultimately determined by
its drug loading relative to its polymer-specific solubility. Just as every drug has an aqueous
solubility, it also has a solubility in the polymer used in the ASD however the polymer now
acts as the solvent. The stability of the ASD depends on both the drug loading and storage
temperature. Figure 1.10 shows an example temperature-composition phase diagram.
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Figure 1.10. Theoretical two-component phase diagram. Adapted from ref. (66). An
illustration of the changing drug-polymer system is overlaid where dark blue lines
represent the polymer, red circles represent amorphous drug, and red diamonds represent
crystalline drug. At high temperatures, the crystalline drug solubility is high and little drug
will recrystallize whereas at low temperatures, solubility is low and only a small fraction
of drug remains amorphous.
The solid line in Figure 1.10 is the solid-liquid equilibrium curve and represents the
equilibrium solubility of crystalline drug in a polymer matrix at a specific temperature.
Above the curve, the polymer is undersaturated with drug and will remain physically stable.
Below the solubility curve, the ASD is supersaturated and drug will eventually crystallize.
Drug will continue to crystallize until the composition of the remaining ASD reaches the
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concentration governed by the equilibrium solubility curve at a given temperature. At this
point, crystallized drug will exist in equilibrium with the saturated ASD (63). Figure 1.10
can be divided into four regions based on tendency to crystallize using the Tg of the
amorphous mixture. Regions 1 and 2 are undersaturated and physically stable at all
temperatures with region 1 an undersaturated melt and region 2 an undersaturated glass.
Regions 3 and 4 are both supersaturated and, therefore, thermodynamically unstable.
Below Tg, region 3 is a kinetically stabilized glass while above Tg, region 4 is both a
kinetically and thermodynamically unstable melt. Consequently, the four regions can be
ordered by the increasing risk of crystallization: I = II < III < IV.
Designing an undersaturated ASD may or may not be feasible depending on the
solubility of the drug in the polymer at storage temperature. Many BCS class II and IV
drugs also have relatively low solubility in polymers typically used for ASD formulations
(68). Therefore, apart from highly potent APIs, formulation of an undersaturated ASD may
not provide an efficacious dose of drug and a supersaturated dispersion may be required.
Samples in region 3 are kinetically stabilized against crystallization due to the decreased
molecular mobility in the glassy state, however the degree to which the system is stabilized
is dependent on a variety of factors including any specific drug-polymer interactions and
the supersaturation ratio. Extensive stability testing is required as the ASD still must remain
stable over the shelf life of the drug. Samples in region 4 pose the greatest risk of
crystallization as they have no kinetic stability. The only stability offered in this region
comes from specific drug-polymer interactions, yet crystallization is often observed to
occur quickly in region 4. Nonetheless, storage in this region should be avoided to help
ensure product stability over the shelf life of the drug.
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Despite the importance of drug-polymer solubility as a formulation parameter, its
determination is non-trivial and often a time-consuming process. The tie lines in Figure
1.10 indicate the four ways in which equilibrium solubility can be approached and are
described in detail by Sun et al (66). Briefly, path AE follow the dissolution of crystalline
drug into an undersaturated solution at a constant temperature. Path BE is also an
isothermal approach which follows crystallization out of a supersaturated ASD. Path CE
begins with an undersaturated solution and measures the temperature at which
crystallization occurs upon cooling. Path DE is opposite to CE and measures the dissolution
temperature or melting point depression upon heating a supersaturated ASD. Despite
approaching equilibrium from different directions, each path should provide a
thermodynamically equivalent measure of solubility.
The solubility of a drug should ideally be measured at the temperature of interest
(i.e., storage or room temperature). This is not an issue for aqueous solubility
measurements as the liquid solvent (water) is not viscous and excess solute (drug) can
quickly precipitate out to form a saturated solution. However, the inverse relationship of
temperature and viscosity complicates drug-polymer solubility measurements as most
pharmaceutically relevant polymers are sufficiently viscous or even solid at ambient
temperatures. Increased viscosity slows the kinetics of dissolution or crystallization
required to achieve equilibrium between a crystalline drug and a saturated ASD to the point
where the required experimental time may become unreasonably long (69).
Because of the difficulties in measuring drug-polymer solubility highlighted above,
solubility measured at elevated temperatures must be extrapolated to relevant temperatures
using a suitable equation of state. Flory-Huggins (FH) theory has been used for this purpose
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most frequently as it is relatively easy to experimentally measure the interaction parameter
(c) using thermal analysis methods. Equation 1.21 is the Flory-Huggins equation:
∆L$
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where ∆Hm is the heat of fusion, R is the ideal gas constant, Tm is the melting point, u1 is
the drug volume fraction, λ is the molar volume ratio of the polymer and drug, and c is the
Flory-Huggins/ drug-polymer interaction parameter. As discussed previously, the FH
equation assumes there are no significant interactions between drug and polymer (62).
However, this often does not hold true for pharmaceutical systems where drug-polymer
interactions, such as hydrogen bonds, are associated with enhanced physical stability (70).
The limitations of FH theory have been recognized and additional predictive methods have
been proposed to better account for specific interactions which usually exist in ASDs (71).
There have been many modifications of the FH theory for modeling ASDs. In
particular, the Kyeremateng and perturbed chain statistically associated fluid theory (PCSAFT) methods have been applied for drug-in-polymer solubility measurements. The
Kyeremateng method uses an empirically derived equation to predict the temperature at
which a specific drug loading is solubilized using the pure drug melting point and a
measure of drug-polymer interactions (72). PC-SAFT was developed by Gross and
Sadowski to measure the residual Helmholtz energy of a binary drug-polymer mixture
based on repulsion, dispersion, and association interaction contributions (73).
While drug-in-polymer solubility is an important formulation parameter, it is
important to note that it measures the crystalline solubility which is typically very low for
most

drug-polymer

combinations.

For

example,

nifedipine’s

solubility

in

polyvinylpyrrolidone is around 2% (w/w). This shows that most reasonable formulations
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are thermodynamically unstable and must be kinetically stabilized by storage below Tg or
sufficient drug-polymer interactions to inhibit crystallization over the shelf life of the drug
product. Further, the polymer molecular weight does not have a significant impact on the
drug’s solubility (74). Therefore, the solubility of an ASD may be improved by changes to
the polymer used rather than varying the polymer molecular weight.
Chapter 4 further examines the difficulties of measuring drug-in-polymer solubility
using the recrystallization method. Specifically, new methods to quantify crystallinity and
approach equilibrium are discussed.
1.4.2

Stability Mechanisms
Depending on the polymer used and its concentration in the ASD, it can act in

different ways to stabilize the amorphous drug. In general, the drug is stabilized against
crystallization through antiplasticization/ reduced mobility, the formation of specific drugpolymer interactions, and/ or dilution effects. The result is typically an increased
crystallization activation energy by the inhibition or slowing of nucleation and/ or
subsequent crystal growth (61).
1.4.2.1 The Glass Transition Temperature and Reduced Mobility
The high degree of molecular mobility in the amorphous state relative to the crystal
contributes to its instability. The glass transition temperature is a rough measure of
molecular mobility where a larger value of Tg indicates a reduction in mobility. Most
polymers have a Tg significantly higher than the API. In a phase separated system, two
separate Tgs equal to each individual Tg are expected (25). However, a single Tg,
intermediate to the Tg of pure drug and polymer, should be observed in intimately mixed
ASDs.
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By raising the Tg of the ASD, the polymer acts as an antiplasticizer and confers its
relatively restricted mobility onto the drug. Conversely, the drug, having a lower Tg, acts
as a plasticizer and lowers the mixture Tg relative to the polymer. Other low molecular
weight additives such as water plasticize amorphous systems and may negate the
stabilizing effects of the polymer through higher mobility and/ or phase separation that may
result in crystallization (67).
The glass transition is likely the most important property of an ASD as it is used to
estimate the physical stability and set storage conditions (75). Therefore, its measurement
and prediction are critically important. The most common way to predict the glass
transition temperature of an ASD is the Gordon-Taylor (GT) equation (76). The glass
transition temperature of the mixture (Tg,mix) is predicted in Equation 1.22 using the
properties of each pure component weighted to account for their relative concentrations in
the ASD.
𝑇𝑇=,E;K =

N0 0/,0 OPN# 0/,#
N0 OPN#

(1.22)

Here, X1 and X2 are the weight fractions of the drug and polymer while Tg,1 and Tg,2 are
the pure drug and polymer Tgs, respectively. The GT equation was originally developed
for copolymers and assumes the two components are roughly the same size (molecular
volume) and do not interact (e.g., hydrogen bond) with one another. Deviations from the
GT-predicted Tg may be a result of specific drug-polymer interactions (75). The effect of
drug-polymer interactions on ASD stability will be discussed in the following section. The
constant, K, is related to the individual properties of each component. The Simha-Boyer
rule (Equation 1.23) uses the density (ρ) and Tg while Couchman-Karasz (Equation1.24)
measures the change in heat capacity (Cp) at Tg (77, 78).
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It is typically assumed that an amorphous solid should be stored at Tg – 50°C or
below to totally inhibit a- and b- motions contributing to crystallization on a
pharmaceutically relevant timescale (i.e., shelf life ~ 2 years) (20). However, indomethacin
has been observed to nucleate in less than five months at 55°C below its Tg (79). Hence,
even storage far into the glassy state may be insufficient to stabilize an amorphous drug.
Increasing concentrations of polymers with a relatively high Tg have been shown to
increase viscosity and suppress the a-relaxations and possibly the b-relaxations involved
in nucleation and crystallization (80).
1.4.2.2 Specific Interactions
Specific interactions including between the drug and polymer may exist based on
the structure of each molecule and the state of mixing in the multicomponent system. These
interactions include hydrogen bonding, ionic bonding, dipole-dipole interactions, and Van
der Waals interactions. The presence of adhesive drug-polymer interactions is known to
contribute to the physical stability of ASDs where the polymer interrupts cohesive drugdrug interactions which are also found in the crystalline state (81). The polymer
accomplishes this through a reduction in mobility which can inhibit nucleation and/ or
prevent subsequent crystal growth (61).
It is typically assumed that stronger and more numerous interactions confer greater
resistance to crystallization in ASDs. Table 1.1 describes the bond strength of each type of
specific interaction. Ionic bonds form the strongest drug-polymer interactions and typically
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confer the greatest physical stability to the amorphous drug. For example, ketoconazole
(KET) forms ionic and hydrogen bonds with PAA and PHEMA, respectively while only
interacting with PVP through dipole-dipole interactions. It was found that the interaction
strength trended with crystallization resistance where, in order of increasing resistance to
crystallization: KET-PVP < KET-PHEMA < KET-PAA (70). However, hydrogen bonds
are observed most often in ASDs and the hydrogen bond strength is also related to physical
stability. Compared to HPMCAS and PAA, nifedipine formed stronger hydrogen bonds
with PVP which reduced a-mobility and slowed crystallization kinetics (82).
Table 1.1. Strength of various drug-polymer interactions. Adapted from ref. (83).
Type of Interaction

Bond Energy (kJ/mol)

van der Waals

~1

Dipole-dipole

2–8

Hydrogen bonding

50 – 170

Ionic bonding

850 – 1700

The effectiveness of drug-polymer interactions in stabilizing ASDs is modulated
by the degree of mixing between the drug and the polymer. Just because hydrogen bond
donator and acceptor groups exist between the two components does not mean hydrogen
bonds will be formed, nor does it mean the system will be sufficiently stable. For example,
physical mixtures of indomethacin and PVP show no spectroscopic evidence of drugpolymer hydrogen bonds whereas ASDs prepared by solvent evaporation showed direct
interactions between the indomethacin carboxylic acid and PVP amide (84). Furthermore,
the relative concentrations of drug and polymer play a large role in the extent of hydrogen
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bonding and miscibility. For instance, nifedipine-PVP ASDs were only partially miscible
at high drug loadings where drug-polymer hydrogen bonding was limited compared to
lower drug loads where nifedipine was extensively hydrogen bonded with PVP and the
system was miscible (85). The examples above highlight the importance of specific
interactions, in ASDs against crystallization. Both the drug-polymer combination,
concentration, and the formulation/preparation method must be considered to help ensure
stabilizing drug-polymer interactions form.
Lastly, environmental factors including temperature and humidity impact the
ability of hydrogen bonds to stabilize the amorphous drug. Hydrogen bond strength
decreases at higher temperatures, therefore the ability of polymers to stabilize the drug at
high temperatures is diminished (86). The presence of moisture at elevated relative
humidity can cause phase separation and crystallization by replacing drug-polymer
hydrogen bonds with drug-water or polymer-water bonds. In addition, the hygroscopic
nature of many pharmaceutical polymers can lead to extensive water sorption and
plasticization resulting in an additional stability risk (87, 88). It was suggested that the
strength of drug-polymer interactions affect the extent to which phase separation and
crystallization occur in PVP-containing ASDs (67). Thus, the polymer partially loses its
drug-stabilizing ability, and it is easier for crystallization to proceed.
1.4.2.3 Dilution Effects
Even in situations where the drug and polymer do not form specific interactions,
the polymer may still be able to stabilize low concentrations of amorphous drug. High
concentrations of polymer physically separate drug molecules in the amorphous matrix and
act as a barrier to their translational motion required for nucleation and crystal growth. For
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instance, the indomethacin (IND) carboxylic acid dimer is the dominant hydrogen bonding
species found in g-IND and is also present in a-IND. In polystyrene ASDs with 5% or less
indomethacin, Yuan et al. observed increasing amounts of free (unbound) indomethacin
(89). In addition, lowering the concentration of drug also lowers its supersaturation ratio in
the polymer. Therefore, the thermodynamic driving force for crystallization is also
reduced.
1.4.3

Formulation Approaches
The formation of an amorphous drug or ASD is usually a top-down method in

which a crystalline drug is transformed into an amorphous drug system. While a vast
number of methods exist for both lab- and commercial-scale production, ASD formulation
can broadly be classified into two categories: fusion based or solvent based (90). The
desired end product is an ASD which is stable over the shelf-life of the drug and offers
improved dissolution performance relative to the crystalline drug (75).
1.4.3.1 Fusion Based
Fusion based methods were first proposed by Sekiguchi and Obi and begin with the
crystalline drug or a physical mixture of crystalline drug and polymer. The mixture is
heated above the melting point of the drug, allowed time for molecular mixing of drug and
polymer to occur, then solidified by cooling (91). Fusion based techniques are easy to
implement as they do not involve the use of a solvent. However, fusion-based applications
are often limited to drug-polymer combinations that are miscible at high temperatures in
order to ensure homogeneous mixing occurs. Phase separation may result if the drug and
polymer are immiscible or cooled at exceedingly slow rates (92). The drug and polymer
should also thermally stable at the temperature chosen or else degradation may occur (93).
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1.4.3.1.1 Hot Melt Extrusion
In its most basic form, the fusion technique can be applied by melting a mixture of
drug and polymer in an oil bath prior to quench-cooling in liquid nitrogen. Similarly,
heating and cooling in a differential scanning calorimeter can produce small amounts of an
amorphous solid dispersion. On a pharmaceutical production scale, the most commonly
applied fusion-based method is hot melt extrusion (HME). Figure 1.11 shows a simplified
schematic of a twin-screw hot melt extruder.

Figure 1.11. Simplified twin screw hot melt extruder diagram. Adapted from ref. (94).
In HME, a powdered physical mixture is introduced into the extruder which
simultaneously heats and mixes the combination until a molten phase is formed. The
mixture if conveyed along a barrel by a single or double screw system. The temperature
and screw speed can be adjusted to tailor the mixture to the desired final properties and/ or
ensure a crystalline-free ASD is formed. Aside from being solvent-free, HME is widely
used in the pharmaceutical industry as it can be operated as either a batch or continuous
process, is high-throughput and easily scalable throughout the drug development process
(95). HME also minimizes processing steps by providing the opportunity to extrude the
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ASD into the shape of the final dosage form including tablets or pellets (96). HME has
been used extensively in the literature as a convenient way to create ASDs (90). HME has
also been successfully used for the commercial manufacturing of Intelence, Isoptin SR,
Kaletra, Norvir, Noxafil, Onmel, and Rezulin (60).
1.4.3.2 Solvent Based
Solvent based methods are often used for thermolabile drugs to avoid the possibility
thermal degradation. Typically, a drug and polymer are dissolved in a common solvent
prior to evaporative drying at low temperatures. Molecular mixing of drug and polymer is
much more efficient in a liquid solution relative to the molten state and should exist after
rapid solvent removal through drying. Solvent based methods include spray drying, freeze
drying, spray freeze drying, rotary evaporation, electrospinning, and supercritical solvation
or anti-solvation (97). The two main limitations of solvent-based methods are finding a
suitable solvent and the removal of solvent below acceptable levels.
Finding a suitable solvent where both the hydrophobic drug and hydrophilic
polymer are sufficiently soluble can be difficult due to differences in polarity. In this case,
a cosolvent system may be used or a surfactant added. However, Baghel et al. point out
that surfactants used in this manner often concentrate in the final dosage form, potentially
lessening drug loading or leading to toxicity issues (90). Even after the initial solvent
removal, residual solvent may remain which may pose health risks to the patient. The
International Council of Harmonization (ICH) has set guidelines for solvent-specific
concentrations of residual solvent that may remain in a final formulation. Removal of
residual solvent to ICH-acceptable levels is system-dependent and may prove difficult even
with secondary drying steps (59). In addition, the residual solvent can act as a plasticizer
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with potentially negative impacts to both chemical and physical stability (98). Solvent
removal also tends to be relatively expensive due to the use of large volumes of organic
solvents. The evaporation of large volumes of organic solvent may, in turn, also pose an
environmental concern. However, despite the many risks of solvent-based formulation
techniques, it is extensively used in the pharmaceutical industry especially during earlystage development as it is applicable to most compounds and material sparing at smallscale (99, 100).
1.4.3.2.1 Spray Drying
Spray drying is the most popular solvent-based production method in the
pharmaceutical industry and has been widely used for API production, micro-particles or capsules, nanoparticles, controlled release particles, liposomes, and ASDs (100, 101).
Broadly, spray drying transforms a crystalline drug into an amorphous drug or ASD
through a multistep process. First, a feed solution containing dissolved drug and polymer
is atomized by spraying through a nozzle to form a stream of droplets. The discharged
droplets contact the surrounding drying fluid (hot air) at which point a heat and mass
transfer reaction occurs on the droplet surface. The rapid solvent removal causes a sharp
increase in viscosity, trapping drug molecules within an amorphous polymer matrix (90).
Dried particles are removed from the drying chamber and collected using a cyclone. A
simplified schematic of the spray drying process is shown below in Figure 1.12.
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Figure 1.12. Simplified spray drying schematic. Adapted from ref. (102).
Figure 1.12 notes various experimental and processing parameters which may be
changed to modify the physical properties of the final product. This includes the inlet and
outlet conditions, nozzle type, air flow rate and orientation, and cyclone dimensions (100).
However, modification of processing conditions alone is not enough to generate a nonphase separated amorphous system as Mahlin et al. and Baird et al. showed the drug and
polymer physicochemical properties also play a significant role (103, 104). Nonetheless,
spray drying offers better process control than other solvent-based techniques and is easily
scalable during the development process. It has been successfully employed in the
production of Crestor, Fenoglide, Incivek, Intelence, Kalydeco, Lozanoc, Noxafil, and
Sporanox (60).
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1.4.3.2.2 Co-precipitation
Another less commonly used solvent-based method is co-precipitation, which takes
advantage of drug-polymer-solvent immiscibility rather than miscibility in common
solvent. Co-precipitation dissolves a drug and polymer in a common solvent before adding
an anti-solvent in which both the drug and polymer are insoluble. The anti-solvent is
miscible with the first solvent yet causes immediate precipitation of drug and polymer. The
precipitated particles are filtered, washed, and dried to yield ASDs. Filtration and washing
of the precipitated particles yield an ASD. Dong et al. found that drug-HPMCAS
precipitates were more porous and dissolved faster than similar ASDs produced by HME
(105). The unique physical properties of co-precipitated dispersions may allow for its
application as an alternative to spray drying or HME. To date, Zelboraf and Certican are
the only commercially available coprecipitated ASDs (60).
1.4.4

Characterization Techniques
Perhaps just as important as formulating an ASD is the ability to adequately

characterize the ASD. The full characterization of ASDs is vital from both a research and
regulatory perspective to achieve a qualitative and quantitative understanding of the drug
product physicochemical properties, stability, and performance upon dosing. Luckily, a
myriad of characterization techniques and are often used in conjunction with one another
to effectively characterize amorphous drug formulations. Of particular interest to ASDs is
the detection and characterization of crystallinity, physical properties (chemical structure,
Tg, Tm, pKa, etc.), drug-excipient interactions, degree of mixing, phase behavior/
transformations, molecular mobility, moisture content, physical stability, and dissolution
performance. While the in vivo performance is also of paramount importance, the
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characterization techniques discussed herein will be restricted to the characterization of
physicochemical properties and some in vivo performance.
1.4.4.1 Differential Scanning Calorimetry
Differential scanning calorimetry (DSC) is perfectly suited for the measurement of
many of the thermal properties of ASDs including the all-important Tg. DSC is widely
available and used in both academic and industrial settings as part of the standard analytical
toolbox used for ASD characterization and drug development (106). Standard DSC heats
both an empty and sample-filled aluminum pan at a linear heating rate and records the
difference in heat flow required to maintain an equal temperature between the two pans.
Thermally induced transitions occurring in the sample require the input of more heat flow
or less heat flow to the sample pan (relative to the reference pan) to maintain its linear
increase in temperature. For example, crystallization is exothermic which requires less heat
flow to maintain the temperature. Similarly, the endothermic heat of fusion upon melting
will require more heat flow in order to continue raising the temperature linearly. However,
simultaneously occurring thermal events cause overlapping heat flow signals, complicating
the analysis of many pharmaceutical materials. Modulated DSC (mDSC) was developed
to help overcome this by imposing a sinusoidal heating rate upon the linear/ underlying
heating rate of standard DSC. The modulated heating rate deconvolutes total heat flow
(Qtot) into two components: reversing (Qrev) and non-reversing (Qnonrev) which are
described by Equations 1.25 and 1.26:
𝑄𝑄ICI = 𝑄𝑄4T! + 𝑄𝑄6C64T!
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(1.25)
(1.26)

where dH/dt is the total heat flow, Cp is the reversing heat capacity calculated from just the
modulated heat flow, and dT/dt is the measured heating rate. CpdT/dt is the reversing heat
flow component and f(T,t) is the kinetic component of total heat flow calculated from the
difference between the total signal and heat capacity (reversing) component. The reversing
heat flow measures transitions that respond to the instantaneously changing heating rate
including the heat capacity, glass transition, and most melting (75, 106). The non-reversing
heat flow signal corresponds to kinetic processes such as enthalpic relaxation, evaporation,
melting, crystallization, curing, and decomposition (106).
As was previously mentioned, the Tg is a defining property of the amorphous state
and is often used as a rough indicator of physical stability. Therefore, the Tg is often the
first thermal property measured and, fortunately, Tg is straightforward using the mDSC
reversing heat flow signal. The Tg corresponds to the change in heat capacity between
glassy and rubbery state and is typically measured as the midpoint or half-height of the
step-change in the reversing heat flow signal (75). However, the Tg is a kinetic event and
the exact location of Tg is heavily dependent on the sample’s thermal history and water/
solvent content as well as the linear heating rate (107). An example of a typical mDSC
heating scan is shown in Figure 1.13 where the Tg (-0.43°C), crystallization onset (Tc =
65.9°C), and melting point (Tm = 90.5°C) are shown for indomethacin methyl ester.
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Figure 1.13. Standard DSC scan for indomethacin methyl ester showing the glass
transition, crystallization, and melting.
DSC is also particularly suited for the measurement of molecular mobility. Tg is a
rough measure of the temperature at which molecular mobility drastically changes and can
be measured as described above. From a physical stability perspective, crystallization is
the main challenge facing an ASD formulation. Crystallization is a two-step process of
nucleation and crystal growth, both of which require varying levels of molecular mobility
to occur (75). DSC can monitor enthalpic relaxation which is a measure of molecular
mobility below the Tg. Below Tg, the amorphous system is in the non-equilibrium glassy
state and has excess volume and enthalpy relative to the equilibrium crystalline state. The
rate of relaxation towards equilibrium is temperature and time dependent and can be
measured by DSC. After storage below Tg, the enthalpy or volume ‘lost’ to relaxation is
regained through reheating the sample through Tg and measured as an enthalpic relaxation
endotherm at Tg. The integrated enthalpic relaxation endotherms can be fit to the various
equations as a function of storage time to yield relaxation times which indicate molecular
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mobility (108-112). Most often, the Adam-Gibbs-Vogel (AGV) or Kohlrausch-WilliamsWatts (KWW) equations are used to model relaxation in the glassy state whereas the
Vogel-Tammann-Fulcher (VTF), Adam-Gibbs (AG), Williams-Landell-Ferry (VLF)
equations predict relaxation times above Tg (75).
Most often, however, DSC measurements use the KWW equation to predict
relaxation times below Tg as it accounts for a wide range of individual relaxation times
occurring simultaneously. Shamblin and Zografi first applied the structural relaxation
method to sucrose mixtures using the KWW equation (113). Since then, variations of the
method have been applied to a wide range of pharmaceutical systems. Marsac et al.
partially attributed different physical stability characteristics to differences in the relaxation
times of nifedipine- and felodipine-PVP ASDs (58). Bhugra et al. also used KWW
relaxation times in conjunction with dielectric spectroscopy to predict crystallization onset
in various BCS class II drugs (114).
DSC has also been employed to help characterize amorphous solid dispersions
through their thermodynamic and kinetic properties and crystallization propensity. Two
particularly important studies conducted using DSC were by Zhou et al. and Baird et al
(40, 56). Zhou et al. determined the configurational properties of five different drugs and
related the configurational entropy amorphous stability (56). The importance of
configurational properties as a screening tool for stability has been investigated further
although the results have been contradictory at times (57, 58, 115). Baird et al. related the
stability of a glass to their glass forming ability (GFA) as measured by their crystallization
tendency during cooling and heating from the melt (40). The GFA of a drug has since been
shown to directly correlate with a drug’s stability in an ASD (116).
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1.4.4.2 Thermogravimetric Analysis and Vapor Sorption
Thermogravimetric analysis (TGA) is often used in conjunction with DSC as a
secondary thermal analysis method. The experimental set up is very simple as only a
microbalance suspended inside a furnace is required. A sample is placed on the balance
and the mass change is recorded as a function of time and/ or temperature during heating
in a controlled atmosphere. As with DSC, TGA can measure kinetic events and absolute
values measured are highly heating rate dependent (117). TGA is operated in isothermal,
quasi-isothermal (multiple isothermal steps), or dynamic (linear heating rate) modes to
study solvent loss, desolvation kinetics, or thermal degradation in ASDs (13). For example,
Bhujbal et al. estimated the initial water content in lumefantrine ASDs from mass loss upon
heating while Calahan et al. found that differences in the water content of different
magnesium stearate forms partially explained differences in lubrication efficiency,
tabletability, and dissolution (118, 119). Furthermore, Ben Osman et al. investigated ASD
thermal stability found that PVP can either stabilize or destabilize indomethacin or
felodipine ASDs to chemical degradation, respectively (120).
TGA is frequently used in tandem with a spectroscopic technique such as Fouriertransform infrared radiation spectroscopy (TGA/FTIR) or mass spectroscopy (TGA/MS)
for the evolved gas analysis of hydrates or solvates. The volatile compounds evolved
during heating have unique FTIR or MS spectra which may be used to identify evolved
species and better characterize the thermal transitions in the TGA thermogram (25). For
example, Rodriguez and Bugay used TGA-FTIR to reveal water and butyl acetate are
sequentially evolved from a hypercholesterolemia drug upon heating (121).
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1.4.4.3 Dynamic Vapor Sorption
Water vapor sorption is a useful tool for the analysis of sample hygroscopicity.
More broadly, dynamic vapor sorption (DVS) can describe the uptake or water and/ or
other solvents in a controlled environment. Both the chemical and physical stability of a
drug or formulation are affected by exposure to elevated levels of moisture. Therefore, the
ability to characterize the moisture uptake behavior of a solid is a necessary part of drug
development.
Sorption broadly encompasses both adsorption (on the surface) and absorption
(penetration into the bulk of the sample). Each mechanism can be observed and, in some
cases separated, using DVS. In prior iterations, samples were stored in sealed desiccators
over saturated salt solutions. Individual samples were analyzed at periodic timepoints for
mass change or water content using TGA or Karl Fisher titration, respectively. Currently,
the DVS process is automated and mixes water-saturated and dry gas streams in varying
proportions to achieve any relative humidity (RH).
A typical DVS experiment records the equilibrium mass uptake at multiple RH
stages at a constant temperature. The amount of water sorbed by the solid as a function of
temperature is referred to as an isotherm. The extent of water uptake decreases with
increasing temperature, a result of the exothermic nature of absorption. Therefore, the
activation energy of absorption can be determined by recording isotherms at various
temperatures. Figure 1.14 illustrates differences in uptake between a crystalline and
amorphous material.
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Figure 1.14. Dynamic vapor sorption of HPMCAS (HF grade) at 25°C. (A) Water uptake
as a function of relative humidity (blue is % relative humidity, red is % change in mass).
(B) Sorption (red) and desorption (blue) isotherms.
It is often difficult or unreasonable to maintain completely dry (nearly 0% RH)
conditions. Since it was established that water typically negatively impacts the stability of
pharmaceutical solids. Therefore, establishing the uptake behavior of a solid is necessary
to ensure stability over the shelf-life of the formulation. Depending on the material, the
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state of the material, and the RH, different phenomena may occur. The consequences of
water uptake are often physical (plasticization, crystallization, deliquescence, or solvate
transformations) but may also include chemical reactions such as hydrolysis. DVS can
monitor or induce moisture-related transformations. Knowledge of the RH at which these
transformations occur can inform manufacturing or storage conditions to avoid said
transformations.
Most crystalline drugs formulated suited for ASD formulation are hydrophobic and
do not absorb much water. The crystalline lattice is generally impenetrable to diffusing
solvent molecules (122). Rather, surface adsorption is the dominant uptake mechanism in
most crystalline solids except for hydrates or solvates. For significantly polar solids,
deliquescence may occur whereby excessive surface adsorption forms liquid water which
then dissolves the sample (123). For example, sodium chloride (table salt) deliquesces
above 75% RH.
Conversely, the lower density and excess free volume of amorphous solids typically
allows greater uptake than the corresponding crystalline phase and may be further aided by
the formation of hydrogen bonds between the solid and solvent (124). Some
pharmaceutical polymers such as PVP have been shown to absorb nearly 40% of their
weight in water (125). Significant amounts of absorbed solvent further increase the free
volume and molecular mobility of the system thereby plasticizing the amorphous solid.
Moisture-induced plasticization manifests as a reduction in Tg (126). In some cases, the Tg
may be depressed below ambient conditions thus pushing a previously glassy system into
the rubbery state. The plasticization of a system can be monitored by DVS and DSC used
in tandem.
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A second moisture-induced transformation of concern is crystallization. The
enhanced mobility imparted by absorbed moisture can either cause direct crystallization or
amorphous-amorphous phase separation prior to crystallization (67). In either case, the
physical stability has been compromised. DVS can monitor the moisture-induced
crystallization of drug from an ASD. An increasing mass is recorded as the ASD
continually absorbs moisture. However, a sudden decrease in mass at constant or increasing
RH indicates crystallization. Water is not able to incorporate into the predefined crystal
lattice (except for solvates) and the excess water is desorbed from the system. The RH at
which an ASD crystallizes can help to better inform recommended storage conditions for
the final dosage form.
In addition to generating isotherms and helping to characterize moisture-induced
transformations, DVS can also be used to quantify crystallinity. Despite their
methodological differences, multiple research groups successfully quantified amorphous
content in a sufficiently crystalline system (127-129). While there were slight
methodological differences, all took advantage of the different uptake characteristics of the
crystalline and amorphous state and/ or the effect of water content on other physical
properties such as Tg.
Ultimately, DVS uptake measurements can be used to predict product stability.
Transformations such as crystallization or plasticization can typically be measured quickly
in DVS and may be used to predict long-term stability. For instance, Marsac et al. and
Rumondor et al. have used DVS with DSC and infrared radiation to investigate the physical
stability of ASDs. It was found that the additional physical stability imparted by increasing
polymer contents outweighed the increased moisture uptake (67, 130). Futhermore, DVS
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has been used to monitor crystallization kinetics of amorphous solids or ASDs at varying
temperature and humidity conditions (131, 132).
1.4.4.4 Powder X-ray Diffraction
Powder X-ray diffraction (PXRD) is often considered the most definitive method
for detecting crystallinity and has been used extensively for the analysis of ASDs and other
pharmaceutical solids. It is a variation of single-crystal X-ray diffraction and better suited
for pharmaceuticals as PXRD can be performed with small amounts of material, is nondestructive, and can provide both qualitative and quantitative phase information. X-rays
are scattered upon impinging on an object with the diffracted intensity governed by the
Bragg equation (Equation 1.27).
𝑛𝑛𝜆𝜆 = 2𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑

(1.27)

The Bragg equation states that, for an incident angle (θ), a multiple (n) of the wavelength
(λ) must equal twice the distance (d) between diffraction planes (13). In other words,
constructive interference is only observed when the additional distance travelled by X-rays
between two planes, is an integer multiple of the wavelength at a particular incident angle.
A typical PXRD experiment measures a sample’s diffraction pattern across all θ.
Incident angles which satisfy Bragg’s condition result in constructive interference. This
occurs within a crystalline lattice and sharp diffraction peaks are observed. Angles which
do not satisfy Bragg’s condition result in destructive interference and a broad background
signal is observed. This is common in amorphous solids where there is a lack of long-range
molecular order. The broad background signal is therefore often called an amorphous halo.
Although PXRD definitively detects crystallinity, it cannot confirm a sample is
totally amorphous. Rather, samples void of diffraction peaks may be considered ‘X-ray
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amorphous’ (20). PXRD typically has limits of detection and quantitation of 1% and 5%,
respectively (133, 134). PXRD is frequently applied for monitoring process-induced phase
transformations and can detect multiple polymorphic forms (135). ASDs are often analyzed
by PXRD for residual crystallinity or the detection of crystallinity during stability studies
(136). Crystallinity can be quantified using a variety of integration methods including
internal or external standards and whole powder pattern fitting (137). Additionally, in-situ
monitoring of crystallization kinetics can be monitored using variable temperature or
variable humidity PXRD.
The utility of PXRD to analyze ASDs has recently been expanded through a pair
distribution function (PDF) (138). Simply put, a PDF is the inverse Fourier-transformed
total scattering pattern and provides the probability of the spacing of atoms over lengths of
a few angstroms (139). PDF has been used to monitor drug-polymer miscibility in ASDs
and has shown that small changes in polymer structure can significantly impact drug
dissolution (140, 141).
1.4.4.5 Vibrational Spectroscopy
Absorption of infrared radiation (IR) causes the vibration of chemical bonds.
Changes to the dipole moment or polarizability of the bond can be observed and form the
basis of vibrational spectroscopy. Vibrational spectroscopy encompasses all spectral
regions in the infrared range including near-IR (12500-400 cm-1), mid-IR (4000-400 cm1

), and far-IR (400-20 cm-1). All three regions are frequently used to characterize ASDs

(134).
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The frequency of absorbed radiation depends molecular structure and the atoms
forming the chemical bond. The resonant or vibrational frequency is governed by Hooke’s
Law (Equation 1.28):
𝜈𝜈 =

*

%,

P

3

.

(1.28)

where k is the force constant and u is the reduced mass (u=m1m2/(m1+m2)). The force
constant reflects bond strength as carbon-carbon double and triple bonds resonate at higher
wavenumbers than single carbon-carbon bonds. Similarly, the reduced mass increases with
molecular mass (mi). Therefore, chemical bonds containing heavier atoms resonate at
lower wavenumbers (e.g., C-H and C-Cl bonds vibrate at 3000 cm-1 and 800 cm-1,
respectively).
Overlapping overtones and complicated vibrational combinations have limited the
limited the widespread use of near-IR spectroscopy (142). However, it is finding increased
use in the pharmaceutical industry as a process analytical technology and is being applied
as an in- or on-line monitoring tool during manufacturing (143). Similarly, far-IR
(terahertz) spectroscopy has not reached its fully potential in the pharmaceutical industry.
Recently, however, terahertz spectroscopy has seen limited use the advanced
characterization of final dosage forms (144).
Mid-IR spectroscopy broadly encompasses all types of IR between 4000 cm-1 and
400 cm-1 including transmission, attenuated total reflectance (ATR), diffuse reflectance,
etc. (25). It is the most frequently used form of vibrational spectroscopy for the analysis of
ASDs and provides insight into any intra- and intermolecular bonds present. Moreover,
Fourier transform infrared (FTIR) spectroscopy is typically used for this purpose and is the
gold standard for the detection of hydrogen bonding. Specific interactions, such as
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hydrogen bonds, between a drug and polymer are observed as a peak shift to a lower
wavenumber or peak broadening (84). FTIR is regularly used to confirm the presence or
absence of intermolecular interactions (70). Additionally, FTIR can monitor phase
separation (67), detect crystallization (58), and aid in polymorph identification (145, 146).
Whereas FTIR results from the absorbed radiation changing the dipole moments of
bonds, Raman spectroscopy is a result of a change in polarizability due to inelastic
scattering of infrared radiation. Raman spectroscopy is often used as a complementary
technique to FTIR and offers the advantages of rapid analysis time, minimal sample
preparation, and can more easily provide quantitative phase data (147). Comparison of
FTIR and FT-Raman spectra have been used to aid in the assignment of individual
hydrogen bonding species in ASDs (84). Raman also provides the additional advantage of
being using shorter wavelengths than FTIR. The spectral region of 150-50 cm-1
corresponds to lattice vibrations characteristic of unique crystal structures (84). Therefore,
Raman spectroscopy is uniquely suited for polymorphic determination in regions not
visible to mid-IR spectroscopy. Recently, confocal Raman spectroscopy has combined the
advantages of Raman with microscopy to provide a non-invasive analytical tool with
applications to drug discovery, drug delivery, and quality control of final dosage forms
(148).
1.4.4.6 Microscopy
Microscopy provides the only way to directly visualize the pharmaceutical system
of interest and can provide insights not available through other analytical techniques.
Broadly speaking, microscopy is used to correlate particle features on the micro-scale to
bulk physicochemical properties observed on the macro-scale (13). In its most basic sense,
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optical microscopy can view surface details invisible to the naked eye (< 1 mm). Reflected
and transmitted light microscopes are commonly used for observation on a micron-scale
(25).
An optical microscope is perhaps most useful in a pharmaceutical sense when
equipped with a polarizer (polarized light microscopy, PLM). In short, the polarizer
converts visible light into plane-polarized light which interacts differently with isotropic
and anisotropic materials (13). Liquids and amorphous materials, among others, are
isotropic and are invisible under polarized light. Most crystals, however, are anisotropic
and the refracted polarized light appears as colorful shapes with high background contrast.
The diffraction of polarized light in anisotropic materials is called birefringence.
Polarized light microscopy (PLM) has been extensively used for confirming
amorphicity or the detection of crystallinity and can discriminate between the different
crystal shapes of polymorphs or crystals grown under varying conditions (149). In addition,
nucleation and crystal growth kinetics can be monitored at different temperatures using a
hotstage (58, 150). A digital camera and imaging software are often used to continuously
record the crystallization process and measure crystal features including particle size.
In addition to PLM, other forms of microscopy can be used in pharmaceutical
analysis. Scanning electron microscopy (SEM) and atomic force microscopy (AFM) have
found the most success in the analysis of ASDs. SEM uses electrons and an electromagnetic
field rather than polarized light and optical lenses to magnify images and offers higher
resolution (on the order of 10’s of nanometers) compared to PLM (25). SEM has been used
extensively with ASDs with applications including, crystallization onset, particle size
distribution and morphology, as well as the homogeneous distribution of drug in polymeric
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dispersions (138, 151, 152). AFM offers resolution on the nanometer-scale and can actually
be used to manipulate atomic level features in addition to imaging (25). Hence, AFM has
the potential observe the initial stages of phase separation and crystallization in ASDs at
previously unattainable length scales (153).
1.4.4.7 Chromatography
Chromatography encompasses a wide range of methods used for the separation,
identification, and purification of target compounds from complex mixtures.
Chromatographic methods used much more regularly in synthetic or medicinal chemistry
than formulation and drug product development. Reaction products must be purified
repeatedly during synthesis to yield an API or other pharmaceutical ingredient of
acceptable purity. However, there are a few instances where liquid chromatography is
useful for the formulation of ASDs which are highlighted below. Thin layer
chromatography (TLC) was used in this thesis work while high performance liquid
chromatography (HPLC) has had limited usage in the literature.
TLC has been used as a quick and qualitative measure of reaction product purity
during synthesis of drug analogues. For example, the methyl ester of indomethacin
(INDME) has been used as a structural analogue of indomethacin (IND) to investigate how
changes in hydrogen bonding affect ASD physical stability (154). INDME was synthesized
by an acid catalyzed reflux reaction of IND in methanol. Different affinities for the mobile
phase result in different retention factors between IND, INDME, and reaction byproducts.
TLC was used to confirm the conversion of IND to INDME and its subsequent purification.
Many types of HPLC have been used for the extensive characterization of drug
candidates during the drug development process including normal phase, reverse phase,
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gel permeation/ size exclusion, and ion exchange (155). HPLC has served two primary
purposes for the examination of ASDs: detection of chemical degradation and solubility
measurements. Aso et al. used HPLC to monitor for thermally-induced chemical
degradation after the storage of ASDs at high temperatures (156). Marsac et al. and Knopp
et al. proposed a shake-flask method to determine the solid-state solubility of the drug in a
polymer using a low molecular weight analogue or monomer. Excess crystalline drug is
equilibrated in the liquid analogue, filtered, and assayed using reverse phase HPLC. Drug
remaining in solution is then quantified using UV-vis spectroscopy (68, 157). A similar
HPLC-based solubility procedure was proposed using drug and polymer solubilized in a
suitable solvent (158). Despite being a liquid-based technique, HPLC has shown promise
for solid-state pharmaceutical analysis.
1.4.4.8 Nuclear Magnetic Resonance Spectroscopy
Nuclear magnetic resonance (NMR) spectroscopy provides molecular-level
information into the specific nuclei present in a sample as well as its surrounding
environment. Solution-state NMR has been used extensively in drug development for
structural elucidation and identification. However, as most drugs exist as solids, solid-state
nuclear magnetic resonance (SSNMR) spectroscopy provides an advanced in-situ analysis
tool for pharmaceutical solids. Chapter 2 provides an in-depth discussion into the theory of
SSNMR as well as its use in the analysis of amorphous solid dispersions.
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1.5
1.5.1

Thesis Outline
Chapter 1
Chapter 1 briefly describes the solubility issues facing the drug development

process and introduces the amorphous state. The manufacture, analysis, and stability of
amorphous solid dispersions are discussed. The goal of the introduction was to provide a
basic understanding of challenges facing the development of ASDs and the analytical
methods used to investigate and better characterize their physical stability.
1.5.2

Chapter 2
Chapter 2 introduces solid-state nuclear magnetic resonance (SSNMR)

spectroscopy as an analytical technique for the advanced characterization of
pharmaceutical solids, specifically amorphous solid dispersions. The basic theory and
pulse sequences used for pharmaceutical analysis are discussed with an added emphasis on
aspects of data acquisition and processing to ensure quantitative data is acquired.
1.5.3

Chapter 3
Chapter 3 expands upon the quantitative aspects of SSNMR with a case study using

patiromer (Veltassaâ). By accounting for cross polarization dynamics, applying
fundamental relaxation analyses, and manipulating the spin speed, a new method is
proposed and validated for determining the block copolymer composition of the insoluble
amorphous polymer, patiromer. The proposed method may be used for the analysis of other
insoluble block copolymers or for ensuring API sameness during the development of
generic drugs containing polymeric APIs.
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1.5.4

Chapter 4
Chapter 4 investigates the thermodynamics of ASDs using a model nifedipine-

polyvinylpyrrolidone (NIF-PVP) system. Annealing studies were conducted to determine
equilibrium crystallinity at various temperatures. The ability of different analytical
techniques to accurately quantify crystallinity were compared at multiple drug loadings. It
was found that typical DSC methods may not provide an accurate measure of crystallinity
in ASDs, but more sensitive analytical techniques can be applied to measure crystallinity.
In addition, for the first time, PXRD and SSNMR were applied to measure drug-in-polymer
solubility. The results of the crystallinity and solubility study in chapter 4 expand the
options available to a pharmaceutical scientist during formulation.
1.5.5

Chapter 5
As chapter 4 focuses primarily on the thermodynamic considerations of ASD

stability, chapter 5 investigates stability from a kinetic perspective using indomethacin-and
indomethacin methyl ester-PVP ASDs. The impact of drug loading, storage temperature,
and hydrogen bonding on preventing crystallization is explored through an expansive
stability study. Differences in crystallization trends between the two structurally similar
molecules, as well as a previously undetected mode of crystallization, will be discussed.
1.5.6

Chapter 6
Chapter 6 provides a high-level summary of the work completed in this dissertation

and its place within the scientific literature. A better understanding of the impact on
hydrogen bonding on physical stability and new methods for the quantitation of
crystallinity and drug product composition should help to better analyze and formulate
amorphous solid dispersions. While this research helped to answer many questions, the
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physical stability of ASDs is still a very complex topic. Therefore, chapter 6 also includes
research questions which were unanswered and the possible next steps to further the
research in chapters 3, 4, 5, and Appendix A.
1.5.7

Appendix A
Chapters 4 and 5 each investigated the thermodynamic and kinetic stability of

ASDs under dry conditions as to eliminate the effects of water. Appendix observes the
moisture sorption and desorption behavior of different pharmaceutical polymers in the
presence of water and/ or acetone. DVS was used to acquire isotherms under different
conditions representative of manufacturing/ processing steps. In addition, the desorption
behavior was used to provide a better understanding of solvent removal during spray
drying.

Copyright © Travis Wayne Jarrells 2022
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CHAPTER 2: SOLID-STATE NMR SPECTROSCOPY
2.1

Introduction
Nuclear magnetic resonance (NMR) spectroscopy was first measured in 1938 by

Rabi using molecular beams (159). In 1946, Bloch and Purcell each observed the
phenomena for the first time in liquids and solids, respectively (160, 161). Soon after, it
was discovered that changes in the Larmor frequencies of materials were caused by
changes in the chemical bonding state of the atoms (162). Hence, NMR spectroscopy was
born as a way to identify and/ or analyze various materials. Since then, NMR has been
applied across a wide range of industries. Solution NMR has become one of the most
powerful analytical techniques for structure elucidation, chirality/ purity analysis, protein
dynamic studies, and cellular metabolism. However, as the majority of marketed drugs are
solid dosage forms, solid-state NMR (SSNMR) spectroscopy has become an especially
powerful analytical technique for the solid-state characterization of marketed drugs and
drug candidates.
Despite its discovery over 80 years ago and similarities to solution NMR, the
adoption of SSNMR has been much slower in the pharmaceutical industry. Complexities
unique to the solid state make acquiring a high-resolution SSNMR spectrum more difficult
relative to solution NMR. However, techniques now exist to significantly improve spectral
quality and enable high quality SSNMR data acquisition.
This chapter highlights the general theory, techniques, advantages, and limitations
of solid-state NMR spectroscopy as well as its application in characterizing crystalline and
amorphous pharmaceuticals. More comprehensive reviews of SSNMR, including the
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theory, experimental setup, and its pharmaceutical applications exist in the literature (163166).

2.2

NMR Spectroscopy Basics
Spectroscopy is the interaction between matter and electromagnetic radiation. A

given state of matter will vary in its interaction with different regions of the
electromagnetic spectrum. In the case of NMR spectroscopy, nuclei (more specifically,
nuclear spins) interact with the radiofrequency region (< 30 GHz) of the electromagnetic
spectrum.
All nuclei have a nuclear spin quantum number I, with values of 0, ½, 1, 3/2, etc.
however only nuclei with non-zero nuclear spins are observable via NMR. Whereas 1H,
13

C, and 15N are all I=1/2 and NMR-active, some highly abundant isotopes (e.g., 12C and

16

O) are unable to be seen with NMR. The work herein will consider only the I=1/2 nuclei

of 1H and 13C.
Non-zero spin number nuclei possess angular momentum and, in the presence of a
static (external) magnetic field (B0), generate an induced magnetic field or magnetic
moment, µ, shown in Equation 2.1:
𝜇𝜇 =

'UG
%,

(2.1)

where g is the gyromagnetic ratio for a specific nucleus, I is the nuclear spin, and h is
Planck’s constant. The gyromagnetic ratio is a nuclei-specific constant relating magnetic
moment to the nuclear spin number. B0 also causes nuclei that have a magnetic moment (I
≠ 0) to precess around their z-axis at a defined rate known as the Larmor or resonance
frequency (ν = gB0/2π). The Larmor frequency is proportional to the external field strength.
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For example, in a 9.4 Tesla external field strength, 1H nuclei resonate at approximate 400
MHz while 13C nuclei resonate at approximately 100 MHz.
1

H and 13C (each spin-½ nuclei) can exist in either of two energy states (I = ±1/2).

In the absence of a magnetic field, the two spin states are degenerate (equal energy).
However, when placed in a static magnetic field, the Zeeman interaction between the
magnetic moment of the nucleus and the external field causes a separation of nuclear spins
where the energy state of the nucleus changes bases on its alignment with respect to B0.
Spins aligning with the magnetic field (α-state) are in a lower energy state than spins
aligning against (β-state) the external magnetic field. Figure 2.1 illustrates the different
spins state for spin-1/2 nuclei.
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Figure 2.1. The splitting of nuclear spin states for I = 1/2 nuclei in an external magnetic
field. Increasing B0 also increases the population difference between the two energy states.
The observed NMR signal intensity is proportional to the population difference
(∆n0 = nα – nβ) of spins between α- and β-states. This population difference is governed by
the Boltzmann distribution (Equation 2.2) where k is the Boltzmann constant, T is absolute
temperature, and nα and nβ are the number of spins in the α- and β-states, respectively.
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∆5

= 𝑒𝑒 167

(2.2)

The spin states are separated by an energy difference (∆E) directly proportional to the
strength of B0 and gyromagnetic ratio, or, by extension, the resonance frequency, ν
(Equation 2.3).
∆𝐸𝐸 =

'GV8
%,

= ℎ𝜈𝜈

(2.3)

At room temperature, the spin population difference, ∆n0, is very small relative to
the total number of nuclei present in a sample, N. Using Equations 2.2 and 2.3, it is shown
that for a 400 MHz 1H field (9.4 Tesla) at room temperature, approximately only 1 in every
125,000 protons contribute to the population difference and, therefore, the NMR signal.
While signal intensity may be improved through stronger magnetic fields and lower
temperatures, it now is easy to see why NMR suffers from poor sensitivity.
Modern NMR spectroscopy has three main components: the superconducting
magnet, the probe, and the spectrometer. All data is acquired and analyzed at a computer
which is connected the spectrometer. Figure 2.2 provides a schematic of a typical NMR
spectrometer setup. Radiofrequency (RF) pulses of varying intensity, duration, and phase
are programmed on the computer and sent to the spectrometer which contains the hardware
necessary to create such pulses. The spectrometer also contains amplifiers to increase the
intensity of outgoing pulses and incoming NMR signals. The pulses travel through wires
connected to a cylindrical probe. At the end of the probe, the sample is housed within a
copper coil which ultimately exposes the sample to the RF pulses generated in the
spectrometer.
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Figure 2.2. Simplified schematic showing the layout of the cryostat, sample probe,
spectrometer, and computer. Modified from reference (167).
The superconducting magnet is a solenoid wound with niobium alloy wire
immersed in a liquid helium bath (-269°C) to achieve superconducting conditions (166).
This is further insulated by multiple radiation shields and a liquid nitrogen bath to maintain
the solenoid at -269°C while minimizing helium boil off. The housing of the solenoid,
liquid cryogen baths, and all insulation layers is known as the cryostat. The sample probe
sets inside the bore of the solenoid and is positioned such that the sample is located in the
center of the magnetic field generated by the solenoid (B0).
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2.2.1

Theory and the Chemical Shift
SSNMR can be thought of as a three-dimensional coordinate system (Figure 2.3)

where the magnetic fields are represented by vectors (i.e., magnetization vectors). The
external or static magnetic field is applied parallel to the z-axis or perpendicular to the x,yplane. While the external magnetic field alone is enough to separate nuclei into different
spin states, no NMR signal can be measured as no magnetization is in the x,y-plane. The
applied magnetic field (B1) is an additional magnetic field applied as a pulse of RF radiation
perpendicular to B0. When B1 is applied at the Larmor frequency, the net magnetization is
pushed from the z-axis and is allowed to precess in the x,y-plane (Figure 2.3).

Figure 2.3. Three-dimensional coordinate system showing the net magnetization vector
due to the external magnetic field (blue) and immediately after excitation by an applied
magnetic field (red).
The return of the net magnetization to equilibrium creates an alternating current
which is detected in a coil surrounding the sample. Changes in the current with time is
collected as the NMR signal as a free induction decay (FID). The FID is Fourier
transformed into the frequency domain to yield the NMR spectrum. This process is
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repeated multiple times and FIDs are summed together until a spectrum of adequate signalto-noise ratio is acquired.
Up to this point, only the nucleus has been discussed. However, all nuclei (except
protons) are surrounded by electrons. The density of electrons surrounding the nucleus
depends both on the nucleus itself and the local environment near the atom. When placed
in a magnetic field, electrons begin circulating which creates an induced magnetic field
opposing B0. The strength of the induced magnetic field varies between chemically
inequivalent nuclei due to differences in electron density at the nuclei of interest. Electron
donating groups increase electron density around a nucleus causing a stronger induced
field. This ‘shielding’ decreases the resonance frequency of the nucleus as it is exposed to
a slightly weaker magnetic field. Conversely, electron withdrawing groups (e.g., F, OH,
Cl, etc.) ‘deshield’ and decrease the electron density around a nucleus, weakening the
induced field. This ultimately exposes the nucleus to a stronger magnetic field which
resonate at higher frequencies. The different frequencies at which chemically inequivalent
nuclei resonate are known as chemical shifts (δ). After the signal is Fourier transformed,
chemical shifts are plotted on the x-axis with parts per million (ppm) units.
Not only is the chemical shift affected by directly bonded adjacent nuclei, but it is
also impacted by the chemical environment surrounding the nuclei of interest (a throughspace interaction). Therefore, changes in concentration, acidity, solvation, temperature,
and/ or the presence of excipients can all impact the chemical shift. This includes the
formation of hydrogen bonds which deshields the 1H or

13

C of interest, resulting in a

downfield shift. Hydrogen bonds are of particular interest as they are critical to the stability
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of many pharmaceutical compounds including both intramolecular hydrogen bonds in
protein formulations and/ or intermolecular drug-excipient interactions (70, 168).

2.3

Solid-state NMR Spectroscopy
Acquiring high quality solid-state NMR data presents unique challenges not

encountered in the solution state. Most of the challenges stem from reduced molecular
motion in the solid state relative to the solution state. In the solution state, anisotropic
interactions are averaged to zero due to rapid molecular tumbling. Molecules are locked in
a rigid structure in the solid state leading to a variety of interactions between nuclei which
broaden peaks and reduces the resolution and sensitivity of SSNMR. This includes the
Zeeman interaction, dipolar interactions, chemical shift interactions, and scalar interactions
(13).
2.3.1

Chemical Shift Anisotropy and Magic Angle Spinning
Electronic shielding within a magnetic field is three-dimensional phenomenon,

meaning the orientation of a molecule within the field will affect its chemical shift (13).
Thus, while the static magnetic field is homogeneous, the shielding produced by the
electrons is orientation dependent and non-homogeneous within the sample creating
microenvironments where otherwise identical nuclei experience magnetic fields of slightly
different strengths. This phenomenon, known as chemical shift anisotropy (CSA), creates
broad peaks which greatly reduce the resolution of SSNMR.
Rapid molecular tumbling in liquids eliminates CSA in solution state NMR.
However, reduced molecular motion in the solid state means that individual molecules
spend different amounts of time in the x-, y-, and z-axis with respect to the applied magnetic
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field. The shape of the resulting peak is defined by the chemical shielding tensor, σ, which
combines the isotropic (σiso) and anisotropic (σaniso) components. Together, σiso and σaniso
are defined in Equation 2.4 and represent the orientation dependence of the chemical shift
where 𝜃𝜃 is the angle of the sample relative to the applied magnetic field.
𝜎𝜎 = 𝜎𝜎;"C + (3𝑐𝑐𝑐𝑐𝑐𝑐 % 𝜃𝜃 − 1)𝜎𝜎D6;"C

(2.4)

By spinning the sample at 𝜃𝜃 = 54.74°, (3cos2𝜃𝜃 – 1) = 0 and effectively eliminates

the anisotropic component (169). This known as magic angle spinning (MAS). Simply
spinning the sample at the magic angle is not sufficient to completely eliminate CSA.

When spinning at a rate less than the width of the CSA, spinning sidebands (SSBs) appear
as spurious peaks flanking the isotropic peak at intervals equal to the MAS speed (170).
Eliminating SSBs solely by spinning at very fast rates is not always feasible due to rotor
material limitations or bearing capabilities. In this case, the total suppression of spinning
sidebands (TOSS) pulse sequence may be used (see sections 2.3.5 and 2.5.2) (171).
2.3.2

Dipolar Coupling and High-power Proton Decoupling
Dipolar coupling results from the dipole-dipole interaction between the magnetic

dipoles of nearby nuclei. Dipolar coupling can be homogeneous (13C-13C or 1H-1H) or
heterogeneous (13C -1H). Due to their high natural abundance and prevalence in organic
molecules and pharmaceuticals, 1H-1H homonuclear coupling is very prevalent and causes
significant peak broadening. Conversely, as
probability of finding two
Therefore,

13

13

13

C is only 1.1% naturally abundant, the

C nuclei close enough together to couple is extremely low.

C-13C homonuclear coupling does not contribute significantly to SSNMR

linebroadening.
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13
13

C-1H heteronuclear coupling interactions are very common and result in broad

C SSNMR line shapes. By applying high-power 1H decoupling (a high decoupling field

at the 1H Larmor frequency), 1H spins rapidly flip between the α- and β-states. This
averages the interaction of 1H nuclei with

13

C nuclei, effectively averaging the dipolar

interaction to zero (165).
2.3.3

Relaxation
Relaxation is the process by which a material property returns to its equilibrium

state after being perturbed by an external stimulus. In the case of SSNMR, the property is
equilibrium magnetization, and the stimulus is a radiofrequency (RF) pulse. There are
multiple types of relaxation in SSNMR, each affecting different portions of experimental
set up and acquisition. The three relaxation parameters of interest for designing
experiments and acquiring data are spin-lattice relaxation in the laboratory frame (T1), spinspin relaxation (T2), and spin-lattice relaxation in the rotation frame (T1r). Figure 2.4 shows
the difference in each magnetization vector after a 90° pulse.
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Figure 2.4. Time evolution of relaxation vectors after a 90° pulse. T1 (green), T2 (red), and
T1r (purple) Adapted from ref. (172).
After a 90° pulse, all magnetization has been pushed from the z-axis to the x,yplane. The return to thermal equilibrium is governed by the T1 and T2 relaxation times.
Exchange of energy between the excited nucler spins and the lattice results in the return of
magnetization to the z-axis and is known as the T1 (spin-lattice or longitudinal) relaxation
(165). The longitudinal return of magnetization (M) is an exponential process defined by
Equation 2.5:
W

W8

= 𝑒𝑒

9

1X7 Y
0

(2.5)

where M0 is the equilibrium magnetization and t is the recovery/ pulse delay time (161).
Practically, the experimental pulse delay (and experimental time) is determined based on
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the T1. Selecting t = 5T1 effectively ensures all magnetization (99.3%) has returned to
equilibrium and maximum signal intensity is observed. While slow, this is often necessary
for acquiring truly quantitative data. Alternatively, a pulse delay of t = 1.26T1 allows for
collecting the highest signal-to-noise for a given time period and may be preferable when
quantitative data is not required (173).
The magnetization vector in the x,y-plane after the 90° pulse is really the observed
sum of all individual spin vectors. While initially coherent, the spins quickly lose coherence
as the magnetization vector begins to precess at the Larmor frequency. The loss of
coherence is a result of spin-spin interactions without energy transfer to the lattice and is
known as T2 (spin-spin or transverse) relaxation (165). In contrast to the T2 relaxation
which occurs after the 90° pulse is switched off, T1r relaxation can occur if the phase of
the 90° pulse is changed by 90°. An applied RF field about 50 – 100 kHz in strength (or
three orders of magnitude lower than the static magnetic field strength) changes the
magnetization vector phase from the positive x-direction to the y-direction. The
magnetization vector is now spin-locked (locked in place) and will relax to the lattice in
the rotating frame (165). In practice, the T2 relaxation time affects the length of time the
free induction decay (amount of signal) can be acquired while T1r informs the choosing of
an appropriate contact time and provides information about molecular mobility in the kHz
regime.
2.3.4

Low Sensitivity and Cross Polarization
As the NMR signal is directly proportional to the number of distinct nuclei present

in the sample, NMR analysis of low naturally abundant nuclei (e.g., 13C and 15N) is plagued
by low sensitivity resulting in extremely long analysis times. Owing to its almost 100%
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natural abundance and high gyromagnetic ratio, protons present in a sample can be used to
improve the sensitivity and reduce the experimental time of
polarization (CP) (174). When CP is used for

13

13

C SSNMR through cross

C SSNMR, the 1H:13C ratio of natural

abundances (100:1.1), coupled with an approximately 4:1 ratio of gyromagnetic ratios
results in a 3.6-fold increase in sensitivity.
The invention of CP by Pines et al. in 1973, followed by its application with MAS
by Schaefer and Stejskal in 1976 ushered in the modern era SSNMR spectroscopy (174,
175). CP transfers the bulk magnetization from the abundant (1H) spins to the dilute (13C)
spins through spin-locking once the Hartmann-Hahn condition is met. Spin-locking
polarizes the magnetization in the direction of the applied pulse so that it relaxes in the
rotating frame (165). Equation 2.6 shows the Hartmann-Hahn condition where gH and gC
are the gyromagnetic ratios of 1H and

13

C, respectively. The magnetic field frequency

experienced by each nuclei is given by B1,i.

1

(2.6)

𝛾𝛾L 𝐵𝐵*,L = 𝛾𝛾J 𝐵𝐵*,J

H and 13C nuclei normally precess at different frequencies equal to the product of

their respective gyromagnetic ratio and the static magnetic field frequency, B0. By
adjusting the frequency experienced by the individual nuclei (B1,i) the precession frequency
of each nuclei can be tuned. The Hartmann-Hahn condition is met when 1H and 13C each
precess at the same frequency. Nuclei in close proximity to one another now experience
strong heteronuclear dipolar coupling and can exchange magnetization through energyconserving spin-spin magnetization transfer from 1H to
magnetization from 1H to

13

13

C (176). The transfer of

C is governed by two time constants: TCH and T1r. TCH

describes the initial buildup of

13

C magnetization and T1r represents the decay of
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magnetization to the lattice. The amount of time that CP is allowed to occur is known as
the contact time (CT). The importance and effects of TCH, T1r, and contact time are
described further in section 2.5.1. It is important to note that CP efficiency is inversely
related molecular mobility (177). Therefore, as molecules gain mobility at higher
temperatures, the transfer of magnetization becomes less efficient and direct polarization
of 13C nuclei may be required.
13

C T1 relaxation times are extremely long relative to 1H T1 to the point that multi-

pulse direct polarization 13C SSNMR experiments rarely used. However, in addition to the
benefits described above, CP further improves experiment time as it uses 1H relaxation
times rather than 13C. Spin-locked 1H magnetization decays minimally during the 13C free
induction decay (FID) allowing for the process to be quickly repeated and an additional
13

C FID to be acquired (165). This allows for many more acquisitions in a given time period

ultimately improving the signal-to-noise ratio and reducing the time required to acquire a
well-resolved 13C spectrum. The effect of each spectral enhancement technique discussed
in sections 2.3.1, 2.3.2, and 2.3.4 are shown in Figure 2.5.
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Figure 2.5.

13

C SSNMR spectra of nifedipine acquired using different spectral

enhancement techniques. (A) Static (MAS = 0 kHz) CP with high power 1H decoupling
(1x vertical scaling), (B) Static (MAS = 0 kHz) CP with high power 1H decoupling (16x
vertical scaling), (C) CP MAS with TOSS and no 1H decoupling, (D), CP MAS with high
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power 1H decoupling and no TOSS, and (E) CP MAS with TOSS and high power 1H
decoupling.
2.3.5

Pulse Sequences
The various methods discussed in sections 2.3.1, 2.3.2, and 2.3.4 are used to address

the difficulties associated with SSNMR spectroscopy through the application of different
pulse sequences. Due to the low natural abundance (1.1%), low gyromagnetic ratio, and
long relaxation times of

13

C, direct polarization of

13

C is rarely used except in cases of

highly mobile species. Similarly, strong 1H-1H homonuclear coupling results in broad
featureless peaks in the solid state ultimately limiting the use of 1H SSNMR. The direct
polarization pulse sequence is shown in Figure 2.6, however only CP will be discussed
further as it is the predominate pulse sequence used in SSNMR.
Figure 2.7 demonstrates the basic CP sequence as a 90° pulse is applied on the 1H
channel to transfer all magnetization from the z-axis to the x,y-plane. Once the HartmannHahn condition is met, spin-locking is applied perpendicular to the direction of the 90°
pulse allowing the transfer of 1H magnetization to 13C. As 1H magnetization is transferred
to 13C, the 13C magnetization is pushed from the z-axis to the x,y-plane. The amount of
time CP is allowed to occur is the contact time. After CP, high power proton decoupling is
applied to the 1H channel while the signal (free induction decay, FID) is observed in the
13

C channel.
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Figure 2.6. Direct polarization pulse sequence.

Figure 2.7. Cross polarization pulse sequence.
While CP MAS is the workhorse experiment in 13C SSNMR, MAS alone is often
insufficient to spin out chemical shift anisotropy at most feasible spinning speeds. To fully
resolve most peaks in the spectrum, CP TOSS is used to suppress spinning sidebands and
improve peak resolution. Figure 2.8 shows a typical CP TOSS sequence.
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Figure 2.8. Cross polarization with total suppression of spinning sidebands.
The CP TOSS experiment begins exactly the same as a normal CP experiment with
a 90° pulse to the 1H channel and a spin-lock applied to transfer magnetization to 13C nuclei.
During high power proton decoupling, multiple 180° (π) pulses are applied to the

13

C

channel at intervals defined by the MAS rate (171). This serves the randomize the phases
of the SSBs ultimately cancelling out their intensity with minimal impact on the isotropic
peak. The 13C spectrum is then observed while decoupling continues.
Just as one-dimensional CP experiments are used to acquire a

13

C SSNMR

spectrum, similar pulse sequences can be used to measure relaxation times through various
pseudo two-dimensional experiments. Most commonly this includes 1H T1 and 1H T1r
experiments. Each will be discussed further in section 2.4.1.

2.4

Solid-state NMR of Pharmaceuticals and Amorphous Solid Dispersions
Solution NMR has long been used for structural identification pharmaceutical

analysis, however the adoption of SSNMR in the pharmaceutical industry has been much
slower. Only in the last few decades has SSNMR begun to be widely used for
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pharmaceutical solids analysis as it has been realized how ideally suited SSNMR is for
analyzing complex drug products. In particular, SSNMR has found extensive application
in the analysis of amorphous solid dispersions as an emerging formulation strategy (178).
SSNMR can simultaneously analyze all components of a formulated drug product (179).
2.4.1

Miscibility, Proton Relaxation Times, and Molecular Mobility
Section 2.3.3 described the main relaxation processes occurring after excitation of

nuclear spins in a SSNMR experiment. Aside from being used to correctly design a pulse
sequence and acquire the desired spectrum, relaxation times can provide useful data for the
system of interest. While T2 has found greater utility for solution NMR and magnetic
resonance imaging, 1H T1 and T1r can be used extensively for the advanced analysis of
ASDs.
1

H T1 and T1r both offer a measure of molecular mobility on different timescales.

T1 provides information on rapidly occurring motional processes on the order of 10’s or
100’s of MHz such as methyl group rotations. 1H T1 relaxation times have been used as an
estimator of the physical stability of amorphous pharmaceutical systems (178). T1r, on the
other hand, provides information on motions in the 10’s of kHz region (165). In the case
of ASDs, T1 and T1r can also provide a measure of the degree of mixing or homogeneity
in a sample as each value is affected by the process of spin diffusion. Spin diffusion, driven
by dipolar coupling (typically 1H-1H), is the spontaneous exchange of magnetization
between nuclei in close proximity (180). Therefore, differences in 1H magnetization can
be averaged over a given distance through spin diffusion if the sample is homogeneous
while differences will remain if the system is heterogeneous. The length scale of spin
diffusion (L) is given by Equation 2.7:

84

𝐿𝐿 = √6𝐷𝐷𝐷𝐷

(2.7)

where D is the coefficient of spin diffusion (estimated between 0.8x10-11 and 1x10-11 cm2/s)
(180, 181) and t is the relaxation time (either T1 or T1r). Spin diffusion experiments have
been used to estimate homogeneous domain sizes in both polymer blends (180, 182) and
ASDs (85, 183).
The radius over which spin diffusion can average magnetization differences is
determined by the 1H T1 and T1r relaxation times of the various components of the system
and their degree of mixing/ homogeneity. In the case of ASDs, this refers to the amorphous
drug and polymer. Assuming typical amorphous pharmaceutical 1H T1 times between 1
and 5 s and typical T1r times between 2 and 20 ms, homogenous domain sizes can be
determined (85). Common relaxation times are observed in the system is intimately mixed
or homogeneous. Therefore, if the drug and polymer each have common 1H T1 and T1r
times, the system is homogeneous on an approximately 2-5 nm length scale. Similarly, a
homogenous domain size of 5-20 nm is predicted for similar T1 times but different T1r
times while different T1 and T1r times are observed for a system homogeneous only down
to 3.5-11 nm. The comparison of relaxation times is commonly used to measure miscibility
in drug-polymer mixtures. The intimate mixing of drug and polymer is thought to be a
requirement for forming a physically stable system. Therefore, domain sizes measured by
SSNMR may be used as a possible indicator of ASD stability and shelf life (85).
1

H T1 is easily measured by monitoring the return of magnetization to equilibrium

after perturbation by a RF pulse. This is commonly accomplished through a saturation
recovery experiment. Figure 2.9 illustrates a saturation recovery pulse sequence for
measuring T1. Alternatively, an inversion recovery sequence may be used by replacing the
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90° pulse with a 180° pulse. Here, the return of magnetization to equilibrium is initially at
its maximum in the -z direction, decreases through zero, then increases back to equilibrium.
The inversion recovery experiment may be useful in determining small differences in
relaxation behavior of multi-component systems such as ASDs (183). Additional methods
to measure T1 exist in the literature which may be useful in cases where significant spectral
artifacts exist (184).

Figure 2.9. Spin-lattice relaxation (1H T1) pulse sequence. For simplicity, the TOSS
component is not shown.
Graphically, the measured signal intensity for a given nucleus is plotted as a
function of pulse delays. Ideally, a range of pulse delays from nearly zero to greater than
5-times the estimated T1 are used. Figure 2.10 overlays the progression of longitudinal
relaxation with the graphical results of a T1 experiment.
Increasing the duration of the pulse delay increases the fraction of net
magnetization that returns to the z-axis. In turn, there is a greater amount of magnetization
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pushed to the x,y-plane by a subsequent 90° pulse, of which the magnitude is directly
proportional to the measured NMR signal intensity.

Figure 2.10. Schematic and graphical representation of the evolution of net magnetization
during longitudinal (T1) relaxation.
The concept of measuring T1r is nearly the same as for T1 except the spin-lattice
relaxation is now measured in the rotating frame rather than the laboratory frame. A similar
pulse sequence is used (Figure 2.11) to measure the decay of magnetization (M) with
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increasing spin-lock times. The decay is described by Equation 2.8 where (M0) is
equilibrium magnetization and t is the spin-lock time.

𝑀𝑀 = 𝑀𝑀Z 𝑒𝑒

17

9

0:

(2.8)

Figure 2.11. Pulse sequence for measuring spin-lattice relaxation in the rotating frame (1H
T1r). For simplicity, the TOSS sequence is excluded.

2.5

Quantitative Solid-state NMR
NMR signal intensity is dependent on a variety of factors including the sample mass

(m), nuclei present (gyromagnetic ratio, g), magnetic field strength (B0), number of scans
(N), RF pulse intensity (B1), and temperature (T), among others (165). The relationship
between signal intensity and each of these factors is shown in Equation 2.9.
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𝐼𝐼 =
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0

(2.9)

Equation 2.9 shows that NMR is an inherently quantitative technique as the signal
intensity is directly proportional to the number of distinct nuclei present in a sample.
However, it is generally assumed that components of many SSNMR pulse sequences, such
as CP and TOSS, are non-quantitative. While these pulse sequences make acquiring
quantitative data more difficult, properly accounting for experimental parameters still
yields quantitative data.
As was previously mentioned, SSNMR is particularly suited for the analysis of
pharmaceuticals. More so than other analytical techniques, SSNMR provides the advantage
of being able to provide quantitative data on a multicomponent system such as a formulated
drug product. There are many examples in the literature of how SSNMR has been used to
quantitatively analyze a pharmaceutical system. Briefly, SSNMR has shown its utility to
quantify polymorphic forms (185), amorphous phases, homogeneous domain sizes (183),
hydrogen bonding distributions (89), crystallinity, copolymer composition (186), particle
size distributions (187), and water content (188). It is important to note that this list is by
no means comprehensive and was meant only to provide an overview of pharmaceutically
relevant analyses performed via SSNMR.
2.5.1

Cross Polarization Dynamics
When CP is applied to a sample spinning at the magic angle, the transfer of

magnetization from 1H to 13C is time dependent and governed by two time constants. The
initial buildup of magnetization in

13

C is controlled by the CP rate constant, TCH.

Simultaneously, however, 13C magnetization decreases as it dispersed to the lattice. This
rate of decay is controlled by the proton spin-lattice relaxation in the rotating frame (1H
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T1r). The

13

C magnetization profile can be visualized by plotting the observed peak

intensity or area as a function of contact time in which the initial rapid increase in
magnetization (TCH) is followed by a relatively slow decay with time (T1r) (Figure 2.12).
Further complicating things is the fact that the CP rate constants vary both intermolecularly
between different molecular species present in the sample but also intramolecularly
between nuclei in the same molecule. For example, CP to a methyl carbon is inefficient
due to the high mobility of the methyl group whereas magnetization transfers more
efficiently from protons to secondary carbons relative to tertiary carbons due to the
increased number or 1H directly bound to

13

C. In other words, magnetization does not

transfer uniformly to each nucleus. Therefore, the rate constants must be experimentally
determined for each nucleus of interest to ensure quantitative data is acquired. If CP
dynamics are not properly accounted for, relative peak intensities of distinct nuclei will not
be proportional to the amount of each component present (unless TCH and T1r are equal
between each form) (189).
In order to measure TCH and T1r, a variable contact time (VCT) experiment is
needed. A VCT experiment varies the contact time (time that cross polarization is allowed
to occur) in successive CP or CP TOSS experiments. Peak area or intensity (I) is plotted as
a function of contact time (t) and fit to the biexponential Equation 2.10.
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Here, I0 is the thermal equilibrium magnetization intensity, and gH and gC are the
gyromagnetic ratios of 1H and

13

C, respectively. The results of a VCT experiment on

patiromer are shown in Figure 2.12.
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Figure 2.12. Results of a variable contact time experiment showing the cross polarization
dynamics for the various functional groups in patiromer. Adapted from ref. (186).
TCH and T1r can be determined by fitting experimental VCT data to Equation 2.10.
Alternatively, T1r can be solved for through a 1H T1r experiment (section 2.4.1 and Figure
2.11). Figure 2.12 illustrates the importance of a properly selected contact time for
acquiring quantitative data. At short contact times, signal intensity has yet to reach its
maximum value while at longer contact times, T1r relaxation causes a decrease in the
observed signal. Again, the contact time at maximum signal is not necessarily the same
between different nuclei due to non-uniform CP dynamics. To remedy this, signal intensity
in Figure 2.12 is extrapolated back to zero-contact time to approximate an instantaneous
CP process and yield the true intensity for a nucleus. Despite the complex nature of CP
dynamics, there are many examples in the literature of SSNMR being used to quantify
pharmaceutical systems. Offerdahl et al. demonstrated the proper characterization of CP
dynamics for the quantitation of multiple neotame polymorphs and an amorphous form
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(185). Through a similar procedure, Jarrells et al. quantified the relative proportions of
different monomer units in the block copolymer, patiromer (186).
2.5.2

Total Suppression of Spinning Sidebands
Total Suppression of Spinning Sidebands (TOSS) is commonly used in acquiring

SSNMR data, particularly for slow spinning speeds or complex spectra. Despite its relative
ease of implementation, TOSS-simplified spectra can still have quantitative issues. TOSS
eliminates the intensity of SSBs leaving only the intensity of the isotropic peak to be
integrated. Thus, the integrated isotropic peak does not account for all signal associated
with a distinct nucleus. The problem lies in that the CSA pattern may not be consistent
between different nuclei. In other words, varying proportions of signal are contained in the
SSBs for different nuclei potentially leading to significant error if only the isotropic peak
is used for integration.
Ideally, using TOSS can be avoided entirely by spinning the sample fast enough to
eliminate all SSBs. In this case, fast CP MAS is sufficient to ‘spin out’ all SSBs. However,
this is not possible for most samples due to the reduced signal intensity caused by using
smaller rotors that contain less sample. As a result, the SSBs for distinct nuclei must also
be integrated to yield truly quantitative data. This often proves challenging as SSBs may
overlap with other isotropic peaks or SSBs. Repeating a CP MAS experiment at multiple
spinning speeds may be necessary to accurately isolate and integrate all SSBs (185, 186).
2.5.3

Relaxation Time Correction
The magnetization or signal intensity increases exponentially towards the

equilibrium or maximum intensity according to Equation 2.8. Theoretically, as signal
intensity asymptotically approaches its maximum value (see Figure 2.10), an infinite pulse
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delay (t) is needed avoid saturation and truly achieve quantitative data. Therefore,
observed signal intensity (I) must be corrected to account for incomplete relaxation
between successive NMR acquisitions. This is shown in Equation 2.11 where Icorr is the
true/ corrected signal intensity.
𝐼𝐼BC44 =
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In practice, using t = 5T1 approaches equilibrium (99.32%) and is the time typically
chosen for acquiring quantitative data but results in long experimental times. In the interest
of time however, t ≤ 2.5T1 and correction with Equation 2.11 will often suffice. It is
important to note that, in the case of a multicomponent system with varying 1H T1 values,
t = 5T1 refers to the T1 of the component with the longest T1. Otherwise, quantitative data
will be acquired for the faster relaxing components (short T1’s) while the slowest relaxing
component (longest T1) will be underestimated.
2.5.4

Deconvolution
Due to the various linebroadening contributors discussed in section 2.3, many

SSNMR spectra often contain overlapping peaks which may complicate spectral analysis.
Various pulse programs have been devised to help avoid overlap and identify individual
peaks including isotopically labelled spectral subtraction (89, 190, 191), T1r-filtering,
interrupted decoupling (192), and two-dimensional SSNMR. However, in many cases,
peak deconvolution is still needed to better analyze a SSNMR spectrum. Deconvolution
typically refers to the separation of observed overlapping peaks into separate peaks
attributed to different nuclei or species present such that the sum of all individual peaks
equals the total shape and intensity of the observed peak(s). The chemical shift of the
contributing individual peaks may be identified by the methods mentioned above and held
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constant in a fitting procedure to minimize differences between the observed and predicted
spectrum. A representative example is shown in Figure 2.13 for the deconvolution of the
crystalline and amorphous components of nifedipine. The chemical shift and lineshape of
the amorphous and crystalline peaks were determined from a crystalline-free ASD
containing nifedipine and a T1r-filtering experiment, respectively.

Figure 2.13. Deconvolution of overlapping crystalline/ amorphous nifedipine peaks in an
80-20 nifedipine-PVP ASD. The experimental spectrum is shown in black, individual
peaks are shown in red, the predicted spectra is shown in green, and the difference between
the experimental and predicted spectra is shown in blue.
Deconvolution can also be used to acquire semiquantitative data from a multicomponent T1 saturation recovery curve. Just as in a typical single component 1H T1
experiment, the intensity or area under the curve for the peak of interest is plotted as a
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function of the pulse delay (t), however in this case, the peak is composed of different
components. For example, this procedure may be applied to peaks containing both
crystalline and amorphous drug or when there is a bi-modal particle size distribution (187).
Fitting the relaxation data to Equation 2.6 would yield a single T1 time albeit a poor fit to
the data. In this case, a biexponential T1 curve (Equation 2.12) is needed to accurately fit
the magnetization (M) data and yield the T1 of each component.
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Here, M0,i and T1,i represent the equilibrium magnetization and 1H T1 time for each
component (drug and polymer), respectively. The equilibrium magnetization of each
component can also be used to estimate the relative amount of each system component
(187). This is shown in Equations 2.13 and 2.14.
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While the deconvolution of a T1 relaxation time curve can provide useful data for
each component, it is necessary to provide good initial guesses such that the line fitting is
performed on only two components (both T1,i or both M0,i) at a time rather than four
components (all T1,i and M0,i) simultaneously. For example, Dempah et al. used dicumarol
samples with uniform particle size distributions to determine initial T1 estimates for
bimodal mixtures of unknown composition (187).
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2.6

Conclusions

The general theory of NMR was discussed and some of the key differences highlighted
between solution-state and solid-state NMR. The intricacies of SSNMR were examined
with an emphasis on ensuring quantitative data is acquired. The various applications for
the advanced analysis of amorphous pharmaceuticals were also surveyed. Chapter 2 has
shown not only the complexity of SSNMR but also the incredible potential it possesses,
particularly for the analysis of amorphous and other complex pharmaceutical systems.

Copyright © Travis Wayne Jarrells 2022
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CHAPTER 3:QUANTIFICATION OF MONOMER UNITS IN INSOLUBLE
POLYMERIC ACTIVE PHARMACEUTICAL INGREDIENTS USING
SOLID-STATE NMR SPECTROSCOPY
3.1

Introduction
Polymers with desirable pharmacological properties are used in some drug

formulations as the active pharmaceutical ingredient (API) rather than their traditional role
as an inactive excipient or drug-delivery vehicle (193-201). The macromolecular size of
polymers, advances in polymerization techniques, and an improved understanding of
ligand-receptor interactions have increased the potential for polymers to be used as the API
(193). Multivalent insoluble polymers have found the most success as sequestrants,
whereby the polymer is typically used to bind excess ions, bile acids, or other unwanted
moieties in the gastrointestinal (GI) tract (202-207). Patiromer (Veltassaâ), sevelamer
(Renagelâ and Renvelaâ), and colesevelam (Welcholâ) have all been approved by the FDA
as

polymeric

APIs

for

treating

hyperkalemia,

hyperphosphatemia,

and

hypercholesterolemia, respectively, through binding in the GI tract (208-211). Polymeric
APIs have also been investigated as potential antiviral (212) and antimicrobial drugs (213215), as well as potential cancer treatments (216, 217).
Pharmaceutical polymers often contain some level of variation. This may come in
the form of molecular weight or chain-length (74), tacticty (218), crystallinity (219), and/
or side-chain substitution (219, 220) and can vary between chemical suppliers (221). The
__________________________
This chapter is adapted with permission from Jarrells, T. W.; Zhang, D.; Li, S.; Munson,
E. J. Quantification of monomer units in insoluble polymeric active pharmaceutical
ingredients using solid-state NMR spectroscopy I. Patiromer. AAPS PharmSciTech 2020,
21 (3), 116. Copyright © 2020 American Association of Pharmaceutical Scientists.
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aforementioned variations in polymers may result in batch-to-batch variations which could
affect drug performance (222). However, when the polymer itself is the API, extensive care
must be taken to control batch-to-batch variability of the polymer (223).
A pharmaceutical manufacturing process is typically monitored for quality control
during or post-production. During manufacture of the API, process analytical technologies
(PAT) are used for in-line, on-line, or at-line analysis techniques to monitor and control
critical parameters to ensure a consistent drug product. Post-production, critical quality
attributes of a drug substance or intact drug product can be analyzed to ensure it is within
acceptable limits. The ability to characterize a formulation across multiple lots or batches
of different dosage strengths is critical for ensuring product uniformity. Similarly, the
ability to conduct a detailed characterization of a drug product is necessary to demonstrate
API sameness in generic drug development. As polymeric APIs do not strictly fit into a
small molecule or biologic drug category, their analysis and characterization pose a
significant regulatory and development challenge (202, 224).
Complex insoluble polymers and polymeric APIs are particularly difficult to
analyze compared to soluble polymers as typical solution-based analytical methods often
cannot be used (225). Fourier transform-infrared (FTIR) spectroscopy and Raman
spectroscopy are used to identify the presence of different functional groups. Peak shifts in
FTIR spectra can indicate changes in drug product composition but is semiquantitative at
best. Near infrared (NIR) spectroscopy has been successfully implemented for PAT
monitoring due to its quick analysis times and little-to-no sample preparation (226, 227).
It has been used for determining copolymer composition (228) and the quantitation of
certain functional groups in pharmaceuticals (229). However, use of NIR for quantitation
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often relies on a reference or calibration standard and/or the use of chemometric methods
(143). Different mass spectrometry (MS) techniques have been used for polymer analysis.
Matrix assisted laser desorption/ionization time-of-flight (MALDI TOF) MS has been
successfully used for the determination of molecular weight distribution and copolymer
composition of poorly soluble and insoluble polymers (230, 231). Despite these successes,
MALDI TOF sample preparation requires the use of a matrix additive while the use of
chain statistics and model optimization is necessary to analyze results (232, 233).
Solid state nuclear magnetic resonance (SSNMR) spectroscopy is a non-destructive
and sensitive analytical technique which can be used to provide information about structure
(190), physical form (179), molecular mobility, miscibility (85), and molecular interaction
(89). Most importantly, SSNMR is an inherently quantitative technique as the signal
intensity is directly proportional to the number of a distinct nuclei present in the sample
that resonate at a given frequency (185). This provides a significant advantage over many
other solid state analytical techniques in that no pure standards are needed nor is a
calibration curve required (234). Cross polarization (CP) is used to increase the sensitivity
of SSNMR by transferring polarization from abundant spin (1H) to dilute spin (13C) nuclei
(174). CP dynamics are governed by two time constants, TCH and T1r, which correspond
to the transfer of magnetization from 1H to

13

C nuclei and the subsequent decay of

magnetization back to equilibrium, respectively. Because CP is not an instantaneous
process, TCH and T1r must be experimentally determined when CP is used in quantitative
SSNMR. Failure to do so can result in misleading quantitation outcomes if the dynamics
vary between distinct nuclei (185, 189). When CP dynamics are properly accounted for,
SSNMR has been used in the quantitation of different polymorphic forms and amorphous
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content (185), drug-polymer hydrogen bonding configurations (89), as well as block
copolymer domain sizes and diffusivity measurements (180). SSNMR can therefore be
used to answer a variety of questions even in complicated formulations.
Patiromer (Veltassaâ) is an FDA-approved drug currently marketed for the
treatment of hyperkalemia (235). It is an amorphous insoluble polymer which is
administered orally by suspending in water and works by binding free potassium ions in
the gut. Patiromer is not systemically absorbed and is eliminated, along with the bound
potassium, through fecal excretion (208, 235). The drug product is a block copolymer
consisting of three monomer units and a calcium-sorbitol counterion (Figure 3.1). Per the
package insert, the potassium-binding portion of the drug, 2-fluoro-2-propenoate monomer
(m-block), makes up 91% of the formulation. The remaining 9% is a combination of the
crosslinking groups diethenylbenzene (n-block) and octa-1,7-diene (p-block). Two grams
of calcium-sorbitol counterion is also included for each gram of patiromer in the
formulation (208). The amount of crosslinker present is used to control the swelling ratio
of patiromer when exposed to water or gastrointestinal fluid while the relative amount of
each crosslinker used presumably helps to fine-tune the amount of swelling for a given
amount of m-block (223, 236). Patiromer was chosen for analysis as a model polymeric
drug product which currently has no approved generic equivalent. Analysis of patiromer
may serve as a model for the analysis of other FDA-approved polymeric APIs, multiple
polymeric APIs in development, as well as for demonstrating API sameness in generic drug
development.
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Figure 3.1. Patiromer chemical structure. m=2-fluoro-2-propenoate groups, n =
diethenylbenzene groups, p = octa-1,7-diene groups. The extended polymeric network is
indicated by the asterisk (*) and •H2O indicates associated water.
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The specific goal of this work was to develop a method to quantify the relative
amounts of each type of monomeric units present in the copolymer patiromer. The method
can be applied as a process analytical technique for quality control between batches during
manufacturing as well as a discriminating tool for demonstrating API sameness for generic
drug development. SSNMR is perfectly suited to meet the goals of this method
development and was used to analyze various patiromer lots. This was done by first
identifying, evaluating, and quantifying the carboxylate, aromatic, and aliphatic groups in
the drug molecule using a variety of 13C-SSNMR techniques. This included accounting for
the CP dynamics to ensure quantitative data. When compared to published values, the
newly developed SSNMR method successfully quantified the amount of carboxylate
groups present in intact patiromer while also providing the previously unknown relative
amounts of aromatic and aliphatic monomer groups. The relative monomer ratios in
different lots of patiromer were then compared to investigate lot-to-lot variations and
further validate the new method. Development of new analytical methods, such as the
SSNMR methodology presented herein, make the advanced characterization of complex
polymeric API possible.

3.2

Materials and Methods
In total, seven lots of patiromer were analyzed. These samples included three

dosage strengths (8.4 g, 16.8 g, and 25.2 g) and samples that had previously expired (Table
3.1). Lots A, B, and C were purchased from the Purdue University pharmacy (West
Lafayette, IN) while four expired lots (lots D, E, F, and G) were also obtained and
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evaluated. All samples were shipped to the University of Kentucky College of Pharmacy
(Lexington, KY) for analysis.
Table 3.1. Properties of analyzed patiromer lots.
Lot

Dose Strength (g)

Expiration Date021

A

8.4

2021

B

16.8

2021

C

25.2

2020

D

8.4

2017

E

8.4

2018

F

16.8

2018

G

25.2

2017

3.2.1

Solid-state NMR
All SSNMR experiments were acquired using a Tecmag Redstone HF3 2RX

spectrometer (Tecmag, Inc., Houston, TX) operating at 75.48 MHz for

13

C. All

experiments were acquired using cross polarization (174), magic angle spinning (MAS)
(169), SPINAL64 decoupling (237) with a 1H decoupling field of approximately 64kHz,
and, unless otherwise noted, performed using a 7.5 mm double-resonance MAS probe
(Varian, Palo Alto, CA) at 20°C. An external standard, 3-methylglutaric acid, was used to
optimize the spectrometer parameters. The methyl peak was referenced to 18.84 ppm (238).
Approximately 350 mg of patiromer was packed into a 7.5 mm rotor with Teflon or Kel-f
endcaps.
The spin-lattice relaxation time (1H T1) was measured using a saturation-recovery
pulse sequence through 13C observation, with 4096 scans collected, each containing 512
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acquisition points. A peak (typically carboxylate) in the Fourier-transformed spectra was
integrated and plotted against recovery delay times according to Equation 3.1.
M = Ma d1 − e1b⁄c0 f

(3.1)

M is the integrated peak intensity and t is the recovery delay time (234). Mo is
obtained from the fitting procedure and T1 is the spin-lattice relaxation time. TNMR
(version 3.3.9) software was used to plot and analyze the data.
When a solid sample is spun at the magic angle in a solid-state NMR spectrometer,
magnetic field inhomogeneities often exist within the sample and result in the presence of
spurious peaks known as spinning sidebands (SSBs) (170). In order to acquire a basic
patiromer spectrum free of SSBs, a sample (lot A) was spun at the magic angle using a CP
with total sideband suppression (TOSS) pulse sequence (171). A 3 ms contact time (CT)
was used and, based on the 1H T1 of the sample, a 10 s pulse delay (PD). A total of 4096
scans with 512 acquisition points were obtained with the data zero-filled to 4096 points
and no line broadening applied.
A variable contact time (VCT) experiment was conducted to determine the CP
dynamics and select an appropriate CT. A series of CP TOSS experiments spinning at 4
kHz varied the CT from 0.5 to 10.0 ms and the integrated signal intensity of each peak was
plotted on a logarithmic scale as a function of CT. The integrated signal intensity is
extrapolated to zero-CT and used as the true intensity for each functional group.
The spin-lattice relaxation time in the rotating frame (1H T1r) and CP rate constant
(TCH) were determined through the VCT experiment by fitting the signal intensity as a
function of CT to Equation 3.2 (234).
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M is the peak area for each contact time (t) and Mo is the thermal equilibrium
magnetization. gC and gH are the gyromagnetic ratios for 13C and 1H, respectively.
T1r can also be determined through a 1H T1r experiment. The same patiromer sample (lot
A) as in the VCT experiment was used in which 512 scans and 512 acquisition points were
collected using a 10 s PD and 3 ms CT. TNMR and Microsoft Excel (version 16.26) were
used to plot and analyze the data.
To further aid in assigning peaks to each functional group, interrupted decoupling
was used. An interrupted decoupling spectrum was acquired identically to the CP TOSS
spectrum only with a 50 µs dipolar dephasing time at the beginning of signal acquisition
to identify the number of protons directly bound to each 13C atom.
To prevent any signal intensity from being lost due to using TOSS (189) or from
SSBs that are located underneath (at the same chemical shift) as other peaks, CPMAS
spectra without TOSS were acquired at varying spin speeds. All CP spectra were acquired
using the same rotors and endcaps as listed previously. Again, 4096 scans each containing
512 acquisition points were collected with a 10 s pulse delay (PD), 3 ms CT, and 64 kHz
proton decoupling field. The MAS frequencies ranged from 3 kHz to 12.5 kHz with 6 kHz
being used for quantitative analysis.
CP efficiency is inversely related to molecular mobility (177). A low temperature
CP TOSS spectrum was acquired to identify and resolve any mobility issues that may exist
in patiromer. Lot A was run at -20°C with TOSS parameters identical to other CP TOSS
spectra acquired. Compressed air gas was diverted through a copper coil that was
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submerged in a liquid nitrogen dewar before being directed towards the spinning rotor.
Once the outlet temperature reached -20°C, the sample was equilibrated for 15 minutes
prior to spectral acquisition.
The calcium-sorbitol counterion was washed out of some patiromer samples to
investigate if the presence of sorbitol in the drug product was affecting the NMR signal
intensity of other functional groups. Two 8.4 g samples of lot A were each dissolved in 100
mL of deionized water, stirred at 400 rpm for four hours, and vacuum filtered through a P5
filter. One sample was dried at 40°C overnight while the other was dried under 25 in Hg at
20°C overnight. Samples were packed in 7.5 mm zirconia rotors and scanned by SSNMR
(CP, T1, and T1r) using the conditions previously described. The resulting spectrum showed
a small peak present between 55 and 80ppm indicating that the counterion was nearly
completely washed from the patiromer (Figure 3.2). Minimal changes in the intensities of
other peaks were detected.

Figure 3.2. Overlaid 13C CP spectra at 6.5 kHz MAS before and after washing in water,
filtering, and drying to remove sorbitol.
It was not possible to formulate standard samples of patiromer to use in method
validation. Therefore, calculations were performed on theoretical standard samples
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containing known amounts of n- and p-block crosslinking groups. Additionally, monomer
compositions of seven different patiromer lots were successfully quantified and served to
help validate proposed SSNMR method.
3.2.2

Data Processing
All quantitative SSNMR spectra were phased identically using TNMR ‘Phase

Adjustment.’ The downfield carboxylate SSB peak (approximately 257 ppm) was phased
using zero-order phasing. Where necessary, minimal first-order phasing was used to phase
the rest of the spectrum.
The baseline of each quantitative CPMAS SSNMR spectrum was corrected using
TNMR ‘Baseline Fix.’ A 14-point spline was applied to the previously-phased spectrum.
Care was taken to avoid fixing the baseline on any SSB. Multiple points were applied far
upfield and far downfield of the spectrum with only two points applied in the chemical
shift range of interest (approximately at 118 and 158 ppm).

3.3

Results and Discussion

3.3.1
3.3.1.1

Initial SSNMR Acquisitions of Patiromer
1

H T1 Relaxation Time

The proton spin-lattice relaxation time (1H T1) was determined using a saturationrecovery pulse sequence. This measured the return of magnetization to equilibrium as a
function of different pulse delays and was used to determine the appropriate pulse delay
for the study of patiromer. The initial lot A sample was spun at 4 kHz MAS for 512 scans
and 1024 acquisition points and the results were fitted to Equation 3.1. The 1H T1 for the
carboxylate was found to be 3.20 ± 0.09 s.
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3.3.1.2 CP TOSS Spectrum at 4kHz MAS
Based on the 3.20 s 1H T1 collected, a pulse delay of 10 s was selected for the initial
acquisition of a patiromer spectrum (173, 234). The same patiromer sample was used to
acquire a CP spectrum. TOSS was used so that SSBs would not complicate the spectrum
nor the subsequent assignment of peaks to each functional group. Based on the reported
chemical structure (Figure 3.1) and literature values, it was expected that the main signals
would resonate at 20 – 50 ppm (aliphatic), 60 – 80 ppm (sorbitol), 80 – 100 ppm
(quaternary), 120 – 140 ppm (aromatic), and 170 – 180 ppm (carboxylate).
Figure 3.3 shows the CP TOSS spectrum of patiromer lot A acquired at 4 kHz MAS
and 1.5 ms CT. As expected, resonances appear in each of the chemical shift regions of
interest. The most intense peak at 177 ppm was assigned to the carboxylate carbon in the
m-block carboxylate group. Similarly, the m-block also contains the quaternary/ a-carbon
which is directly bound to fluorine at 95 ppm. The two peaks at 127 and 144 ppm were
both assigned to aromatic carbons. Presumably, as the n-block can have meta- or paralinkages, the peak at 127 ppm has a bound proton while the peak at 144 ppm has no bound
protons. The broad aggregate of peaks centered at 45 ppm is assigned to all aliphatic
carbons in patiromer. This includes all of the p-block as well as the backbone aliphatic
carbons in the m- and n-blocks. The remaining broad peak between 60 and 80 ppm is
assigned to the three distinct carbons in sorbitol. The bound hydroxyl groups act to deshield
each carbon and resonate farther downfield than the aliphatic nuclei.

108

Carbonyl (m)
Sorbitol
Aliphatic (p)

Quaternary (m)
Aromatic (n)

CPTOSS
Interrupted Decoupling
180

160

140

120

100

80

60

40

20

0 ppm

Figure 3.3. Initial CPTOSS spectrum acquired at 4 kHz MAS with labeled functional
group ranges (top) and interrupted decoupling CP TOSS spectrum (bottom). (m, n, and p
correspond to the patiromer polymer block in which each functional group is found).

As an additional check to confirm the peak assignments were correct, a CP
spectrum was acquired using interrupted decoupling. For a short time prior to signal
acquisition, the proton decoupler was turned off and 13C nuclei strongly coupled to protons
(-CH- and -CH2) rapidly dephased. The dephased peaks were expected to show reduced or
no signal relative to the CP TOSS spectrum (Figure 3.3). The peak at 127 ppm disappears
in the interrupted decoupling spectrum which confirmed its assignment as the aromatic
carbon with a bound proton.
Likewise, the peak at 144 ppm showed no change in intensity as it is the aromatic
carbon with no bound protons. Furthermore, the peak between 60 and 80 ppm (sorbitol)
completely dephased along with the broad aliphatic peak (45 ppm) as each carbon contains
one or two bound protons.
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3.3.2

Quantitative Aspects of Cross Polarization
As CP was used to acquire data, multiple parameters had to be measured and

optimized before quantitative SSNMR data was acquired.
3.3.2.1 Cross Polarization Dynamics
The transfer of polarization from abundant spin nuclei (1H) to dilute spin nuclei
(13C) is a non-instantaneous process which is highly dependent on the number of protons
directly bound to the dilute spin nuclei (174, 177). Depending on the time allowed for the
sample to cross polarize (contact time), certain nuclei may appear to have a greater
integrated intensity than is actually present (185, 234). To account for this and choose an
appropriate CT, a VCT experiment was performed. CP TOSS experiments were performed
in series with the CT ranging from 0.5 ms to 10.0 ms.
The rise and decay in peak intensity is displayed graphically in Figure 3.4. The
intensity of different peaks can change drastically, and at different rates as a function of
CT. All functional groups in patiromer reached their maximum magnetization intensity
within 2 ms. However, the aliphatic peak reached its maximum quicker than the
carboxylate group. Using data points at long contact times, extrapolating back to zero
yields the ’true’ signal intensity (234). For the carboxylate, aromatics, quaternary, and
aliphatic peaks, the signal area at zero CT was 2.245, 2.548, 2.585, and 2.419 times as
intense as it was for a 3 ms CT, respectively. The total signal intensity of carbon (which
includes the isotropic peak and all associated SSBs) was multiplied by its appropriate ratio
which better approximates the peak area of each carbon if the CP process was
instantaneous.
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Figure 3.4.

13

C CP TOSS 4 kHz MAS variable contact time trends for different carbon

atoms in Patiromer. The intensity scale is in arbitrary units.
3.3.2.2 Chemical Shift Anisotropy
While TOSS is useful for simplifying spectra and identifying isotropic peaks, some
signal is typically lost when SSBs are suppressed (189). When integrating peaks for
quantitative purposes, it is critical to include all signal, including that from SSBs. For this
reason, a CPMAS spectra without TOSS was acquired to determine if significant signal
intensity was contained in SSBs. As can be seen in Figure 3.5, compared to the CP TOSS
spectrum, CP exhibits significant SSBs. The SSBs are particularly noticeable at 16, 207,
224, and 257 ppm. Failure to include all SSBs during peak integration would underestimate
the number of carboxylate and aromatic groups present in each lot of patiromer.
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Figure 3.5. Overlaid 13C CP and CP TOSS spectra at 6kHz MAS used to identify signal
loss due to the use of TOSS in patiromer lot A.
Once it was identified that the patiromer spectrum contained sufficient SSBs, CP
MAS spectra were acquired at varying spin speeds to determine the location and intensity
of each SSB. SSBs are located on each side of the isotropic peak, and, as shown in Equation
3.3, separated by intervals directly proportional to the MAS frequency (239).
SSB Spacing =

eij klfmnf:op (qr)

jhfoslatfsfl klfmnf:op (eqr)

(3.3)

As spin speed is increased, SSBs spread out and reduce in intensity relative to the
isotropic peak. At speeds (frequencies) greater than the chemical shift anisotropy, SSBs
are fully eliminated and all intensity is contained in the isotropic peak.
Spinning at 4 kHz, the SSBs were located approximately 53.5 ppm apart. Figure
3.6 shows that 4 kHz CP exhibits significant SSBs which overlap with other peaks. As the
TOSS pulse sequence is known to reduce the absolute intensity of the isotropic peak, the
contribution of the SSB relative to the peaks it overlaps with is unknown without further
investigation. Spinning at 3 kHz makes SSBs more prominent yet increases the amount of
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overlap in the spectral range of interest. Spinning at 6 kHz, separates carboxylate and
aromatic SSBs while causing the carboxylate and quaternary SSBs to overlap.
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C CP spectra acquired at varying MAS speeds used to

identify the location and change in intensity of spinning sidebands. Black, green, blue, and
red symbols above peaks correspond to the peaks for carboxylate, aromatic (without bound
protons), aromatic, (with bound protons), and aliphatic carbons, respectively. ^ indicates
the peak is the isotropic peak while * indicates a spinning sideband.
Typically, quantitative SSNMR spectra should be acquired at the fastest spin speed
possible to minimize chemical shift anisotropy. However, in the current experimental set
up, the 7.5 mm rotor was only able to spin to a maximum of 6.5 kHz. In order to spin faster,
a switch to a 4 mm rotor was made with spin speed capabilities up to 12.5 kHz. While
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spinning at 12.5 kHz eliminated all overlapping SSBs, the sensitivity was also largely
reduced (data not shown). The gain in spin speed is offset by the decrease in sensitivity due
to a reduced sample volume (350 mg vs. 50 mg). Within a reasonable timescale, this results
in a signal-to-noise ratio inadequate for quantitative data acquisition. For this reason, the
decision was made to use a 7.5 mm rotor spinning at 6 kHz for all quantitative calculations.
It should be noted that in cases where potent or expensive APIs may limit the amount of
drug available, the longer acquisition time may be necessary to obtain adequate quantitative
data using this method.
Despite the carboxylate and quaternary SSBs overlapping at 6 kHz MAS, this spin
speed was chosen for analysis as it provides good separation of other SSBs. The chemical
shift of all isotropic peaks, along with any SSBs are listed in Table 3.2. Additionally, as
the carboxylate and quaternary carbons only appear in the m-block of patiromer, this was
not a major issue for quantitative purposes. As seen in Figure 3.6, the carboxylate and
aromatic carbons express only first-order SSBs (one on each side) while the quaternary
carbon also contains second-order SSBs, each of which is integrated and added to its
respective isotropic peak intensity.
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Table 3.2. Isotropic chemical shifts and associated spinning sidebands at 6kHz MAS.
Peak

Isotropic

Downfield 1st-

Upfield 1st-

Downfield

Upfield 2nd-

Chemical

Order SSB

Order SSB

2nd-Order SSB

Order SSB

Shift (ppm)

(ppm)

(ppm)

(ppm)

(ppm)

Carboxylate

177

257

97

N/A

N/A

Aromatic (no 1H)

144

224

64

None

None

Aromatic (w/ 1H)

127

207

47

None

None

Quaternary

96

176

16

256

-64

3.3.2.3 Molecular Mobility
Certain functional groups inherently possess greater molecular mobility than
others. As CP efficiency is inversely related to mobility, different functional groups may
polarize to varying degrees if their molecular mobility is different (177, 240). Therefore, a
patiromer (lot A) sample was cooled to -20°C using liquid nitrogen-cooled air while
spinning at 4 kHz in the NMR spectrometer. This ensured that signal intensity was not lost
due to mobility-induced variations in CP efficiency.
Figure 3.7 overlays patiromer spectra at two different temperatures. The spectral
shape of each resonance is roughly the same, indicating that there are no major differences
between the room temperature and cooled samples. When the low-temperature spectrum is
normalized to the 20°C sorbitol resonance, the intensities of the carboxylate, aromatic, and
quaternary carbons all increase slightly while the aliphatic intensity is approximately the
same. This may indicate that the carboxylate, aromatic, and quaternary carbons possess
greater mobility than the aliphatic carbons at higher temperatures. It should be noted that
the TOSS parameters were not fully optimized at 20°C (evidenced by the partially folded
SSB at ~230 ppm). Properly optimized TOSS parameters completely eliminate SSBs and
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fold their intensity back into the centerband. In this case of suboptimal TOSS parameters,
the SSBs of the carboxylate, aromatics, and/ or quaternary peaks may exist underneath
other peaks and contribute to their reduced intensity at 20°C. Therefore, it may be safely
assumed that mobility is not an issue when quantifying patiromer.
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4 kHz MAS CP TOSS spectra of Patiromer lot A acquired at

different temperatures. Peak intensities were normalized to the sorbitol peak.
3.3.2.4

1

H T1 & T1r Relaxation Times

Both the 1H T1 and T1r values were calculated for different carbon atoms as part of
accounting for CP dynamics. The proton spin-lattice relaxation time (1H T1) for each lot of
patiromer was determined using a saturation-recovery pulse sequence. The T1r for each
patiromer lot was calculated either by fitting Equation 3.2 to the results of the VCT
experiment or by varying the spin-lock duration following a 90° pulse (T1r experiment)
(181, 241). Table 3.3 shows the T1 and T1r for each patiromer lot as well as for each
isotropic peak in the spectrum. Aromatic T1r values (127 and 144 ppm) were not
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determined as the signal-to-noise was too low in the chemical shift range to acquire
accurate values.
Table 3.3. Isotropic peak 1H T1 and T1r values for each patiromer lot.
Lot

Dose (g)

Exp. Date

A

8.4

2021

B

C

D

E

F

G

16.8

25.2

8.4

8.4

16.8

25.2

2021

2020

2017

2018

2018

2017

177ppm

144ppm

127ppm

95ppm

71ppm

44ppm

T1

1.76 ± 0.05

1.60 ± 0.09

1.41 ± 0.09

1.71 ± 0.04

1.75 ± 0.05

1.81 ± 0.10

T1r

3.01 ± 0.19

3.13 ± 0.22

3.26 ± 0.07

3.33 ± 0.15

T1

1.80 ± 0.04

1.72 ± 0.02

1.74 ± 0.03

1.75 ± 0.03

T1r

3.11 ± 0.26

3.07 ± 0.26

3.18 ± 0.15

3.01 ± 0.17

T1

2.18 ± 0.06

2.07 ± 0.06

2.16 ± 0.06

2.23 ± 0.11

T1r

3.09 ± 0.14

3.58 ± 0.37

3.21 ± 0.16

3.86 ± 0.21

T1

1.55 ± 0.03

1.42 ± 0.02

1.42 ± 0.02

1.45 ± 0.02

T1r

2.98 ± 0.30

3.69 ± 0.44

3.06 ± 0.11

3.40 ± 0.29

T1

1.84 ± 0.06

1.70 ± 0.05

1.77 ± 0.07

1.79 ± 0.09

T1r

3.36 ± 0.21

3.37 ± 0.36

3.13 ± 0.06

3.71 ± 0.19

T1

1.63 ± 0.03

1.53 ± 0.03

1.58 ± 0.02

1.56 ± 0.03

T1r

3.23 ± 0.13

3.26 ± 0.57

3.15 ± 0.17

3.45 ± 0.26

T1

1.61 ± 0.03

1.51 ± 0.02

1.52 ± 0.02

1.52 ± 0.03

T1r

3.30 ± 0.21

3.26 ± 0.49

3.05 ± 0.09

3.70 ± 0.23

1.48 ± 0.16

1.68 ± 0.19

1.32 ± 0.09

1.56 ± 0.15

1.32 ± 0.12

1.40 ± 0.10

1.43 ± 0.08

1.83 ± 0.11

1.24 ± 0.09

1.53 ± 0.09

1.31 ± 0.07

1.35 ± 0.09

The 1H T1 provides a measurement of the time it takes for magnetization to return
to equilibrium in the sample. Other pharmaceutical systems have observed variations in T1
linked to differences in formulation/ processing, which, in turn, has also been related to the
physical stability of samples and their predicted dissolution profiles (221, 242).
In general, all peaks have similar T1 values, indicating a homogeneous sample.
However, both aromatic peaks have significantly shorter T1 values compared to the
carboxylate peak. Shorter aromatic T1 values may simply be a result of inherently lower
mobility in aromatic crosslinkers relative to other functional groups.
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T1 values were compared on a lot-to-lot basis, particularly looking at whether any
changes in sample mobility were observed for different dosage strengths and/ or the
expiration dates. When the dosage strength was investigated, the average T1 value for each
peak was compared across 8.4 g, 16.8 g, and 25.2 g samples. No differences were found at
any peak as a function of dosage strength. However, the T1 of each peak within a single
dosage strength was not always the same. For 8.4 g (A, D, and E) and 16.8 g (B and F) lots,
the carboxylate showed a significantly longer T1 than the aromatic at 127 ppm. Similarly,
in 16.8 g lots, the carboxylate had a significantly longer T1 than both aromatic peaks while
sorbitol and the aliphatic groups also had longer T1 values than aromatic groups. No
differences were observed within the 25.2 g lots (C and G).
When patiromer lots were grouped based on expiration date, there were no
significant differences found for any peak, nor for any expiration year. It is interesting to
note that the sorbitol T1 decreases from 1.88 ± 0.24 s to 1.57 ± 0.15 s (mean ± SD, n = 3
and 4, respectfully) in expired samples. Concurrently, the carboxylate T1 also decreases
from 1.91 ± 0.23 s to 1.66 ± 0.13 s. If the sorbitol counterion, which is included in the last
step of the API manufacturing to help stabilize the carboxylate portion of the m-block
(202), begins to degrade or dissociate, it is possible that the carboxylate would exhibit
enhanced mobility as evidenced through a reduced T1.
Similar to T1 values, T1r values were also compared based on dosage strength and
expiration date. The aliphatic T1r was found to be significantly longer in 25.2 g samples
than in 16.8 g samples. Additionally, the same aliphatic value was greater than any other
peak in the 25.2 g lots. When the expiration date was compared, the T1r of sorbitol was
significantly shorter in expired samples relative to samples which had not yet expired. In
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both expired and non-expired, the sorbitol T1r was different than the carboxylate.
Interestingly, in expired samples, the T1r of sorbitol was less than the carboxylate while in
non-expired samples, the sorbitol T1r was greater than the carboxylate value. It is important
to note that in both T1 and T1r, the small sample size can make it difficult to attribute
differences in relaxation values solely to the dosage strength or expiration rather than lotto-lot variation. Nonetheless, differences are observed in some samples.
3.3.3

Evaluation and Quantitation of Block Copolymer Species Present in
Patiromer
All relevant peaks were integrated using TNMR ‘Integrals.’ This included

downfield carboxylate (257 ppm) and aromatic (215 ppm) SSBs as well as the upfield first
order quaternary/ second order carboxylate (15 ppm) and second order quaternary (-68
ppm) SSBs. Each peak was integrated with zero slope and zero offset. Second order
downfield carboxylate (337 ppm) and aromatic (295 ppm) SSBs, as well as the second
order upfield aromatic (-25 ppm) SSBs were not integrated as their signal-to-noise ratio
was too low to be used in quantitative calculations. Each integrated peak area was
normalized to the carboxylate peak (area = 1.0000).
To account for CP dynamics, the integrated peak areas of each functional group
were extrapolated back to a CT of zero. Using data points at sufficiently long contact times
such that the signal was only decaying, an exponential line was fit and extrapolated back
to zero. The ratio of the line’s y-intercept (CT = 0 ms) intensity and 3 ms CT intensity were
used to scale the area of each functional group’s peaks. The ratio of each functional group
was also applied to its SSBs.
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Each peak in Figure 3.8 was given a letter label. Table 3.4 lists each peak along
with its associated carbon atom and integrated intensity while Table 3.5 lists integrated
values used for quantifying each monomer block in patiromer. There are three types of
carbon in the m-block contributing to the signal, corresponding to the carboxylate, fluorineattached carbon (quaternary), and methylene (CH2) carbon.

The carboxylate and

quaternary carbons were relatively well resolved compared to signals from the other blocks
although at 6 kHz MAS, their SSBs overlapped with each other. However, the methylene
carbon overlapped with multiple carbons from the n- and p-blocks. Therefore, to determine
the amount of m-block carbons, the sum of all peaks associated with the carboxylate carbon
and quaternary carbon were taken. This includes peaks A, C, F, A, and I. Peak H (15 ppm)
is not counted towards the carboxylate and quaternary intensity as it is likely composed of
two peaks including the carboxylate/ quaternary SSB and a portion of aliphatic peak G.
Instead, peak A (257 ppm) is counted twice as it is assumed that it is of approximately the
same intensity as the SSB component in peak H). The total m-block intensity (assigned
peak J) is then divided by 2 to yield the average m-block signal (peak K).
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Figure 3.8. Patiromer lot A 13C 6 kHz MAS CP spectrum with peaks labeled for use during
the quantitation procedure.
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Table 3.4. Peak identification information and integrated values used for monomer block
quantitation of patiromer lot A.
Label

Peak

Chemical

Area at 3

Area at

Shift (ppm)

ms CT

Zero-CT

Label

Signal

Area at 3

Area at

ms CT

ZeroCT

A

Downfield

257

0.0851

0.1910

J

Carboxylate SSB
B

Downfield

Total m-

1.8220

4.3120

0.9110

2.1560

block
215

0.0714

0.1819

K

Aromatic SSB

Average mblock

C

Carboxylate

177

1.0000

2.2450

L

n- & p-block

0.3874

1.0165

D

Aromatic (no

144

0.1198

0.3053

M

Average n-

0.0718

0.1829

0.2872

0.7318

0.1002

0.2847

0.0125

0.0356

0.9953

2.3745

protons)
E

Aromatic (with

block
127

0.1682

0.4286

N

protons)

Total nblock
Backbone

F

Quaternary

96

0.6091

1.5745

O

Total pblock

G

Aliphatic

45

1.2911

3.1232

P

Average pblock

H

Upfield

16

0.1341

0.3466

Aliphatic/

2nd Order Upfield

Total m-, n-,
& p-block

Carboxylate SSB
I

Q

-68

0.0427

0.1104

Quaternary SSB
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Next, the average signal from the n-block is determined. Peak G (45 ppm) contains
the aliphatic signal for all of patiromer. Subtracting peak A from peak H eliminates the
SSB signal from peak H and yields only the additional aliphatic signal contained between
15 and 20 ppm. This was added to the peak G aliphatic signal. There is also a portion of
the upfield aromatic SSB that falls underneath the aliphatic peak G. This was accounted
for by assuming that the downfield aromatic SSB was of equal intensity as the upfield SSB.
The aromatic signal is found in two peaks, at 127 (peak E) and 144 ppm (peak D),
presumably due to aromatic carbons with and without attached protons, respectively.
Spinning at 6 kHz, only the SSB associated with peak E would be found underneath the
aliphatic peak. Therefore, the area of peak E relative to peak D is scaled to the upfield
aromatic SSB intensity and subtracted from peak G. Lastly, the average m-block signal
(peak K) is subtracted from the aliphatic intensity. In total, the n- and p-block aliphatic
signal is equal to G+(H-A)-K-((E/(D+E)*B). This is designated as peak L.
The aromatic signal consists of the two aromatic peaks (D and E), the downfield
aromatic SSB (B), and the upfield SSB (assumed to be of equal intensity as peak B). To
find the average aromatic signal in the n-block, the sum of B, D, E, and B is divided by six
to account for the 6 aromatic carbon nuclei present in the benzene ring. The resulting value
is assigned as peak M.
In addition to the six aromatic carbons, the n-block also contains four backbone
aliphatic carbons. Therefore, peak M is multiplied by four to determine the aliphatic signal
in the n-block (peak N). Subtracting the n-block aliphatic signal (N) from the total aliphatic
signal (L) yields the total aliphatic signal of the p-block (peak O). Peak O is divided by
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eight to account for the 8 aliphatic carbons in the p-block. This yields the average p-block
aliphatic signal and is designated as P.
The last step in the quantitation procedure involves dividing the average signal from
each patiromer block by the sum total of the carboxylate (K), aromatic (M), and aliphatic
(P) signals. The total signal from the analyzed patiromer is designated as Q (K+M+P).
Therefore, the relative amounts of carboxylate, aromatic, and aliphatic blocks present are
found by K/Q, M/Q, and P/Q, respectively.
3.3.3.1 Example Quantitation Calculations for Lot A
As described above, all peaks were integrated and normalized to the carboxylate
peak. Table 3.4 contains all peak labels and the normalized signal intensity values for lot
A. Using the signal ratios from CT extrapolated to zero (Figure 3.4), the carboxylate peak
and its SSBs were multiplied by 2.245, the aromatic peaks and its SSBs were multiplied
by 2.548, and the quaternary peak and its SSBs by 2.585. Similarly, the aliphatic peak was
multiplied by 2.419. Therefore, when corrected for CT, the m-, n-, and p-blocks had
average signals of 2.1560, 0.1829, and 0.0356, respectively.
Taking the ratio of each block’s signal to the total signal gives the relative amount
of each species present. Patiromer lot A was found to contain 90.8% m-block, 7.7% nblock, and 1.5% p-block. This compares well with the manufacturer-reported values of
91% m-block and a combined total of 9% n- and p-block (208). In addition to confirming
the previously reported amount of m-block (the potassium-binding polymer block) present,
this also provides the relative amounts of the n- and p-blocks (crosslinkers) which was not
previously reported.
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3.3.3.2 Theoretical Quantitative Values
Patiromer patent literature suggests that based on the specific polymerization
procedure used, various amounts of the crosslinker components divinylbenzene and 1,7octadiene (starting monomer components of the n- and p-blocks, respectively) could be
used in the polymerization of patiromer (223, 243, 244). Depending on the results of the
polymerization process, different amounts of the n- and p-blocks would be expected to be
found in the final product. If the polymerization was 100% efficient, all divinylbenzene
and 1,7-octadiene would incorporate into patiromer and the n- and p-blocks would show
signal intensities corresponding to the amount of each monomer present in the
polymerization reagents. If the polymerization is not completely efficient or favors the
incorporation of one molecule relative to the other, the n- and p-block intensities will vary
in the final product.
Ideally, standards of known n- and p-block contents would be synthesized and
analyzed, however, this is not possible. In the absence of patiromer standards, calculations
were used to verify the relative quantitative values obtained are in line with results for a
theoretical patiromer standard of similar crosslinker composition. Table 3.5 shows the
theoretical normalized signal intensities that would be expected for patiromer formulated
with a constant amount of m-block (91%) and varying amounts of n- and p-blocks (9%
total).
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Table 3.5. Theoretical signal intensities for patiromer (at 91% m-block and 1x Signal at
0.91) with varying n- and p-block compositions.
n (%)

Signal (x4)

p (%)

Signal (x8)

Total (n & p)
Signal

0

0.00

9

0.72

0.72

1

0.04

8

0.64

0.68

2

0.08

7

0.56

0.64

3

0.12

6

0.48

0.60

4

0.16

5

0.40

0.56

5

0.20

4

0.32

0.52

6

0.24

3

0.24

0.48

7

0.28

2

0.16

0.44

8

0.32

1

0.08

0.40

9

0.36

0

0.00

0.36

If patiromer contained equal amounts of n- and p-blocks (4.5% each), their total
signal would be approximately 0.18 and 0.36, respectively. Conversely, a sample with 9%
n-block and no p-block would show an n-block signal of 0.36. As is seen in Table 3.4, the
observed total n-block signal is 0.2872 (peak N) and total p-block signal is 0.1002 (peak
O). This corresponds to theoretical values of 7-8% n-block and 1-2% p-block, which agrees
well with the reported values in all analyzed patiromer lots. The theoretical exercise above
aids in validating the method proposed herein. Furthermore, as different patiromer lots are
presumed to contain identical monomer compositions, analyzing multiple lots of should
yield similar quantitative results and further validate the proposed method.
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3.3.4

Lot-to-lot Variation in Patiromer Samples
In order to validate the new SSNMR methodology on multiple lots, six additional

patiromer lots were run under identical SSNMR parameters (6 kHz CP MAS, 10 s PD, 3
ms CT, 64 kHz 1H-decoupling, 4096 scans, and 512 acquisition points). To look at any
differences that may exist between lots, the stacked spectra of each lot are shown in Figure
3.9.

Lot G (25.2g, 2017)
Lot F (16.8g, 2018)
Lot E (8.4g, 2018)
Lot D (8.4g, 2017)
Lot C (25.2g, 2020)
Lot B (16.8g, 2021)
Lot A (8.4g, 2021)

280

240

200

160

120

80

40

0

-40 ppm

Figure 3.9. Stacked 13C 6 kHz MAS spectra for all patiromer lots. Lot, dosage strength,
and expiration date are listed next to each spectrum. Peak intensities are normalized to the
carbonyl in lot A.
The stacked spectra show that each lot has the same peaks at the same chemical
shift values. As expected, each lot shows a single carboxylate peak (177 ppm), two aromatic
peaks (144 and 127 ppm), one quaternary peak (96 ppm), a broad aliphatic peak (45 ppm),
and the appropriate SSBs. Each lot also shows a sorbitol counterion peak between 60 and
80 ppm. The intensity of each isotropic peak and SSBs are approximately the same. In
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order to look more closely at the subtle differences between lots, the normalized spectra of
different lots were overlaid (Figures 3.10A and 3.10B).

A)
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Lot C
Lot B
Lot A
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Figure 3.10. Overlay of 13C 6 kHz MAS CP spectra for patiromer lots. (A) Lots A, B, C,
and E. (B) Lots A, D, F, and G. All peaks in the figure were normalized to the carbonyl
intensity of lot A.
The overlaid spectra help to confirm the results of the quantitation procedure that
all patiromer lots contain approximately the same relative amounts of each block
copolymer (Table 3.6). The average was 90.9 ± 0.4% m-block, 7.6 ± 0.3% n-block, and
1.5 ± 0.4% p-block (mean ± SD, n = 7). Similar to the results of lot A, this compares
remarkably well with reported values of m-blocks while adding the additional information
of the relative amounts of n- and p-blocks. This is especially important from a quality
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control standpoint in that the final product contains a consistent amount of the
physiologically active polymer (m-block) and each crosslinker (n- and p-blocks) as the
total (9.1%) and relative (7.6% and 1.5% n- and p-block, respectively) crosslinker content
controls the degree of swelling when exposed to water or gastrointestinal fluid (223).
Table 3.6. Relative amounts of each block copolymer in different patiromer lots.
Lot

Dose

Expiration

m-block (%)

n-block (%)

p-block (%)

A

8.4

2021

90.8

7.7

1.5

B

16.8

2021

90.2

7.9

1.9

C

25.2

2020

90.9

7.7

1.4

D

8.4

2017

91.2

7.2

1.7

E

8.4

2018

90.4

7.7

1.9

F

16.8

2018

91.4

7.4

1.2

G

25.2

2017

91.2

8.0

0.9

90.9 ± 0.4

7.6 ± 0.3

1.5 ± 0.4

Average

As the m-block contains both the carboxylate and quaternary groups, the intensity
of the quaternary peak in all lots is also approximately identical. Similarly, the aromatic
peaks at 144 and 127 ppm only show slight variations which are mostly reflected in the
quantified n-block values in Table 3.6. The largest differences between spectra occur in the
aliphatic block, particularly in Figure 3.10A. Of the non-expired samples (A, B, and C), lot
B shows the highest intensity aliphatic peak and highest p-block value in Table 3.6 (1.9%)
while lot A shows the least intense peak and only 1.5% p-block. Of the expired lots in
Figure 3.10B, most variation is found near 30 and 50 ppm. This is reflected in variable pblock values for expired lots in Table 3.6. It should be noted that, as described in the
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quantitation procedure, the p-block is determined by the difference between the combined
aliphatic signal in the n- and p-blocks and the aliphatic signal contained only in the n-block.
This inherently results in the p-block values having the most uncertainty as any errors in
measuring/ calculating the m- and n-blocks is also contained in the p-block calculation.
The quantitative differences discussed above could be a result of testing different
dosage strengths and/ or samples of varying expiration dates. Tables 3.7 and 3.8 look at
quantitative differences in composition of patiromer as a function of the dosage strength
and expiration date, respectively. It should be noted that with a small sample size, it is
difficult to analyze the effect of dosage strength independent from the lot as each patiromer
lot is only produced at a single strength. Furthermore, each sample was analyzed at a single
time point rather than continuously analyzed over the course of its shelf-life and beyond
which complicates whether spectral differences result from lot variation or expiration.
Nonetheless, while there are slight differences in the average relative amounts of each
copolymer present in various dosage strengths and lots with different expiration years,
these differences are not significant.

Table 3.7. Average relative amounts of each block copolymer in different strength lots.
Dose (g)

m-block (%)

n-block (%)

p-block (%)

8.4 (n=3)

90.8 ± 0.4

7.5 ± 0.3

1.7 ± 0.2

16.8 (n=2)

90.8 ± 0.8

7.6 ± 0.4

1.6 ± 0.5

25.2 (n=2)

91.1 ± 0.2

7.8 ± 0.2

1.2 ± 0.4
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Table 3.8. Average relative amounts of each block copolymer in different expiration date
lots.
Expiration

m-block (%)

n-block (%)

p-block (%)

2017 (n=2)

91.2 ± 0.0

7.6 ± 0.6

1.3 ± 0.6

2018 (n=2)

90.9 ± 0.7

7.6 ± 0.2

1.5 ± 0.5

2020 (n=1)

90.9 ± 0.0

7.7 ± 0.0

1.4 ± 0.0

2021 (n=2)

90.5 ± 0.4

7.8 ± 0.1

1.7 ± 0.3

Additionally, the spectral differences between each lot could also be caused by a
variety of other phenomena. Variations in temperature would likely have the most profound
impact on signal intensities due to increased mobility at higher temperatures. However,
extensive care was taken to ensure the temperature of the spectrometer was consistent
between runs. Each sample was given adequate time to equilibrate to 20°C prior to spectral
acquisition. In addition, a spectrum acquired at -20°C was found to not significantly effect
quantitative procedure. Instrumental variations (variable MAS rate, the magic angle not
being precisely set, different CP parameters, etc.) could also have an effect on differences
seen between spectra. The spectrometer was calibrated prior to each sample change to
ensure experimental conditions were consistent between each lot. Therefore, the variations
observed are likely within the uncertainty of measurement.

3.4

Conclusion
Polymers with multivalent structures and high binding capacities are becoming

more prevalent as polymeric APIs, particularly as sequestering agents. However,
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polymeric drugs, particularly insoluble formulations, do not fall into traditional small
molecule or biologic drug categories which have well-established analytical techniques.
Therefore, there is a significant need to develop new analytical methods for the quantitative
characterization and analysis of insoluble polymeric drug products. Patiromer (Veltassaâ)
is one such drug product containing three monomer units and calcium-sorbitol counterion.
Controlling the relative amounts of each type of monomer incorporated in patiromer is
critical for maintaining the quality standard and therapeutic effect. A novel SSNMR
method was developed and validated for quantifying the relative amounts of each monomer
present in different patiromer lots.
Various 13C-SSNMR techniques were used to account for CP dynamics and ensure
that quantitative data was acquired. From this, a quantitation procedure was developed by
integrating the peaks of all functional groups and their associated SSBs. The signal
attributed to each polymer block was normalized for the number of carbon nuclei present
and compared to the total signal to yield quantitative values.
The average patiromer sample analyzed contained 90.9 ± 0.4%, 7.6 ± 0.3%, and 1.5 ± 0.4%
m-, n-, and p-block, respectively. The results agree very well with values reported in the
package insert while providing previously unpublished data in the relative amounts of nand p-block rather than the total between the two monomers. To validate the method,
theoretical calculations were performed, and the results compared to seven different
patiromer lots, including three dosage strengths and four expired samples. Little to no
differences existed between different dosage strengths or expiration date and the
calculations agreed well with experimental results. Only slight lot-to-lot variations existed
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between the relative amounts of each block copolymer present in each lot, likely caused by
the inherent uncertainty of measurement.
Overall, SSNMR was found to yield good quality quantitative data which agrees
will with literature values. If all aspects of CP dynamics are accounted for, SSNMR and
the quantitative method reported herein can be used to accurately quantify intact patiromer.
Adaptation of this method can be used to establish API sameness during generic drug
development, or as a tool for the advanced characterization and analysis of other complex
polymeric drug products. While this method works best for non-material-limited samples,
it may also be applied using much smaller amounts of drug, albeit with the cost of longer
experimental times.

Copyright © Travis Wayne Jarrells 2022
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CHAPTER 4: COMPARISON OF DIFFERENTIAL SCANNING
CALORIMETRY, POWDER X-RAY DIFFRACTION, AND SOLID-STATE
NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY FOR
MEASURING CRYSTALLINITY IN AMORPHOUS SOLID DISPERSIONS –
APPLICATION TO DRUG-IN-POLYMER SOLUBILITY
4.1

Introduction
The majority of drug candidates under development are poorly water soluble (3, 4).

Amorphous formulations are seen as a viable approach for improving the solubility of
many biopharmaceutical classification system (BCS) class II and IV drugs (2). Amorphous
solid dispersions (ASDs) are formed through the intimate mixing of drug and polymer to
help to improve the physical stability of amorphous drugs while also maintaining improved
solubility relative to the crystalline state. Still, the number of ASDs on the market is
limited, likely due to the amorphous drug’s potential for devitrification which can also
impact bioavailability (245, 246).
The amorphous state is inherently higher in energy than the crystalline state.
Because of this, amorphous drugs are often limited by their physical instability (i.e.,
tendency to recrystallize) (66). Characterization and quantification of the amorphous and
potential crystalline phases is a necessary part of amorphous pharmaceutical development.
The difference in energetics between the crystalline and amorphous forms
__________________________
This chapter is adapted with permission from Travis W. Jarrells and Eric J. Munson,
Comparison of Differential Scanning Calorimetry, Powder X-ray Diffraction, and Solidstate Nuclear Magnetic Resonance Spectroscopy for Measuring Crystallinity in
Amorphous Solid Dispersions - Application to Drug-in-Polymer Solubility, Journal of
Pharmaceutical Sciences (2022), doi: https://doi.org/10.1016/j.xphs.2022.04.004
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leads to vast differences in the physicochemical properties, stability, and in vivo
performance of the two phases.
Most ASD formulations begin with a crystalline drug which is transformed to the
amorphous state through varying process unit operations. Crystals may remain as residual
crystals from unoptimized processing conditions or form during ASD storage and can
affect the stability of different formulations (247). An adequate knowledge of the
processing parameters is required to keep crystallinity below levels that are detrimental to
product performance.
Moseson and Taylor demonstrate how the hot melt extrusion (HME) operating
space impacts initial levels of crystallinity as well as the analytical methods available to
quantify them (248). Crystals present in the initial formulation may also induce secondary
nucleation and additional crystal growth. Haser et al. showed that ASDs produced by spray
drying and HME had varying levels of initial crystallinity which also directly affected the
extent of subsequent crystallization during storage (249).
Increasing levels of crystallinity negatively impact ASD in vitro dissolution rate,
absorption, and bioavailability (250). Commercially available tacrolimus formulations
showed varying crystallization kinetics which directly impacted their dissolution
performance (251). Tacrolimus tablets increasingly failed USP dissolution tests I and II
with increasing levels of crystallinity (250). However, the absolute amount of crystallinity
in different dispersions does not necessarily indicate the effect on product performance.
The same study by Haser et al. went on to suggest that spray dried dispersions containing
higher levels of crystallinity may still perform better than HME during dissolution (249).
Que et al. demonstrated that the impact on dissolution performance for equivalent amounts
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of crystallinity is largely dependent on the crystal morphology (252). Purohit et al. found
that endogenously formed crystals had less of an impact on dissolution than physical
mixtures created to simulate residual crystallinity (253). Both studies underscore the
importance of crystal properties on dissolution and the need to both characterize and
quantify crystals present to determine their impacts on drug delivery. Furthermore, it has
been shown that while increasing crystallinity leads to increasingly poor in vitro dissolution
and absorption, it has varying effects in vivo. In fact, celecoxib-polyvinylpyrrolidone
ASDs with up to 20% crystallinity were nearly bioequivalent to crystalline-free ASDs
when dosed in rats (254).
Multiple techniques currently exist for characterizing and quantifying crystallinity.
Differential scanning calorimetry (DSC), powder X-ray diffraction (PXRD), solid-state
NMR (SSNMR), Raman spectroscopy, dynamic vapor sorption, solution calorimetry,
isothermal microcalorimetry, dynamic mechanical analysis, Fourier-transform infrared
spectroscopy, near-infrared spectroscopy, thermally stimulated current spectroscopy, and
inverse gas phase chromatography have all quantified crystallinity at low levels in
pharmaceutical systems (255). In particular, DSC, PXRD, SSNMR, and Raman are often
applied to multi-component systems with PXRD and SSNMR being better suited to detect
and quantify crystallinity in drug formulations relative to DSC (133, 185, 255).
DSC, PXRD, and SSNMR quantify the amount of crystalline and amorphous
material using different properties associated with the material. For example, DSC
measures changes in heat flow upon heating the material. Crystalline and amorphous
phases react differently to changes in temperature where the magnitude of heat flow
associated with various thermal events is directly related to the amount of a specific phase
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present. The glass transition temperature (Tg) is related to the amount of an amorphous
phase present and is usually an easily accessible parameter used to determine crystallinity.
Even within DSC, variables other than Tg may be used to quantify crystallinity. The heat
of fusion (∆Hfus) or heat of dissolution (∆Hdiss) correspond to the crystalline phase rather
than Tg, which corresponds to the amorphous phase (256, 257). Any crystalline drug
present after annealing will dissolve back into the polymer upon reheating the ASD through
the drug’s melting point. Comparing ∆Hdiss to ∆Hfus should, in theory, also yield drug
crystallinity in the sample. However, using DSC for crystallinity measurements can be
time-consuming and is reliant on the sensitivity of the calorimeter for detecting and
quantifying crystals in a polymer matrix.
PXRD detects molecular order by differences in a materials interaction with X-ray
radiation and is a powerful technique for detecting and quantifying crystals (133).
Constructive interference occurs when X-rays diffracting off crystalline phases satisfy
Bragg’s law at a given incidence angle and is observed as sharp diffraction peaks.
Amorphous regions of short-range molecular order do not satisfy Bragg’s law and result in
featureless ‘halo’ diffraction patterns. The diffraction intensity of the crystalline and
amorphous phases is directly proportional to their respective fractions in the sample (258).
The magnitude of diffraction can be measured either as peak intensity or integrated peak
area and can be compared for a single peak, multiple peaks, or the entire diffraction range
(whole powder pattern). Peak intensity or integrated peak areas are commonly used for the
quantitation of single- or multi-component mixtures however whole pattern techniques
may also be used to minimize the effects of preferred orientation which is common in small
molecule pharmaceutical crystals (259).
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SSNMR utilizes the signals from nuclei in the crystalline and amorphous phases
and is an inherently quantitative technique because the response function of the signals
from nuclei are the same regardless of phase. In other words, the integrated crystalline and
amorphous peak areas of 13C SSNMR spectra acquired with direct polarization are directly
proportional to the amount of crystalline and amorphous content in the system,
respectively. However, direct polarization pulse delays rely on
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C T1 relaxation times

which are extremely long and typically hinder its use for quantitation. Cross polarization
(CP) may also be used quantitatively provided that relaxation rates, CP dynamics, and the
Hartmann-Hahn conditions are accounted for during data acquisition (189). Aside from
integration, chemometric and relaxation-based methods can also be used to quantify
mixtures, including crystalline versus amorphous (260). For example, the difference in 1H
T1 relaxation times between crystalline and amorphous phases has been used for
quantifying crystallinity. Direct exponential curve resolution algorithm (DECRA) is a
chemometric method which quickly resolves mixtures into the weighted fractions of their
pure components (261). Quantitative signal-filtering methods have also been proposed to
isolate the crystalline signal in samples with overlapping resonances where deconvolution
is difficult (262).
Another benefit to determining crystallinity is the measurement of drug-in-polymer
solubility. Up to this point however, DSC has been almost exclusively used for these
solubility measurements. Solubility measurement using DSC is a time-consuming
procedure, is limited to certain systems which can accurately measure/ detect Tg or melting,
and often requires additional heating of the sample, all of which can limit its applicability.
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Development of a robust quantitative crystallinity method using analytical methods more
sensitive than DSC may also be applied to improve drug-polymer solubility measurements.
Despite the importance of crystallinity in ASDs, little has been done outside of DSC
to investigate the limitations of its measurement and application to drug-in-polymer
solubility. There is a clear need to investigate different analytical techniques for their
ability to quantify crystallinity as well as how external factors affect its measurement.
Therefore, this chapter was designed to evaluate the ability of DSC, PXRD, and SSNMR
to quantifying crystallinity in a single ASD system crystallized under different conditions.
Specifically, the effects of drug loading, temperature, and annealing conditions on the
quality of crystals formed were investigated as it pertains to the ability of a given analytical
method to quantify crystallinity.
Nifedipine (NIF) and polyvinylpyrrolidone (PVP) K12 were chosen as a model
drug-polymer system to compare techniques for quantifying ASD crystallinity. NIF is a
poorly soluble drug which crystallizes relatively quickly and has been studied extensively
for solubility-enhancing techniques. PVP is commonly used in polymeric ASDs due to its
high aqueous solubility and crystallization inhibition properties. Together, NIF and PVP
have shown to form miscible dispersions ideal for studying ASD physical stability (85).
NIF-PVP presents a nearly ideal system to study recrystallization as it exhibits fast
crystallization kinetics, displays a single, well-resolved Tg, and crystallizes into a single
polymorph.
In this chapter, ASD crystallinity was quantified and compared using five different
methods across three analytical techniques including DSC (Tg and ∆Hdiss), PXRD (full
powder pattern integration), and SSNMR (peak deconvolution and T1 relaxation). The
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results were then used to determine drug-in-polymer solubility. Initially amorphous ASDs
of varying drug loadings were partially crystallized using in-situ (DSC) and ex-situ (oven)
annealing methods. We report that in-situ and ex-situ annealing methods yielded equal
amounts of crystallinity given sufficient annealing times. Despite its widespread use in the
literature, both DSC techniques (Tg or ∆Hdiss) struggled to accurately quantify crystallinity
for ASDs containing high initial drug loadings. PXRD and SSNMR provided consistently
accurate quantitative results even at high drug loadings. The SSNMR relaxation time
method found that changes in the crystalline material (shown as changes in 1H T1) as a
function of annealing temperature must be accounted for to accurately quantify crystallinity
and helps to explain the shortcomings of enthalpy-based DSC quantitation methods. The
results of the comparative crystallinity study may be directly applied for drug-in-polymer
solubility measurements. This is the first report of SSNMR and PXRD being used for
determining drug-in-polymer solubility. They have the potential to greatly expand the
number of systems by which drug and polymer solubility can be measured. The advantages
and limitations of each proposed technique are discussed, and it is found that SSNMR and
PXRD each provide valuable information to better inform formulation development which
would otherwise be missed using DSC. In situations where the DSC recrystallization
method fails, PXRD or SSNMR techniques are proposed to enhance the characterization
of ASDs and expand the options of formulations scientists for designing stable ASDs.
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4.2

Materials and Methods

4.2.1

Materials
Nifedipine (lot YT4QE-BP) was purchased from TCI Americas (Portland, OR) and

was used as received. Polyvinylpyrrolidone K12 (lot 0001970609) was kindly donated
from Ashland Global (Covington, KY) and dried ≥ 18 hours under vacuum at 75°C prior
to use. Figure 4.1 shows the chemical structures of NIF and PVP.
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Polyvinylpyrrolidone (PVP)

Figure 4.1. Chemical structures of nifedipine and polyvinylpyrrolidone. (* indicates the
carbon atoms used for SSNMR quantitation).
4.2.2

Preparation of Amorphous Solid Dispersions
A melt-quench procedure was used to create ASDs of varying NIF contents. 70-30,

80-20, and 90-10 (% w/w) physical mixtures of nifedipine and dried PVP K12 were
cryomilled at 10 Hz using a SPEX 6875 cryogenic grinder (SPEX SamplePrep LLC,
Metuchen, NJ). A 5 min precool was following by 10 cycles of 2 min grinding and 2 min
cooling at -196°C. The powdered sample was melted at 180°C for 5 min, quench-cooled
in liquid nitrogen, then lightly ground using a mortar and pestle. The resulting ASD was
dried for a minimum of 18 hr under vacuum at 25°C. Each ASD was annealed at elevated
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temperatures in an oven or in the DSC to approach equilibrium through NIF crystallization.
Table 4.1 summarizes each method used for quantifying crystallinity in ASDs and its
corresponding abbreviation.
Table 4.1. Crystallinity quantitation methods.
Method

Annealing

Analytical

Description/ Variables

Abbreviation

Mechanism

Technique

Measured

OvTg

Oven

DSC

Tg (Gordon-Taylor
equation)

OvHd

Oven

DSC

Heat of dissolution

DSCTg

DSC

DSC

Tg (Gordon-Taylor
equation)

DSCHd

DSC

DSC

Heat of dissolution

PXRD

Oven

PXRD

Full powder pattern
integration

NMRDec

Oven

SSNMR

Peak deconvolution

NMRT1

Oven

SSNMR

Biexponential T1
measurement

4.2.3

Oven Annealing of Samples – Methods OvTg and OvHd
To ensure sample handling/ preparation was consistent between analytical methods,

all samples were annealed together for a given annealing temperature (Ta). Powdered ASD
samples were spread thinly over a flat aluminum weigh boat and placed into a dry oven
between 130 and 160°C for at least 2 hours (methods OvTg and OvHd). Samples were
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removed, lightly ground with mortar and pestle and stored over desiccant at -23°C until
analysis by DSC, PXRD, or SSNMR.
4.2.4

Differential Scanning Calorimetry – Methods DSCTg and DSCHd
The Tg and ∆Hdiss (methods DSCTg and DSCHd, respectively) of all samples were

determined using a Discovery DSC 2500 (TA Instruments, New Castle, DE). (All DSC
performed herein used modulation and will be referred to simply as DSC). The system was
nitrogen purged at 50 mL/min and equipped with a RCS90 refrigerated cooling system.
The DSC was calibrated for temperature and heat capacity using indium and sapphire
standards, respectively. 3-4 mg of sample was loaded into a Tzero aluminum pan with a
hermetic pinhole lid. Freshly prepared samples underwent a heat-cool-heat cycle in which
they were heated at 5°C/min with modulation (+/- 0.7°C every 40 s) from 20°C to the Ta
(130-160°C) and held for at least 2 hr. The sample was then cooled at 30°C/min to 0°C,
held for 5 min, and reheated to 185°C at 5°C/min. Samples previously annealed in the oven
were only scanned from 20°C to 185°C using the same heating rate and modulation
(methods OvTg and OvHd).
A step-change in the baseline of the reversing heat flow signal indicated the glass
transition. Reported Tg values correspond to the midpoint of the Tg. Methods OvTg and
DSCTg used the measured Tg and the GT equation (76) to determine the weight fraction
of amorphous NIF remaining in the ASD (XNIF) (Equation 4.1).
𝑋𝑋[Uu =

PX0/, *H* 10/ (NIJK )Y

PX0/, *H* 10/ (NIJK )Y10/, IJK O0/ (NIJK )

(4.1)

Tg(XNIF) is the glass transition temperature of an ASD at a given NIF-loading. Tg,PVP and
Tg,NIF are the glass transition temperatures of pure PVP and pure NIF, respectively. K is
the ratio of change in heat capacity for PVP and NIF at their respective Tg’s.
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Equation 4.2 compares the amount of amorphous NIF that remains after annealing
;6;I;D5
(XNIF) to the initial amorphous NIF-loading (𝑋𝑋[Uu
) to determine the NIF crystallinity

(XC).

𝑋𝑋J = 1 −

'-'L'MN
S
NIJK R*1NIJK
'-'L'MN (*1N
NIJK
IJK )

(4.2)

Upon further heating, the reversing and non-reversing heat flow signals were used
for ∆Hdiss measurements. The endothermic reversing heat flow signal was integrated from
approximately 125°C to 175°C while a running integral was performed on the nonreversing heat flow signal from just after Tg to slightly above the melting/ dissolution event.
Subtraction of the non-reversing integral from the reversing integral corrects for any
additional crystallization occurring upon heating to yield the pure NIF heat of fusion
(∆Hfus) or NIF-PVP ASD heat of dissolution (∆Hdiss). Using Equation 4.3, methods OvHd
and DSCHd take the ratio of ∆Hdiss to ∆Hfus to determine NIF crystallinity (XC).
𝑋𝑋J =

∆LO'((

(4.3)

∆L.P(

From Equation 4.3, the fraction of amorphous NIF remaining in the ASD can also
;6;I;D5
be determined where 𝑋𝑋[Uu
and XPVP are the initial fractions of amorphous NIF and PVP

in the ASD, respectively (Equation 4.4).
𝑋𝑋[Uu =

4.2.5

'-'L'MN (*1N )
NIJK
>

'-'L'MN (*1N )ON
NIJK
>
*H*

(4.4)

Powder X-ray Diffraction – Method PXRD
Powder X-ray diffraction patterns were obtained using a Rigaku SmartLab

diffractometer (Rigaku Americas, The Woodlands, TX). 135-140 mg of oven-annealed
sample was placed on a glass sample holder and scanned from 5-50°C 2q at 2°/min and
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0.02° step size. The diffractometer was operated at 40kV and 44mA in Bragg-Brentano
mode with a Cu-Ka radiation source and d/tex ultra detector. As the samples investigated
using PXRD were sensitive to preferred orientation, the entire 2q range was used for the
quantitative analysis to help minimize this effect. Instrumental background intensity was
subtracted from the observed diffraction intensity. The remaining amorphous area (Ahalo)
was subtracted from the corrected intensity to yield only sharp peaks (total crystalline area,
Apeaks). ASD crystallinity was determined by dividing Apeaks by the total diffraction
intensity. Equation 4.5 corrects for the initial fraction of amorphous NIF in the ASD
;6;I;D5
(𝑋𝑋[Uu
) to yield the drug crystallinity.

𝑋𝑋J =

v1QM6(

'-'L'MN Rv
NIJK
1QM6( OvRMN, S

(4.5)

Likewise, the weight fraction of amorphous NIF remaining in the ASD after
annealing (XNIF) was solved via Equation 4.6.
𝑋𝑋[Uu =
4.2.6

'-'L'MN
NIJK
1N>

*1N>

(4.6)

Solid-state Nuclear Magnetic Resonance Spectroscopy – Methods NMRT1 and
NMRDec
Method 4 used
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C solid-state NMR experiments performed either on a Bruker

Avance 400 (Bruker Corporation, Billerica, MA) or Tecmag Redstone HF3 2RX (Tecmag
Inc., Houston, TX) spectrometer operating at a 1H resonance frequency of 399.66 MHz or
300.05 MHz, respectively. The same oven-annealed sample used in methods OvTg, OvHd,
and PXRD were used for SSNMR analysis. The Bruker spectrometer used approximately
200 mg of powdered sample packed into a 6 mm zirconia rotor with Teflon of Kel-f
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endcaps while the Tecmag used 300 mg packed into a 7.5 mm rotor. Each spectrum was
acquired using cross polarization (CP) (174), total sideband suppression (TOSS) (171),
magic angle spinning (MAS) (169) at 4 kHz, SPINAL64 decoupling (237) with an
approximately 62.5 kHz (Bruker) or 61 kHz (Tecmag) 1H decoupling field and 1.5 ms
contact time (CT). The methyl peak of an external standard, 3-methylglutaric acid, was
referenced to 18.84 ppm to optimize spectrometer properties (238).
Deconvolution of CP TOSS spectra was performed for 80-20 ASDs (method
NMRDec). Each CP TOSS spectra was acquired on the Tecmag spectrometer with 4096
acquisition points and a PD approximately 5 times the crystalline T1 (vide infra) for at least
24 hours. This ranged from 616 scans at a 140 s PD to 1024 scans at an 86s PD.
Overlapping crystalline and amorphous peaks were deconvoluted using MestReNova
version 14.2 (Mestrelab Research S.L., Santiago de Compostela, Spain). Amorphous and
crystalline line shapes (isotropic chemical shift, width at half-max, and Lorentzian/
Gaussian ratio) were determined from the unannealed ASD and annealed T1 experiment
with 128 ms T1r filter, respectively. Deconvolution parameters were kept approximately
constant when fitting at all Tas to avoid biasing results.
Method NMRT1 used relaxation experiments performed on the Bruker
spectrometer at 20°C in a 6 mm Phoenix HX probe (Phoenix NMR, Loveland, CO) for 8020 and 90-10 ASDs. The proton spin-lattice relaxation time (1H T1) was determined using
a saturation-recovery experiment through
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C observation. 160 scans, each with 3996

acquisition points were acquired for a list of 21 different pulse delays (PD). The integrated
area (M) of the NIF doublet peak at 102.6 ppm was fit to the biexponential recovery
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equation to determine the T1 of the crystalline (T1,C) and amorphous NIF (T1,A) (Equation
4.7).
𝑀𝑀 = 𝑀𝑀Z,J o1 − 𝑒𝑒

1

9
70,>

p + 𝑀𝑀Z,v o1 − 𝑒𝑒

1

9
70,S

p

(4.7)

M0,C and M0,A are the preexponential coefficients of crystalline and amorphous
NIF, respectively and can be used to approximate the amount of each phase present. The
fraction of crystalline NIF present in the ASD after annealing is shown in Equation 4.8.
𝑋𝑋J = W

W8,>

8,> OW8,S

(4.8)

Similarly, Equation 4.8 can also be used to calculate the weight fraction of
amorphous NIF remaining in the ASD. A variable CT experiment was also performed and
the ratio between signal intensity at 1.5 ms CT and the extrapolated intensity at 0 ms CT
taken to correct for differences in CP dynamics between the crystalline and amorphous
NIF.
4.2.7

Polarized Light Microscopy
Crystals formed during the annealing process were visualized using an Axio

Imager.A2m polarized light microscope (Carl Zeiss Microscopy, LLC, White Plains, NY)
equipped with a LTS 420 hotstage (Linkam Scientific Instruments, Ltd., Surrey, UK).
Powdered ASD was melted on a microscope slide, then quench-cooled by placing on a
precooled stainless-steel block. The microscope slide was heated on the hotstage and held
at Ta for a minimum of four hours. Images were captured using a Zeiss AxioCam MRc
digital camera.
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4.2.8

Drug-in-Polymer Solubility Measurements
The crystalline solubility of NIF in PVP K12 was determined using XNIF values

obtained through annealing at high temperatures for a minimum of 2 hours. This assumes
that annealing allowed sufficient time for crystallization to occur and the system reached
equilibrium. While most samples reached equilibrium in 2 hours, lower Tas, particularly
for 70-30 ASDs, required upwards of 24 hours of annealing to reach equilibrium
crystallinity. The amorphous weight fraction was converted into the amorphous volume
fraction (uNIF) and used in the Flory-Huggins solubility equation (Equation 4.9):
∆L.P(
?

5

*

0$

*

*

− 6 = 𝑙𝑙𝑙𝑙(𝜐𝜐[Uu ) + 51 − 6 (1 − 𝜐𝜐[Uu ) + 𝜒𝜒(1 − 𝜐𝜐[Uu )%
0

M

(4.9)

where ∆Hfus and Tm are the pure NIF heat of fusion at its melting point, respectively. R is
the ideal gas constant and T is the annealing temperature. l is the molar volume ratio and
c is the drug-polymer interaction parameter, an indication of the miscibility of drug and
polymer upon mixing c is optimized by linear regression to extrapolate from high
temperatures to the glassy state (65).

4.3
4.3.1

Results
Creating Supersaturated Amorphous Solid Dispersions
Supersaturated ASDs were created by mixing NIF and PVP K12 at concentrations

of 70-30, 80-20, and 90-10 % (w/w). After mixing and cryogrinding, samples were heated
above the melting point of NIF in a teflon beaker in an oil bath then quench-cooled before
lightly grinding with mortar and pestle. Freshly prepared NIF-PVP ASDs were analyzed
for initial crystallinity using PXRD. The PXRD diffraction patterns for NIF, PVP, and each
ASD are shown in Figure 4.2. Crystalline NIF shows well defined Bragg peaks
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corresponding to the a-NIF polymorph (263). The a-NIF pattern lacks any amorphous halo
nor any unexpected diffraction peaks indicating a fully crystalline starting material
containing no other NIF polymorphs. PVP and all NIF-PVP ASDs studied lack any Bragg
peaks indicating the cryomill/ melt-quench procedure was successful in producing X-ray
amorphous ASDs.

Figure 4.2. Sample and reference PXRD diffractograms for the initial analysis of NIF-PVP
ASDs.
The ASDs were also analyzed by DSC to confirm the absence of crystallinity and
determine the Tg at each NIF concentration. The lack of a dissolution endotherm in the
Figure 4.3 thermograms suggests the ASDs do not have any crystallinity. They also exhibit
a single Tg intermediate to the Tg of pure components suggesting miscibility over an
approximately 30 nm domain size (264, 265). Increasing amounts of polymer raised the Tg
from 50.5°C at 10% PVP to 68.2°C at 30% PVP, consistent with values predicted by the
GT equation. This indicates the GT equation predicts the Tg of NIF-PVP ASDs very well
across a wide compositional range and are consistent with previously reported results from
our laboratory (Figure 4.4) (85).
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The initial ASDs were also analyzed by

13

C SSNMR for signs of residual

crystallinity and a more sensitive measure of miscibility to ensure completely amorphous
systems were created. Spectra for all initial ASDs contained spectral features which were
consistent with a fully amorphous ASD (85). The 1H T1 of NIF and PVP were equal in all
initial ASDs indicating PVP initially stabilized amorphous NIF by homogeneous molecular
mixing on a length scale of ≤ 40 nm, also consistent with our previous results (85).
4.3.2

Annealing-induced Crystallinity
Samples were heated either in a DSC cell or in an oven to temperatures between

the ASD Tg (50.5 – 68.2°C) and Tm of NIF (173°C) and held isothermally for 2 – 24 hours
to allow the supersaturated NIF to crystallize. Annealing at temperatures significantly
above Tg (130 – 160°C) provided NIF with the molecular mobility required for rapid
crystallization. No chemical degradation was observed in the annealed samples, consistent
with the results of Aso et al. and Sun et al. (66, 156).
4.3.3

Analytical Methods for Quantifying Crystallinity
Three different analytical techniques and five different methods were used to

quantify the resulting crystallinity of samples annealed between 130°C and 160°C. DSC
either applied the GT equation by measuring Tg or integrated the dissolution endotherm to
determine ∆Hdiss. PXRD used a full powder pattern integration and background subtraction.
SSNMR quantified crystallinity using either a two-component saturation recovery (T1)
experiment or deconvolution of overlapping crystalline and amorphous peaks. Each
method was first compared for its ability to quantify crystallinity across a range of
temperatures. Methods which provided comparable crystallinity values were then applied
to predict drug-in-polymer solubility.
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4.3.3.1 Differential Scanning Calorimetry
Figure 4.3 shows the final heating scan of DSC-annealed NIF-PVP ASDs at
different annealing temperatures, and Table 4.2 lists the Tg and ∆Hdiss values for each
dispersion. Crystallinity was measured in all samples using the reversing and non-reversing
heat flow signals shown in Figure 4.3A. Tg is measured as the midpoint of the step change
in the baseline of the reversing heat flow while ∆Hdiss is measured from the reversing and
non-reversing signals. A running integral is applied to the non-reversing heat flow from
just above Tg to above the offset of the dissolution endotherm to account for any
crystallization occurring upon heating. The non-reversing integral is subtracted from any
reversing dissolution endotherm which may be present to yield the heat of dissolution
attributed only to crystals formed during annealing. For simplicity, Figures 4.3B, C, and D
show only the total heat flow (sum of reversing and non-reversing) thermograms during
the final heating scan to show both the glass transition and dissolution endotherm. Tgs
depicted in the total heat flow in Figures 4.3B, C, and D are slightly higher than the Tg used
in GT calculations, a result of enthalpic recovery upon heating through the Tg (Figure
4.3A).
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Figure 4.3. Thermograms of NIF-PVP ASDs annealed for 2 hours in the DSC. (A)
Example reversing and non-reversing heat flow trace from an 80-20 ASD used to calculate
crystallinity. (Reversing heat flow shown in black, non-reversing heat flow shown in red.)
(B – D) Heating scan measuring total heat flow of NIF-PVP ASDs as a function of Ta for
different drug loadings. (B) 70-30, (C) 80-20, and (D) 90-10 (smaller window shown to
easily view Tg). From top to bottom: unannealed, 160°C, 155°C, 150°C, 145°C, 140°C,
135°C, and 130°C.
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Figure 4.4. Experimentally observed and glass transition temperatures predicted by the
Gordon-Taylor equation for NIF-PVP K12 ASDs at varying drug loadings.
Table 4.2. Tg and ∆Hdiss values for DSC-annealed NIF-PVP ASDs.
70-30
Ta (°C)

Tg (°C)

80-20
∆Hdiss

Tg (°C)

(J/g)

90-10
∆Hdiss

Tg (°C)

(J/g)

∆Hdiss
(J/g)

130

85.2

39.35

83.9

60.67

70.3

79.60

135

84.4

37.39

82.5

58.19

69.6

77.86

140

82.8

35.24

80.9

56.45

70.3

77.35

145

80.7

31.23

79.3

55.16

70.2

77.44

150

77.5

25.77

77.0

53.06

69.7

78.39

155

74.5

19.19

74.9

49.54

68.8

76.99

160

68.3

2.07

71.0

43.95

65.9

76.56
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The Tg was measured and used with the GT equation to determine the weight
fraction of amorphous NIF present in the resulting ASD (methods OvTg and DSCTg). The
Tg of ASDs generally decreased with either increasing annealing temperature (Ta) or
annealing times. The Tg of an annealed ASD at a given Ta should be the same regardless
of the initial drug loading because any excess NIF above the supersaturation limit should
crystallize out leaving a saturated ASD of NIF-PVP. As Ta decreases, NIF becomes less
soluble in PVP and Tg will increase at lower annealing temperatures. However, these
equilibrium conditions may not be reached at short annealing times or if the NIF
concentration does not exceed the supersaturation level. The Tg of 90-10 ASDs were
particularly difficult to measure due to a broad glass transition as well as a small change in
heat capacity because of the low mass of amorphous drug/polymer remaining after
annealing. The Tg of 90-10 ASDs appeared approximately constant (~69°C) from Ta = 130
– 155°C before decreasing at 160°C. The Tg of 70-30 and 80-20 ASDs decreased slightly
up to Ta = 150°C then decreased more significantly above 150°C. At Ta = 160°C, the Tg of
the annealed 70-30 ASD is equal to the unannealed 70-30 ASD indicating no crystallization
has occurred due to either significant melting point depression or insufficient
supersaturation in 70-30 NIF-PVP mixtures at 160°C. Crystallization was observed at
160°C for the 80-20 and 90-10 dispersions (vide infra).
Figures 4.3B, C, and D also measure ∆Hdiss as crystallized NIF redissolves into PVP
at high temperatures. The intensity of the dissolution endotherm decreases as Ta increases
across all drug loadings while the integrated ∆Hdiss increases with drug loading. The
endotherm value decreases slowly up to Ta = 150°C for 70-30 and 80-20 ASDs before
rapidly decreasing. At Ta = 160°C for the 70-30 ASD, only a small endotherm is observed
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and is attributed only to the non-isothermal crystallization of NIF upon reheating. Again,
similar to the Tg, the dissolution endotherm of 90-10 ASDs remains approximately constant
up to 155°C before finally decreasing.
Melting point depression (MPD) is observed as the onset and end point of
dissolution are decreased relative to the melting point of pure NIF (173°C). Although
particularly noticeable for 70-30, this is observed in ASDs of all drug loadings tested
indicating miscibility between NIF and PVP K12 (65). The absence of crystallization at
160°C for the 70-30 ASD is explained by MPD, a minimal dissolution endotherm, and no
change in Tg relative to the unannealed ASD. The additional NIF present in 80-20 and 9010 dispersions is enough to cause measurable crystallization in ASDs at 160°C despite the
decreased thermodynamic driving force for crystallization at temperatures approaching the
NIF melting point.
Lastly, it was also observed that the dissolution endotherm was asymmetric, and a
shoulder was present near the onset of dissolution, especially visible for 70-30 and 80-20
ASDs. The width of the dissolution endotherm showed opposite trends for the 70-30 and
80-20 ASDs with the peak narrowing and slightly broadening as Ta increased, respectively.
90-10 ASDs exhibit a small shoulder and constant peak width across all Ta. The likely
cause is the presence of a metastable polymorph (β-NIF) which has been observed in NIFPVP ASDs previously (266, 267). However, PXRD data confirmed that only the stable aNIF polymorph was formed during annealing (vide infra) indicating β-NIF would have
formed during the final heating scan.
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4.3.3.1.1 Oven-Annealed versus DSC-Annealed Dispersions
The Tg of DSC-annealed samples was greater than the Tg of oven-annealed samples
at short annealing times, particularly at lower Tas and drug loadings. However, this effect
was minimized at longer annealing times as samples annealed via DSC were observed to
have approximately the same Tg and ∆Hdiss as those annealed in an oven (Figure 4.5 and
Table 4.3). In turn, this resulted in almost identical levels of crystallinity regardless of the
annealing method at long annealing times (see Figure 4.10). It should be noted that the
DSC-annealed and oven-annealed thermograms (Figures 4.3 and 4.5, respectively) are
shown after annealing for 2 hours. Crystallization kinetics in the oven are slower and results
in incomplete crystallization. Upon reheating, some amorphous NIF recrystallizes as
evidenced by the small exotherm in some samples.
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Figure 4.5. Thermograms of NIF-PVP ASDs annealed for 2 hours in an oven. (A) 70-30,
(B) 80-20, and (C) 90-10. From top to bottom: unannealed, 160°C, 155°C, 150°C, 145°C,
140°C, 135°C, and 130°C.
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Table 4.3. Tg and ∆Hdiss values for oven-annealed NIF-PVP ASDs.
70-30

80-20

90-10

Ta (°C)

Tg (°C)

∆Hdiss (J/g)

Tg (°C)

∆Hdiss (J/g)

Tg (°C)

∆Hdiss (J/g)

130

85.2

37.58

82.2

55.92

68.5

76.21

135

83.9

37.01

82.0

56.28

69.6

76.69

140

80.8

32.17

81.1

54.37

69.5

76.74

145

79.0

29.37

78.6

51.47

69.5

75.54

150

75.9

25.30

76.8

49.59

69.7

74.18

155

73.4

19.63

73.8

44.42

64.3

70.84

160

65.3

1.20

68.1

38.60

59.4

69.23

4.3.3.2 Powder X-ray Diffraction
PXRD diffractograms for each ASD as a function of Ta are shown in Figure 4.6.
The amount of crystallinity was quantified using the entire powder diffraction pattern to
minimize the error due to preferred orientation. The relative intensity of the diffraction
peaks and amorphous background remain approximately the same in 70-30 ASDs from
130°C to 150°C indicating the crystallinity does not change significantly over that
temperature range. The crystalline peaks disappear above 150°C corresponding to an
absence of crystallinity. While similar trends are observed for 80-20 and 90-10 NIF-PVP
ASDs, small crystalline peaks remain at 160°C as small amounts of crystalline NIF are
present. The peak positions were compared to reference standards and indicated that NIF
crystallized to the stable a-polymorph at all drug loadings and Tas (263). While it is
possible that polymorphic form changes during the course of annealing, the diffraction
patterns shown indicate only the a-polymorph is present in the equilibrated ASDs.
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Figure 4.6. PXRD patterns for (A) 70-30, (B) 80-20, and (C) 90-10 NIF-PVP ASDs after
annealing. From top to bottom Ta = 130°C, 135°C, 140°C, 145°C, 150°C, 155°C, 160°C.
Instrumental background has been subtracted.
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4.3.3.3 Solid-state NMR
Two different approaches were used to quantify the equilibrium crystallinity using
SSNMR. First, overlapping NIF peaks were deconvoluted into their underlying crystalline
and amorphous peaks to provide a direct measure of crystallinity. Second, the difference
in crystalline and amorphous T1 relaxation times provided an indirect measure of the
relative proportions of each phase present in the equilibrated sample. The two SSNMR
methods will be described first in this section, followed by experimental results for
crystallinity in the following section.
Figure 4.7 shows SSNMR spectra of NIF, PVP, and ASDs made from NIF and
PVP. Figure 4.7A shows CP TOSS spectra of PVP, a-NIF, and an initial 80-20 NIF-PVP
K12 ASD. Figure 4.7B shows CP TOSS spectra acquired at room temperature for samples
annealed at each Ta.
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Figure 4.7. 13C SSNMR CP TOSS spectra at 4 kHz MAS spectra. (A) From top to bottom:
Unannealed 80-20 NIF-PVP K12 ASD, a-NIF, and PVP K12. The structure of NIF is
shown in the inlay where the asterisks represent the carbon atoms used for quantitation. (B)
80-20 NIF-PVP ASDs annealed at varying temperatures (From top to bottom: Ta = 160°C,
155°C, 150°C, 145°C, 140°C, 135°C, and 130°C).
The crystalline a-NIF spectrum shows a single sharp peak for each unique

13

C

nuclei present in the sample indicating there is one molecule in an asymmetric crystalline
unit (263, 268). Peak assignments were made previously (269). The alpha carbons of NIF
ester groups (denoted by * in Figure 4.1) were chosen for quantitation as they are
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completely resolved from PVP or other NIF resonances in ASD spectra. They appear as
two sharp peaks at 101.9 and 103.4 ppm or as a single broad peak at 103.2 ppm in the acrystalline and amorphous states, respectively. Samples annealed between 130°C and
160°C show a combination of broad amorphous peaks and sharp crystalline peaks
indicating a significant fraction of the sample crystallized during annealing.
CP TOSS spectra were acquired for 80-20 ASDs as a direct measurement of NIF
crystallinity at each Ta (method NMRDec). The doublet at 102.6 ppm was deconvoluted
into two sharp crystalline peaks and an underlying broad amorphous peak. To avoid biasing
results, the line shapes of the two crystalline peaks and broad amorphous peak were
determined from a CP TOSS T1r-filter experiment and the unannealed 80-20 ASD CP
TOSS spectrum, respectively. The line shapes and isotropic chemical shifts were held
approximately constant for the deconvolution at each Ta. The spectral deconvolution at
each annealing temperature is shown in Figure 4.8.
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Figure 4.8. Deconvolution of CP TOSS 13C SSNMR spectrum of 80-20 NIF-PVP ASDs
annealed at different temperatures. From top to bottom: Ta = 160, 155, 150, 145 (on left),
140, 135, and 130°C (on right). The experimental spectrum is shown in black, the fitted
peaks representing the crystalline and amorphous NIF are shown in red, the sum of the
fitted peaks are shown in green, and the residual difference between experimental and fitted
peaks is in blue.
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After the relative amounts of crystalline and amorphous NIF were determined using
deconvolution, CP dynamics, TOSS signal loss, and differences in the T1 of each
component were accounted for to ensure the results were quantitative. Each is briefly
discussed; however, the interested reader is referred to the literature for excellent examples
of ensuring quantitative CP data is acquired (185, 189). A variable CT experiment revealed
the CP dynamics were not equal between crystalline and amorphous NIF. The crystalline
1

H T1r decreased significantly with annealing temperatures while the amorphous 1H T1r

increased slightly. The TCH of both components was approximately constant with Ta. This
results in crystallinity being underestimated across all temperatures, especially at lower
Tas. The ratio between the observed signal at 1.5 ms CT and the predicted signal at 0 ms
CT served as a correction factor for variable CP dynamics between the crystalline and
amorphous NIF. For example, correction factors of 1.25 and 1.03 were applied to the
crystalline and amorphous NIF, respectively, at 130°C. Other correction factors can be
found in Table 4.4. Conversely, no correction was made for TOSS as the centerband signal
lost to the spinning sidebands of the crystalline and amorphous NIF phases was expected
to be approximately equal (vide infra). The pulse delay (PD) used to acquire each CP TOSS
spectra in Figure 4.7B was also considered to account for the differences in relaxation rate
between crystalline and amorphous NIF and ensure quantitative data was collected. A PD
of nearly 5-times the crystalline NIF T1 was chosen to avoid saturating the crystalline NIF
signal. Although the effect was minimal, the observed integrated peak area (Aobs) of each
phase was corrected to the predicted integrated area after full relaxation (A∞) using
Equation 4.10:
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where τ is the pulse delay and T1,i is the 1H T1 of either the crystalline or amorphous phase.
Table 4.4. Variable contact time correction factors for crystalline and amorphous NIF in
80-20 NIF-PVP ASDs based on the amount of signal observed at 1.5 ms relative to
instantaneous CP dynamics.
Crystalline NIF

Amorphous NIF

Ta (°C)

% Signal

Correction Factor

% Signal

Correction Factor

130

80

1.25

96.9

1.03

135

80.3

1.25

94.9

1.05

140

90.6

1.24

92.9

1.08

145

80.9

1.24

90.8

1.10

150

81.2

1.23

88.8

1.13

155

81.5

1.23

86.8

1.15

160

81.8

1.22

84.7

1.18

In the second method, saturation-recovery 1H T1 experiments were used to
indirectly determine crystallinity by fitting a biexponential relaxation curve corresponding
to the crystalline and amorphous NIF relaxation times (NMRT1 method). The detailed
explanation for how the biexponential curves and relaxation times were measured can be
found in the Methods section. The saturation recovery curves for the NIF peak at 103.2
ppm acquired under standard and T1r-filtering conditions are shown in Figure 4.9.
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Figure 4.9. One- and two-component 1H T1 fits of 80-20 NIF-PVP K12 ASDs acquired
with (black) and without (blue) a 128 ms T1r-filter at different annealing temperatures: (A)
130°C, (B) 135°C, (C) 140°C, (D) 145°C, (E) 150°C, (F) 155°C, and (G) 160°C.
Magnetization intensity shown is for the NIF peak at 102 ppm. Experimental data is shown
as circles, predicted 1H T1 relaxation is shown as solid lines.
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The standard T1 experiment corresponds to the crystalline and amorphous
components while the T1r-filter shows only the crystalline NIF. The T1r-filtering results
were used to determine the crystalline T1 (T1,C). Integrated peak area data from a standard
saturation-recovery experiment was fit to Equation 4.7 to determine the amorphous T1
(T1,A) and preexponential factors (M0,C and M0,A), corresponding to the relative fractions
of crystalline and amorphous NIF. M0,C and M0,A were then used to calculate crystallinity
via Equation 4.8. This process was repeated for all Ta with results shown in Figure 4.12.
The 1H T1 values for crystalline and amorphous NIF, as well as PVP, are found in
Table 4.5 and Figure 4.10. Figure 4.10A demonstrates how a-NIF T1 changes after
cryomilling while Figures 4.10B and C plot the T1 relaxation time of each phase as a
function of annealing temperature.
Table 4.5. 1H T1 values for crystalline and amorphous NIF and PVP.
80-20 T1 (s)

90-10 T1 (s)

Ta (°C)

PVP

Amorphous

Crystal

PVP

Amorphous

Crystal

130

2.95

3.90

16.65

2.17

2.17

20.88

135

3.20

3.52

17.28

3.71

3.76

21.73

140

2.27

2.85

16.95

3.79

4.31

23.33

145

2.50

3.04

20.57

4.26

3.32

25.67

150

2.32

1.94

24.97

4.74

3.93

27.28

155

2.89

2.89

26.11

2.72

3.19

28.51

160

3.05

2.80

28.07

5.84

3.58

29.80
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Figure 4.10. (A) 1H T1 of a-NIF cryomilled for varying times representing changes in
crystal quality. (B and C) 1H T1 measured at various annealing temperatures for all
components is shown for (B) 80-20, and (C) 90-10 NIF-PVP ASDs and cryomilled NIF.
In (B) and (C) PVP is represented by black symbols, amorphous NIF is red, and crystalline
NIF is blue. The crystalline NIF T1 was determined using a modified saturation-recovery
1

H T1 pulse sequence with a 128 ms T1r-filter.
Amorphous NIF and PVP share a common 1H T1 value which is constant with

increasing Ta. This indicates the resulting ASD remains intimately mixed on an
approximately 40 nm domain size (85). The 1H T1 of crystalline NIF is different from pure
a-NIF and increases with Ta, nearly doubling over the 30°C annealing range. This is likely
due to the combined effect of a reduced crystallite size and greater crystalline defects at
lower temperatures. The differences in crystalline T1 are visually explained by the
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polarized light microscopy (PLM) images in Figure 4.11 which show NIF crystals grown
at different annealing temperatures.

Figure 4.11. Polarized light microscopy images of NIF crystals formed during 80-20 NIFPVP ASD annealing at (A) 130°C, or (B) 160°C.
An increase in crystalline T1 with Ta is explained by a corresponding increase in
crystal quality despite a decrease in NIF crystallite size (see Figures 4.10B and 4.11).
Crystals grown at lower Ta show a wide crystallite size distribution and contain a high
degree of crystal defects including fractures and rough edges. Crystal growth is highly
irregular and occurs mainly in clusters (Figure 4.11A). It also appears that a small amount
of b-NIF, whose T1 is nearly 20 s shorter than a-NIF, may form at lower Ta and was not
detected by DSC or PXRD (Figure 4.11A bottom right panel) (85). Crystals formed at
160°C are much more uniform in size, smaller, appear to be of higher quality, and are
homogeneously dispersed throughout the entire sample (Figure 4.11B). The causes and
implications of changing crystalline T1 times are examined further in section 4.4.2.2.
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4.3.4

Crystallinity Method Comparison
Figure 4.12 compares the drug crystallinity in 70-30, 80-20, and 90-10 NIF-PVP

ASDs calculated using DSC (heat of dissolution and GT equation), PXRD, and SSNMR
(T1 and deconvolution). As the polymer content increases, the amount of drug required to
saturate the polymer also increases, thereby decreasing the amount of crystalline drug after
annealing. At higher annealing temperatures, NIF is more soluble in PVP, also resulting in
lower crystallinity. Methods OvHd and DSCHd consistently yielded 10 – 35% less
crystallinity than Tg-based methods across all drug loadings regardless of whether samples
were annealed in-situ (DSC) or ex-situ (oven). This difference was amplified at lower drug
loadings. Likewise, methods OvTg, DSCTg, and PXRD all show almost identical levels of
crystallinity across all annealing temperatures for 70-30 and 80-20 ASDs indicating a
similar ability of DSC (GT equation) and PXRD to quantify crystallinity in NIF-PVP ASDs
of moderate drug loadings. Crystallinity measured using methods NMRT1 and NMRDec
agreed well with one another and provided slightly lower levels of crystallinity in 80-20
ASDs compared to Tg- and PXRD-methods. Likewise, method NMRT1 agreed very well
with PXRD results in 90-10 ASDs.
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Figure 4.12. NIF crystallinity in (A) 70-30, (B) 80-20, and (C) 90-10 NIF-PVP K12 ASDs
measured using different methods. The color of the data points indicates the method used:
black (DSC GT), red (DSC ∆Hdiss), blue (oven GT), gray (oven ∆Hdiss), purple (PXRD),
orange (SSNMR T1), and pink (SSNMR deconvolution).
90-10 ASDs appeared mostly crystalline after annealing and crystallinity was
constant with Ta when analyzed by the GT equation (methods OvTg and DSCTg). The
accuracy of the measurements was suspect because the Tg values were poorly resolved.
Similar trends were again observed measuring ∆Hdiss. Methods OvHd and DSCHd
measured 15% lower crystallinity than that predicted by methods OvTg and DSCTg.
Methods PXRD and NMRT1 were the only methods to observe a continual decline in
crystallinity with increasing Ta for 90-10 ASDs.
Crystallinity measured by PXRD agreed well with results of the GT equation and
SSNMR (Figure 4.12) for lower drug loadings. At high drug loadings, PXRD crystallinity
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decreases more with Ta than methods OvTg or DSCTg and predicts greater crystallinity at
lower Tas and less crystallinity at higher Tas in agreement with SSNMR. PXRD relies
mostly on the crystalline component for quantitation which is much more prevalent and
easily measured compared to methods OvTg and DSCTg which rely on the small
amorphous fraction remaining after annealing to quantify crystallinity.
Lastly, two SSNMR techniques (NMRT1 and NMRDec) were used to quantify
crystallinity and agree very well with one another. Each exhibited similar trends compared
to methods OvTg, DSCTg, and PXRD although the measured crystallinity was 5-10%
lower for 80-20 ASDs. Interestingly, both NMRT1 and NMRDec measured lower
crystallinity at 130°C relative to 135°C, disagreeing with DSC and PXRD techniques and
suggests equilibrium crystallinity was not achieved during the annealing time.
4.3.5

Solubility Method Comparison
The solubility plot in Figure 4.13 displays the amorphous weight fraction of NIF

remaining in the ASD at a given temperature. Predicted solubility at 25°C, 100° C, and Tg
using each analytical method is shown in Table 4.6. Figure 4.13 shows that methods OvTg,
DSCTg, PXRD, NMRT1, and NMRDec yield comparable levels of crystallinity.
Therefore, each method was expected to predict similar solubility. Conversely, methods
DSCTg and DSCHd yielded significantly lower levels of crystallinity so it follows that the
predicted solubility would be significantly higher.
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Figure 4.13. The equilibrium weight fraction of amorphous nifedipine at different
temperatures determined using different analytical methods. Experimental data (filled
circles) fitted to the Flory-Huggins equation is represented by the solid lines and used to
predict solubility at low temperatures. (A) 70-30, (B) 80-20, and (C) 90-10 NIF-PVP K12
ASDs. The color of the data points indicates the method used: black (DSC GT), red (DSC
∆Hdiss), blue (oven GT), gray (oven ∆Hdiss), purple (PXRD), orange (SSNMR T1), and pink
(SSNMR deconvolution).
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Table 4.6. Predicted solubility of NIF-in-PVP at 25°C, Tg, and 100°C using different
analytical methods.

Method

70-30

80-20

90-10

Temp.

Oven

(°C)

GT

25

Oven ∆Hdiss

DSC GT

DSC ∆Hdiss

PXRD

1.3

(7.6)c

1.1

(7.2)c

1.5

Tg=68.2

8.2

(23.3)c

7.1

(22.8)c

9.3

100

20.6

(38.2)c

(18.9)c

(37.7)c

22.4

25

1.4

(15.6)c

1.2

(13.4)c

1.3

2.2a (2.4b)

Tg=58.6

6.2

(28.9)c

5.6

(26.3)c

5.7

8.8a (7.3b)

100

21.5

(46.5)c

20.2

(44.4)c

20.4

26.0a (23.7b)

25

(11.2)c

(32.8)c

(7.7)c

(30.0)c

0.7

4.8

Tg=50.5

(20.6)c

(41.5)c

(16.3)c

(37.2)c

2.5

11.9

100

(42.3)c

(58.4)c

(38.3)c

(55.3)c

14.9

33.6

SSNMR

--

Calculated with method NMRDec. bCalculated with method NMRT1. cData did not fit to
the Flory-Huggins equation.
a

NIF solubility in PVP decreases with temperature from approximately 70% at
160°C to less than 2% at 25°C, agreeing well with the literature (66). Use of the GT or
PXRD methods (OvTg, DSCTg, and PXRD) yields similar solubilities of approximately
1.3% at 25°C when measured with 70-30 or 80-20 ASDs. Likewise, both SSNMR methods
NMRT1 and NMRDec predict similar, albeit slightly higher solubilities. The way in which
the sample is annealed seems to have no impact on crystallinity and solubility for moderate
drug loadings as the solubility of oven- (OvTg) and DSC-annealed (DSCTg) samples is
nearly identical at all temperatures in 70-30 and 80-20 ASDs, respectively. However, DSC
methods consistently overestimated solubility when high drug loadings were used while
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PXRD is able to accurately detect and quantify the remaining amorphous NIF in ASDs
with high drug loading resulting in a similar solubility measured even in 90-10 ASDs.
Crystallinity data was fit to the Flory-Huggins equation by linear regression while
solving for the drug-polymer interaction parameter, c. Table 4.7 lists the calculated c for
each method and drug loading.
Table 4.7. Experimental Flory-Huggins drug-polymer interaction parameter, c, measured
for each technique and drug loading.
DSC

Oven

DSC GT

∆Hdiss

Oven GT

∆Hdiss

PXRD

SSNMR

70-30

-1.5

(-3.9)c

-1.7

(-3.9) c

-1.9

N/A

80-20

-1.7

(-5.1) c

-1.8

(-5.6) c

-1.7

-2.4a (-2.0b)

90-10

(-4.0) c

-(8.4) c

(-4.7) c

(-9.8) c

-1.1

-3.2

Calculated with method NMRDec. bCalculated with method NMRT1. cData did not fit to
the Flory-Huggins equation.
a

For 70-30 and 80-20 ASDs, the Flory-Huggins equation fit the solubility data
predicted by methods OvTg, DSCTg, PXRD, NMRT1, and NMRDec very well. Each had
comparable c values similar to those reported in the literature and indicated similar drugpolymer miscibility regardless of the method used (66, 157). The Flory-Huggins equation
was a very poor fit to solubility predicted by ∆Hdiss regardless of the annealing method
(OvHd or DSCHd). This is a result of ∆Hdiss being a poor parameter for calculating
crystallinity. Consequently, methods OvHd and DSCHd inaccurately predicted solubilities
between 5 and 12 times greater than methods OvTg, DSCTg, and PXRD at 25°C.
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4.4
4.4.1

Discussion
DSC Analysis
The Tg (via the Gordon-Taylor equation) and ∆Hdiss were two DSC-based methods

chosen to compare their ability to measure crystallinity and determine solubility. While
other DSC methods exist for predicting solubility (66, 157), all DSC methods suffer from
the same challenges including calorimeter sensitivity, long analysis times, and sample
heating. However, the primary focus of this research was on quantifying crystallinity so
the two methods in this study were chosen as they first calculate crystallinity as opposed
to other DSC methods which focus solely on solubility.
4.4.1.1 Tg and Gordon-Taylor
Using Tg and Gordon-Taylor (GT) equation, methods OvTg and DSCTg easily
measured crystallinity and compared well with most other methods in this study. However,
their application is still limited in some cases; most notably at high drug loadings (90-10)
which resulted in a Tg which was poorly resolved and difficult to measure. While the
absolute value of Tg is independent of sample mass, the magnitude of heat capacity change
at Tg (i.e., Tg resolution) is directly related to the amorphous mass present.
NIF-PVP shows an experimental adherence to Tg values predicted by the GT
equation which is required for accurate quantitation. Typically, the GT equation fails when
specific drug-polymer interactions exist (76), however, the formation of weak NIF-PVP
hydrogen bonds energetically balance the breaking of NIF-NIF hydrogen bonds and no
significant deviation in Tg is observed across all drug loadings (82, 85). Deviation from the
GT equation would result in a systematic error between the measured and actual amorphous
fraction but may be corrected through an empirical Tg vs. drug fraction relationship.
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The usefulness of methods OvTg and DSCTg is also affected by a combination of
glass forming ability, drug-polymer combination, and sensitivity of the calorimeter. Small
differences in Tg between the drug and polymer result in changes too small to accurately
measure as a function of amorphous content. Complex polymers with a poorly resolved Tg
(e.g., HPMCAS) make measuring the pure or mixture Tg more difficult. Similarly, drugs
with a poor glass forming ability may also lead phase separation and errors in Tg
measurement (40). Faster DSC heating rates may be used to improve sensitivity and better
detect weak glass transitions, but the corresponding loss of resolution may ultimately limit
its applicability.
4.4.1.2 Heat of Dissolution
The attractiveness of methods OvHd and DSCHd stem from directly measuring the
crystalline component rather than probing the amorphous phase and may be useful in
situations where Tg is difficult to measure. In theory, any crystals present will melt upon
heating through Tm and should be captured by the heat of fusion (∆Hfus). However, in the
presence of polymer, a more appropriate depiction is crystalline drug dissolving into an
undersaturated dispersion which is measured by the heat of dissolution (∆Hdiss). The
proposed methods OvHd and DSCHd require an accurate measure of ∆Hfus and ∆Hdiss
which may be difficult using DSC (270). Certain difficulties associated with enthalpybased crystallinity measurements are well documented in the literature and include
assumptions which must be satisfied (75). The methods assume: (1) that ∆Hfus represents
a perfect crystal free of defects and remains constant regardless of crystal growth
conditions, (2) the reference ∆Hfus value corresponds to the same polymorph as the crystals
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being analyzed, and (3) that any amorphous drug already dissolved in the polymer does not
contribute to the excess crystalline drug which dissolves into the polymer upon heating.
Crystallinity measured using ∆Hdiss was consistently found to be significantly lower
than crystallinity measured using Tg-based DSC techniques, PXRD, or SSNMR.
Measuring ∆Hdiss requires reheating the annealed sample through its Tm which introduces
the possibility for changes to occur in the sample (crystallization, dissolution, polymorphic
transitions, melting point depression (MPD), etc.) prior to melting which can convolute
crystallinity and/ or solubility measurements. For instance, Ostwald’s rule of stages states
that certain systems may crystallize into a metastable polymorph prior to either melting
and recrystallizing into the stable polymorph or a solid-state polymorphic transition (271).
The metastable β- and g-NIF polymorphs observed in other NIF-PVP systems were not
observed in this work and are likely not the cause of low predicted crystallinity (266, 267).
Even in non-ideal systems where polymorphic transitions are known, they are often
difficult to detect, let alone obtain accurate values of ∆Hfus (75, 85, 263). Without
knowledge of specific polymorphic transitions or a reliable deconvolution method, the
∆Hdiss method may be limited to ASDs containing drugs with a single polymorph or
sufficient polymer present to retard polymorphic transitions. Previous studies using
enthalpy-based measurements have only employed standard DSC with fast heating rates in
an attempt to kinetically suppress any additional crystallization or dissolution upon
reheating (272-274). The results were heating rate dependent and consistently lower than
identical studies using Tg-based or melting point depression methods. Methods OvHd and
DSCHd used modulated DSC to eliminate the heating rate dependence and better
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deconvolute any simultaneous thermal events upon heating yet still predicted significantly
lower crystallinities than Tg-based methods.
Methods OvHd and DSCHd are further complicated by MPD which was observed
at all drug loadings, particularly for 70-30 ASDs. NIF and PVP are miscible and mix during
dissolution causing a reduction in the observed ‘melting’ temperature. As enthalpy is
temperature dependent, the integrated area of the dissolution endotherm is therefore
artificially lower than in reality (75). Therefore, it was not surprising that ∆Hdiss
underestimated crystallinity while overestimating solubility, particularly at lower drug
loadings.
The results indicate that, although additional thermal events are suppressed,
crystallinity is still poorly predicted and the first two method-specific assumptions
mentioned above likely do not hold true. Therefore, the results indicate that ∆Hfus does not
remain constant across the range of annealing temperatures used in this study. Drug
crystallization at varying conditions will change the properties of the crystal especially
when polymers are present (253). Imperfect NIF crystals formed in the presence of PVP
require less energy to melt or dissolve. A less endothermic dissolution would underestimate
crystallinity relative to the dissolution of perfect drug crystals and explain the deviations
of methods OvHd and DSCHd. Still, the explanation proposed above is only speculative
and cannot be easily explained by DSC without calibration standards. It would be
beneficial from a formulation perspective to have a quantitative method which also can
probe the quality of the crystals formed during annealing while avoiding potential heating
induced changes encountered during DSC analysis (vide infra).
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4.4.2

Alternative Analytical Methods
It is shown above that DSC is often adequate for quantifying crystallinity in ASDs.

However, there are many caveats when calculating crystallinity using Tg or ∆Hdiss. In
particular, it was especially difficult to measure the thermal events of interest in ASDs with
high initial drug loadings, ultimately restricting existing DSC methods to certain drugpolymer ratios. There are more sensitive analytical techniques which avoid many of the
issues associated with using Tg or ∆Hdiss for quantitation. Ideally, these methods would be
robust enough to characterize any drug-polymer system, including ones with high drug
loadings, slow crystallization kinetics, and poorly resolved thermal events. Since oven- and
DSC-annealing yielded equivalent results, oven-annealed samples were also used for
PXRD and SSNMR analysis to provide a direct comparison of the impact of the analytical
method on solubility determinations. Hence, the crystallinity and solubility at a given
temperature should be equivalent in each sample with differences only arising due to the
analytical method.
4.4.2.1 PXRD
PXRD has been used extensively for the detection and quantitation of molecular
order (i.e., crystallinity) in pharmaceutical systems (133). As the integrated intensity of a
phase’s diffraction peak can be directly related to the phase’s concentration in the sample,
PXRD is naturally suited for crystallinity and solubility measurements for ASD systems
containing only drug and polymer (133, 275, 276). Similar to ∆Hdiss methods, PXRD
probes the crystalline component rather than the amorphous component (Tg in DSC) for
quantitation. However, unlike DSC methods, PXRD does not require any additional sample
heating and, because a full powder pattern integration was used, variations in crystal
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quality, particle size, or preferred orientation have less of an effect on quantitation (133).
Quantitation based on the prominent crystalline peaks rather than the small amorphous
component is preferable and provides the option for faster solubility analysis for high drug
loadings. Maximum drug loadings found in the literature typically range from 80 – 85%
for the recrystallization method while much lower contents are often used for other
solubility methods such as melting point depression (68, 277).
PXRD gives better crystallinity results and exhibited much better adherence to the
Flory-Huggins equation compared to DSC-based methods even at 90% NIF. The predicted
solubility at 90% drug loading compared very well to PXRD measurements in 70-30 and
80-20 ASDs, as well values reported in the literature. The unique diffraction pattern of
distinct crystalline phases can be used to help clarify any thermal events, including
crystallization or polymorphic transitions, that may have occurring during annealing that
were obscured by reheating in the DSC to measure ∆Hdiss. This includes the identification
of various polymorphs and temperature regimes in which they may exist. MPD has also
been observed in miscible drug-polymer systems and may hide the melting of a metastable
polymorph and/ or recrystallization to another polymorph (65). PXRD analysis at ambient
temperatures avoids the issues involved with sample reheating and provides a snapshot of
the equilibrated system at an individual Ta.
4.4.2.2 SSNMR
SSNMR was also used as an alternate method for quantifying crystallinity as it is
an inherently quantitative technique where the signal intensity is directly proportional the
number of distinct nuclei present. In this case, this refers to the number of amorphous and
crystalline NIF molecules. Spectra acquired using cross polarization (CP) and total
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suppression of spinning sidebands (TOSS) were deconvoluted to directly measure the
populations mentioned above however CP TOSS is often assumed to be non-quantitative
(185). Quantitative phase data was acquired by deconvolution of CP TOSS spectra by
properly characterizing and accounting for CP dynamics, chemical shift anisotropy (CSA)
and signal saturation. Differences in CP dynamics were found to vary with Ta and were
corrected using the results of a variable CT experiment. TOSS was used to simplify each
spectrum as carbonyl and aromatic peaks exhibited spinning sidebands (SSBs). Without
TOSS, there was no single spinning speed which isolated the aromatic (isotropic peak =
102 ppm) SSBs from other peaks. Thus, deconvolution of the isotropic peak into its
crystalline and amorphous components may be erroneous if there are differences in the
intensity of SSBs relative to the isotropic peak between crystalline and amorphous phases.
Chemical shift anisotropy and the spinning SSB powder pattern is determined by the
structure of a molecule and the resulting asymmetric three-dimensional distribution of
electrons around a

13

C nucleus. In other words, the chemical structure, rather than the

phase, of the molecule determines the proportion of signal intensity contained in the SSBs
relative to the centerband. Shen et al. found that the SSB intensity ratio of crystalline to
amorphous poly(3-hexylthiophene) was approximately the same as that in the isotropic
peak (278). Similarly, crystalline and amorphous NIF exhibited almost identical SSB
patterns in CP spectra acquired without TOSS (data not shown). Therefore, the proportion
of signal lost to TOSS in each NIF phase was expected to be approximately equal.
Direct and indirect measurement of crystallinity with SSNMR was similar albeit
slightly lower than GT and PXRD methods but estimated solubilities at 25°C were ≤1%
higher. Like PXRD, SSNMR may also be applied to higher drug loadings as either the
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crystalline or amorphous component (or both) component can be used for quantification.
SSNMR can also be used for the simultaneous detection and quantification of polymorphic
and amorphous phases with superior limits of detection (185).
Deconvolution has been used previously for crystalline/ amorphous quantitation.
However, this was typically performed or verified using physical mixtures of crystalline
and amorphous drug assuming that the crystalline T1 in the mixture was constant and equal
to the pure component T1 in each system (185, 279). While beneficial from a quantitation
viewpoint, this looks at the final product and provides no information as to how the system
crystallizes. However, Figure 4.10A showed that T1 varied with cryomilling time and
reflects the fact that the 1H T1 of pharmaceuticals is sensitive to changes in crystal quality
as well as polymorphic form, purity, particle size, and sample preparation (85, 187, 242).
Therefore, any changes to the crystal would lead to error in quantitation. Thus, it would be
beneficial from a formulation perspective to develop a quantitative method which can also
probe differences in crystals formed.
Method NMTR1 was proposed based on the different T1 relaxation behavior of
crystalline and amorphous solids as a way to account for differences in crystal quality (187,
261). Although the peak at 102.6 ppm contains both crystalline and amorphous phases
relaxed according to Equation 4.7, fitting the relaxation data was undesirable as it would
require solving for four parameters simultaneously. Previous studies have assumed a
constant crystalline T1 to simplify the fitting procedure (279). The pure crystalline NIF 1H
T1 was easy to measure but values ranging from 29.3 – 32.4 s have been reported in the
literature (85, 269). However, since crystal quality is directly affected by crystallization
conditions and the presence of polymers, it follows that processing parameters (i.e., drug
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loading, annealing temperature, etc.) will also affect the quality of crystalline material
formed (61, 253). Therefore, the pure a-NIF T1 was not considered constant nor
representative of crystals formed during the annealing study. A T1r-filter was applied to a
separate T1 experiment to eliminate any signal from amorphous NIF and allow for an
accurate in-situ measurement of the crystalline T1.
Figures 4.10B and C showed that differences in T1 exist between pure a-NIF and
a-NIF crystallized in the presence of PVP. The crystalline T1 increases with drug loading
and Ta and is explained by crystallite size and quality. Namely, polymers used to inhibit
crystallization (e.g., PVP) caused the formation of imperfect crystals with the degree of
imperfections modulated by the crystal growth temperature (Ta). The T1 of amorphous NIF
and PVP remained approximately constant indicating the formation NIF crystals has no
effect on the mobility of the remaining ASD and the NIF and PVP remain intimately mixed
on an approximately 40 nm domain size (85). SSNMR can therefore be used to distinguish
between residual crystals after processing and crystals formed in situ during storage. The
differences in crystalline T1 are visually explained by the polarized light microscopy
(PLM) images in Figure 4.11 which show NIF crystals grown at different annealing
temperatures.
The difference in crystal size and quality can be explained through the kinetics of
crystallization and supersaturation. The Hoffman equation predicts the thermodynamic
driving force for crystallization of NIF at 130°C is over three times greater than at 160°C
(44). In reality, the difference in driving force is likely greater as the Hoffman equation
does not consider the presence of polymer and the relative supersaturation at each
temperature. The Flory-Huggins equation predicts nearly a two-fold increase in NIF
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solubility from 130°C to 160°C. Specifically, the supersaturation ratio at 130°C is
approximately 1.75-times that at 160°C and directly affects both crystal quality and growth
rate (280). Equilibrium is reached rather quickly at 160°C while the lower supersaturation
ratio at 160°C is more conducive to growing higher quality crystals. Conversely, the greater
supersaturation ratio at 130°C results in the faster growth of larger crystals before
equilibrium is reached. Additionally, samples at 130°C are also closer to the temperature
regime of maximum nucleation rate which increases the likelihood for continuous
nucleation during the crystallization process and a reduction in crystal quality (38).
Method NMRT1 is shown to be a useful approach to accurately quantify
crystallinity even at high drug loadings while also providing a way to further characterize
the entire system. Perhaps most importantly, the T1 relaxation times determined using
method NMRT1 shed light on the changing crystal properties and help to explain the failure
of other methods in accurately predicting crystallinity. In particular, the heat of dissolution
methods assumes that ∆Hfus is constant and representative of crystals formed at all
conditions and does not account for imperfect crystals formed in the presence of PVP. In
addition, crystal quality further changes as a function of Ta as indicated by a reduction in
crystalline T1. Reduced crystal quality and particle size reduces the effective ∆Hfus causing
an underestimation of crystallinity and explain the large temperature- and compositiondependent changes in Figure 4.12. Crystalline quality (measured with 1H T1 values)
increased with annealing temperature with the highest quality crystals most similar to pure
a-NIF formed at high Ta. Further, the crystal quality is inversely related to the amount of
polymer present (Figures 4.10B and C). As a result, the difference in crystallinity measured
with methods OvHd/ DSCHd and other methods decreases with increasing drug loading
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(Figure 4.12). Smaller T1 values at low annealing temperatures indicate the lowest quality
of crystals formed in this study whereas high annealing temperatures resulted in T1 values
closer to pure a-NIF. The magnitude of crystallinity deviation between ∆Hdiss-based
methods and other methods also decreases with temperature. Further, the amount of
polymer present is inversely related to crystal quality. Crystals formed in the presence of
20% PVP (Figure 4.10B) have a lower T1 at all annealing temperatures than crystals formed
with only 10% PVP (Figure 4.10C). This difference is also reflected in Figure 4.12A, B,
and C where the average crystallinity difference between methods OvHd or DSCHd and
other methods decreases with increasing drug loading.
The changing crystalline T1 for crystallization out of an ASD also has implications
for quantification using peak deconvolution. Previous techniques including direct
exponential curve resolution algorithm (DECRA) or similar reference methods often
assume a constant T1 which we can now assume is incorrect and leads to systematic errors
for ASD analysis (260, 261). Similarly, the proposed T1r-filter method improves upon
existing methods to isolate the crystalline and amorphous T1 times in solid dispersions by
requiring minimal optimization and the ability to easily discriminate between physical
mixtures and ASDs (262).
Information pertaining to the crystal quality would also be beneficial for
troubleshooting or root cause analysis in situations in which the amorphous drug product
fails quality testing. Using the 1H T1 relaxation time measurements provides additional
information as to where in the production process the crystals formed. For instance, a short
crystalline T1 measured would suggest the crystals formed during a low-temperature stage
of processing while a longer T1 would indicate high-temperature crystallization.
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4.4.3

Equilibrium Crystallinity and Drug-in-Polymer Solubility
The predicted NIF-PVP solubility using SSNMR, PXRD, and Tg-based methods is

approximately 1.5% at 25°C and agrees relatively well with values reported in the literature
(65, 66). The structurally similar drug, felodipine, has a predicted solubility between 5 and
8% in PVP at 25°C based on the method used regardless of polymer viscosity (68, 157).
Other drugs, including indomethacin (IND), have much higher predicted solubilities of 30
– 40% at 20°C in various PVP grades (66, 74, 277). The solubility of some drugs, including
NIF and IND may be improved by changes in the polymer, the magnitude of which is
dependent on the drug. For instance, at 25°C, IND and NIF are essentially insoluble in
PVA but switching to PVP K12 improves IND solubility to nearly 40% while NIF is only
increased to 2% (66).
The low crystalline solubility of most drugs in polymers means that high polymer
contents are required to thermodynamically stabilize a drug formulated in an ASD. This is
undesirable as it would only be feasible for low dose formulations of a highly potent drug
(65). Therefore, it seems that the potential of ASDs lies in the ability to kinetically stabilize
the amorphous drug. Indeed, the predicted NIF-PVP solubility agrees well with the
literature but was only ca. 1.5% at 25°C (65, 66). Still, the drug-polymer solubility is an
important system property which, when correctly calculated, remains useful for the rational
design of ASD formulations.
The correct measurement of drug-in-polymer solubility using ASD crystallinity
requires that equilibrium is reached. While there is more than one way to reach equilibrium,
the results of this study can be directly applied to the recrystallization method. The most
difficult part of measuring a solid-state solubility is the attainment of equilibrium. A
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decreasing chemical potential difference results in the considerable slowing of
crystallization kinetics out of a supersaturated dispersion as equilibrium is approached.
Although recrystallization is thought to be faster than dissolution/ mixing, it is likely that
previous studies measuring drug-in-polymer solubility suffered from not truly reaching
equilibrium as the extent of crystallization or mixing is limited by practical in-situ
annealing times and DSC heating rates, respectively (65, 66, 69, 157, 277). Failure to reach
equilibrium through the recrystallization method will overestimate solubility, possibly
resulting in the formulation of an ASD falsely believed to be thermodynamically stable. In
this study, variable annealing time experiments showed complete crystallization took up to
24 hours in some system indicating sufficiently long annealing times must be allowed for
crystallization to conclude.
Achieving equilibrium is non-trivial as it is dependent on time, temperature, and
drug loading. Almost all approaches to determine drug-in-polymer solubility to this point
have used DSC for annealing and analysis which limited the time allowed to reach
equilibrium to reasonable experimental times. Therefore, three options exist to improve the
likelihood that equilibrium is achieved: raise the temperature, increase drug loading, or a
non-time-constrained ex-situ annealing method (i.e., oven annealing).
4.4.3.1 In-situ DSC Annealing versus Ex-situ Oven Annealing
In order to achieve equilibrium at lower temperatures either the annealing time must
increase, or the thermodynamic driving force must increase through a higher drug loading.
There are practical limits on each of these approaches when recrystallizing out of a
supersaturated ASD to approach equilibrium. At high temperatures and moderate drug
loadings, crystallization occurs quickly, reaching equilibrium relatively fast. Increasing
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viscosity reduces molecular mobility and slows crystallization kinetics at lower Tas despite
an increasing thermodynamic driving force. The change in system dynamics with
temperature limits crystallinity and solubility measurements to high temperatures which
are then extrapolated to temperatures of interest.
Annealing would ideally be performed at the temperature of interest (storage or
processing) or as low as possible to minimize the extrapolation of the Flory-Huggins
equation. Shake-flask methods have been proposed at ambient temperatures however they
are limited to polymers with low molecular weight liquid analogues and tend to
overestimate solubility (68, 157, 158). In theory, the lower temperature limit, Tx9ytys , is

reached at Ta=Tg but in practice is slightly higher due to slowing crystallization kinetics as

Tg is approached with the exact difference in temperature between Ta and Tg being system
dependent. At temperatures below Tg, the system is not in equilibrium and may lead to
overestimated solubility using the Flory-Huggins equation. Nonetheless, the FloryHuggins equation is a useful tool for extrapolation when comparing between analytical
methods. Thus, it is of great interest to reduce Tx9ytys through increased drug loadings or
new anneal techniques.

The measured solubility is a thermodynamic property and should theoretically be
constant regardless of the initial drug loading. Increasing the initial drug loading increases
the supersaturation ratio which is directly related to the crystal growth rate. Therefore,
changing the thermodynamic driving force (supersaturation ratio) at a constant temperature
will only affect the rate at which equilibrium is achieved through faster crystal growth and
possibly a decreased nucleation induction time (280).
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Selecting an appropriate drug loading for determining solubility from crystallinity
measurements is a balance between experimental time, stability, and analytical sensitivity.
Low drug loadings are easily quantified by DSC but are sufficiently stabilized by the
polymer and require long annealing times. Increasing the drug loading is usually preferred
to increasing the annealing time as experimental throughput is improved for DSCannealing methods. However, DSC struggles to accurately quantify crystallinity in high
drug loadings while PXRD and SSNMR may not always be readily available. Hence, it
may be preferred to use a lower drug loading that is more representative of the final
formulation and more easily quantified by DSC despite the longer annealing times. It is
therefore desirable to develop a method to allow sufficient annealing times when lower
drug loadings are required.
Annealing in ovens (methods OvTg and OvHd) rather than DSC (methods DSCTg
and DSCHd) was proposed as a way to overcome the annealing time limitations of DSC
and better represents an annealing process encountered in the drug development process.
Comparison of DSC- and oven-annealed samples confirmed that each technique showed
equivalent levels of crystallinity across almost all drug loadings and temperatures (ovenannealed crystallinity was slightly lower at high Tas) regardless of whether Tg or ∆Hdiss was
used for quantitation. We believe this is the first instance of using ex-situ crystallization
for measuring drug-polymer solubility. Provided that the drug remains chemically stable,
this methodology can overcome the experimental time limitations which often restrict the
use of recrystallization for solubility calculations to fast-crystallizing drugs and high drug
loadings.
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4.4.4

Summary of Methods
This research demonstrates that a while variety of analytical methods may be used

to determine crystallinity in ASDs, there are caveats to each technique that must be
accounted for in order to accurately measure crystallinity. Furthermore, crystallinity may
be used to predict drug-in-polymer solubility provided that sufficient annealing time is
allowed to reach equilibrium. Table 4.8 provides a summary of each method used and its
potential limits to application for drug-polymer solubility measurements.
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Table 4.8. Summary of each technique used for drug-in-polymer solubility measurements.
Method

Advantages

Disadvantages

Gordon-Taylor

Relies only on amorphous content

Potentially difficult to

DSC

Small sample volume

measure Tg
Assumes GT equation
adherence

Heat of

Measurement at given temperature

Poor crystallinity prediction

Dissolution

Small sample volume

(insensitive to crystal quality
and polymorphic changes)

DSC
PXRD

Potential to use higher drug loadings

Potentially large sample

Sensitive to polymorphic changes and

volume

potentially crystal quality

Requires background
subtraction
Preferred orientation
May mistake nanocrystals
for amorphous material

SSNMR

Enhanced sensitivity of crystalline and

Large sample volume

amorphous components

Long analysis time

Sensitive to polymorphs and crystal quality
Potential to apply to formulated products
Distinguishes between residual and
induced crystals
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These results demonstrate not only the importance of a method which can
accurately quantify the crystallinity of various drug-polymer combinations but also the
difficulties facing the stable formulation of an ASD. The newly presented use of PXRD
and SSNMR to measure drug-in-polymer solubility expands the ways in which a critical
formulation parameter can be accessed from a previously DSC-dominated field. However,
it is crucial to understand how the strengths and weaknesses of each method limit the
applicability of each to certain situations. In situations where all analytical methods are
available, concurrently using multiple methods allows for a range of crystallinity and
solubility values to be determined including conservative and liberal estimates. PXRD or
SSNMR may be preferred as they provide additional information including polymorphic
forms and crystal quality which is missed using DSC. Similarly, if only DSC is available,
analysis may be limited to moderate drug loadings and or systems with a single polymorph.

4.5

Conclusion
This work compared various analytical methods and techniques for quantifying

endogenous crystallinity in an ASD. Annealing-induced crystallinity was analyzed using
various DSC, PXRD, and SSNMR techniques. DSC measurements of the Tg (GT method)
accurately quantified crystallinity while ∆Hdiss was a poor measure of crystallinity. PXRD
and two different SSNMR methods agreed well and also provided a good measure of
crystallinity. The results of the crystallinity analysis at various temperatures were used to
determine the solubility of NIF in PVP via extrapolation of the Flory-Huggins equation. At
moderate drug loadings, the GT method, PXRD, and SSNMR all produced results in
agreement with published literature values. While the GT or other DSC methods are the
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industry standard, they are often limited by high drug loadings or to ‘ideal’ systems. PXRD
and SSNMR can overcome these limitations and expand crystallinity and drug-polymer
solubility measurements to high drug loadings and non-ideal systems including where Tg
is poorly resolved, Tg is similar between drug and polymer, multiple polymorphs exist,
and/ or slow crystallization kinetics. For the first time, it was shown that ex-situ annealing
in ovens provided equivalent results to in-situ DSC annealing and provides a way to
increase experimental throughput while ensuring equilibrium crystallinity was achieved.
Additionally, PXRD and SSNMR enable the advanced in-situ characterization of the
equilibrated system beyond what is possible with DSC. A new SSNMR T1 relaxation time
method showed that crystalline T1 changes with annealing conditions and must be
accounted for to obtain accurate quantitative data. In addition, SSNMR may be used to
distinguish between residual crystals and crystals formed during storage. The PXRD or
either SSNMR technique can help improve the reliability of measurements and expand the
number of systems able to be analyzed for drug-polymer solubility.

Copyright © Travis Wayne Jarrells 2022
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CHAPTER 5: IMPACT OF STORAGE CONDITIONS ON THE PHYSICAL
STABILITY OF AMORPHOUS SOLID DISPERSIONS CONTAINING TWO
STRUCTURALLY SIMILAR DRUGS
5.1

Introduction
A significant number of drugs on the market and drug candidates in development

suffer from poor solubility (281). An increasingly common formulation strategy to improve
dissolution and apparent solubility is the amorphization of drugs. The improved solubility
of the amorphous state is offset by its inherent physical instability and propensity to
recrystallize. Homogeneous incorporation of the drug with a water-soluble polymer to
create an amorphous solid dispersion (ASD) has been shown to result in improved
solubility relative to the crystalline state while also improving stability relative to the purely
amorphous drug.
The drug should remain in the amorphous state during manufacture, storage, and
dissolution to maintain the solubility advantage relative to the crystalline form. For
example, Hate et al. showed that residual crystallization in tacrolimus-HPMC leads to
decreased solubility, absorption, and bioavailability with the effects exacerbated as
crystallinity increases (247). Extensive research has been done to improve the
understanding of how to stabilize ASDs against crystallization (282-286). This includes
strategies for the selection of polymers, processing techniques, storage conditions, and their
effect on product performance. Despite a general knowledge of amorphous stability, ASDs
must still be analyzed over the course of a stability study to ensure crystallization is
inhibited over the course of the shelf life.
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There are three main ways by which a polymer typically acts to prevent or delay
crystallization in ASDs depending on the drug-polymer combination and their relative
concentrations: antiplasticization, specific interactions, and dilution/ physical barrier. First,
antiplasticizing polymers raise the glass transition temperature (Tg) of the mixture relative
to the pure drug while reducing drug’s molecular mobility. Second, the polymer may also
form specific interactions with the drug when certain functional groups are present on the
drug and polymer. These bonds may form in the amorphous state and resist
recrystallization. The strength and number of drug-polymer interactions are thought to
correlate directly with the physical stability of the ASD (282, 287). Systems in which the
drug-polymer interactions are energetically more favorable than crystalline drug-drug and
polymer-polymer interactions are expected to have improved amorphous stability (58).
Third, polymers present in high enough concentrations can dilute the drug molecules in the
solid solution and/ or may act as a physical barrier between drug molecules thereby
stabilizing the amorphous phase (89, 288). Understanding and applying the specific
mechanisms by which a polymer stabilizes the amorphous API improves the likelihood
that the ASD will remain stable over its shelf life.
The ability of ASDs to resist crystallization is a complex relationship involving
storage temperature, drug loading, and other factors, such as humidity, which can impact
molecular mobility. This complicates the ability to predict the shelf life of an amorphous
formulation. Kinetic data observed in the supercooled liquid state can ideally be
extrapolated to predict crystallization near and well below Tg. However, unlike chemical
degradation, physical instability (i.e., crystallization) typically does not follow Arrhenius
kinetics and cannot necessarily be extrapolated to relevant storage conditions. Molecular
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mobility and various thermodynamic properties are dynamic and their temperature
dependence can change dramatically as the ASD passes through the Tg, yet some molecular
motions have been successfully linked to crystallization (20). Crystallization onset was
coupled to molecular mobility above Tg to predict crystallization onset below Tg from
relaxation measurements in amorphous sucrose and three poorly soluble drugs (114, 289).
Later, these results were expanded to ASDs (290). Similarly, dynamic dielectric
spectroscopy was used to predict stability in amorphous itraconazole and itraconazoleASDs (287, 291). However, their predictions only were valid above the Tg. The molecular
motions contributing to crystallization above Tg (a-relaxation) may not necessarily be the
main contributors to crystallization below Tg (Johari-Goldstein β-relaxations). Conversely,
Greco et al. did not measure molecular mobility yet were still successful in predicting
crystallization onset below Tg over a year after thermal and gravimetric measurements
above Tg (292). Therefore, the stability of amorphous systems must be observed both in
the glassy and supercooled liquid states with particular attention paid near Tg where
viscosity and heat capacity change drastically.
Predicting the rate of crystallization in some organic systems is further complicated
by an acceleration in crystal growth kinetics near and just below Tg. Crystal growth rate in
supercooled liquids is normally well predicted by diffusivity. However, certain molecules
unexpectedly exhibit an increase in growth rate of up to four orders of magnitude near Tg
relative to their diffusion-controlled crystal growth rate. This anomalous change in crystal
growth kinetics is termed glass-crystal (GC) or diffusionless crystal growth. It was first
observed in o-terphenyl and has since been studied extensively (51-53). The exact origin
of this anomalous change in growth rate is still unknown although multiple theories have
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been proposed including homogeneous-nucleation-based crystallization, tension-induced
interfacial mobility, crystal growth by local mobility, and, recently, free surface accelerated
crystal growth (52, 54, 55, 293). Diffusionless crystal growth has been observed in
indomethacin and 99-1 (w/w) IND-polyvinylpyrrolidone ASDs and may help to explain
experimental observations herein (294, 295). To the best of the authors’ knowledge, GC
growth has only been observed to affect crystal growth rate. However, its often difficult to
separate the two steps of crystallization: nucleation and crystal growth (131). Presumably,
the similar phenomenon (now termed ‘diffusionless crystallization’) could be observed for
nucleation rate or crystallization onset times. Regardless, the existence of diffusionless
crystallization underscores the need for sufficient characterization of ASD stability near Tg
in addition to accelerated stability in the supercooled liquid state.
The purpose of this study was to compare the physical stability of indomethacin
(IND)-polyvinylpyrrolidone (PVP) and indomethacin methyl ester (INDME)-PVP ASDs
containing different ratios of drug and polymer that were stored both above and below Tg.
IND is a poorly soluble nonsteroidal anti-inflammatory drug that has been used extensively
as a model drug for ASD formulations. PVP is a commonly used polymer to help stabilize
amorphous formulations through antiplasticization and the formation of drug-polymer
hydrogen bonds (84, 284). INDME is a structural analogue of IND which lacks the ability
to donate hydrogen bonds through the carboxylic acid and provides a unique opportunity
to directly measure the impact of hydrogen bonding on physical stability while minimizing
confounding structural effects. ASDs of varying drug-polymer ratios were prepared and
stored at temperatures 7-40°C for INDME and 40-100°C for IND. It was found that the
crystallization onset time of both IND and INDME is exponentially related to the polymer
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content in the dispersion. INDME generally crystallized faster than IND at a constant drug
loading above Tg but crystallization rates were much closer in the glassy state. IND
crystallization occurs faster than expected near and below Tg while INDME onset times
above Tg could be extrapolated below Tg. IND crystallization was governed by a
combination of storage temperature and drug-polymer hydrogen bonding while INDME
lacks strong hydrogen bonds with PVP and its crystallization is controlled only by
antiplasticizing effects. IND was better stabilized by PVP above Tg while INDME was
better stabilized near and below Tg. For the first time, diffusionless crystallization was
observed in amorphous systems with formulation-relevant polymer contents. Changes in
molecular mobility, similar hydrogen bonding configurations between the crystalline and
amorphous state, and an increased thermodynamic driving force are found to contribute to
diffusionless crystallization in IND-PVP ASDs.

5.2
5.2.1

Materials and Methods
Materials
The g-polymorph of IND (lots YT4QE-OC and YT4QE-BP) was purchased from

MilliporeSigma (St. Louis, MO) and used as received in all experiments. PVP K12 (lot
0001970609, MW = 4 – 6 kg/mol) was a generous gift from Ashland Inc. (Covington, KY).
PVP was dried overnight in a vacuum oven at 75°C and stored over Drierite at all times to
minimize absorbed moisture prior to use. Indomethacin methyl ester (INDME) was
synthesized in a method similar to Yuan (154). 7.5 g of IND (lot YT4QE-BP), 150 mL
high-purity methanol, 0.375 mL sulfuric acid, and ca. 2 g of molecular sieves (3Å, 4x8
mesh size) were refluxed at 70°C while stirring for 40 hours. The reaction product was

199

filtered and purified by recrystallization and repeated washing with methanol and milliQ
water. INDME purity was confirmed through thin layer chromatography, powder X-ray
diffraction (PXRD), differential scanning calorimetry (DSC), thermogravimetric analysis
(TGA), and 1H nuclear magnetic resonance (NMR) spectroscopy. The chemical structures
of IND, INDME, and PVP are shown in Figure 5.1.
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Figure 5.1. Chemical structures of indomethacin (IND), indomethacin methyl ester
(INDME), and polyvinylpyrrolidone (PVP).
5.2.2

Preparation of Amorphous Solid Dispersions
ASDs of IND or INDME and PVP were prepared by a cryo-mill and melt-quench

method. Physical mixtures were milled using a SPEX 6775 Cryogenic Grinder (Metuchen,
NJ). A 2 minute precool was followed by 6 cycles of 2 minutes grinding and 2 minutes
cool-down. IND or INDME samples were equilibrated to room temperature then melted in
Teflon beakers at 190°C or 150°C, respectively, for 5 minutes. The molten sample was
then placed directly into liquid nitrogen. The resulting glassy ASDs containing IND were
lightly ground into a fine powder using a mortar and pestle. ASDs containing 80% (w/w)
or more of INDME were not ground due to its low Tg and stickiness at room temperature.
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Powdered samples were dried overnight at 25°C using a vacuum oven to remove any
moisture absorbed during formulation.
5.2.3

Differential Scanning Calorimetry
DSC experiments were performed using a Discovery DSC 2500 (TA Instruments,

New Castle, DE). They system was purged with 50 mL/min nitrogen gas and cooled with
a RCS90 cooling accessory. Indium and sapphire were used to calibrate the DSC for
temperature and heat capacity, respectively. Unless otherwise noted, 3 – 5mg of sample
was placed in Tzero Hermetic Aluminum pans with a single pinhole.
5.2.3.1 Glass Transition Temperature Measurement
The Tg of dried ASDs and pure amorphous IND or INDME were determined using
modulated DSC (+/- 0.7°C every 40 seconds). IND-PVP ASDs were first heated from 20°C
to 200°C at a rate of 10°C/min, cooled to -10°C at -30°C/min, then reheated to 200°C at
5°C/min. INDME-PVP ASDs were heated from 20°C to 150°C at 10°C/min, cooled to 50°C at -30°C/min, then reheated to 150°C at 5°C/min.
The Tg was recorded as the midpoint of the glass transition event and used to assign
storage temperatures such that the ASDs were stored both above and below the Tg. The
dried ASDs were divided into scintillation vials and placed into desiccators filled with
Drierite. Desiccators containing IND ASDs were placed into ovens at between 40°C and
100°C for at least 6 months. Desiccators holding INDME ASDs were stored at between
7°C and 40°C for a minimum of 2 months.
5.2.3.2 Crystallization Thermodynamics
The thermodynamic driving force for crystallization of pure drug above Tg was
estimated using the Hoffman equation (Equation 5.1) (44).
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(5.1)

The change in free energy (∆GC) upon crystallization at a given temperature (T) is
determined using pure drug melting temperature (Tm) and heat of fusion (∆Hfus). Tm and
∆Hfus were determined using standard DSC at a 2°C/min heating rate. The Hoffman
equation assumes that enthalpy is a linear function of temperature for both the supercooled
liquid and crystal. This is not necessarily true, particularly near Tg (58). Therefore,
configurational properties were also determined based on the difference in the amorphous
(CP,amorph) and crystalline (CP,crystal) heat capacity. Equations 5.2 – 5.5 shows the
configurational heat capacity (CP,config), enthalpy (Hconfig), entropy (Sconfig), and free energy
(Gconfig) (56).
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(5.2)
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(5.4)
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Here, the entropy of fusion (∆Sfus) equals ∆Hfus/Tm. Configurational properties were
determined using a modulated DSC heat-cool-heat procedure of 2°C/min heating,
30°C/min cooling, +/- 0.5°C every 60 seconds.
5.2.4

Powder X-ray Diffraction
Samples were analyzed via PXRD for crystallization. The samples were scanned

initially (before storage at elevated temperatures) and then periodically for upwards of 9
months using either a Rigaku MiniFlex 600 PXRD or Rigaku SmartLab diffratometer
(Rigaku Americas, The Woodlands, TX). Initial powder samples were used ‘as is’ in the
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MiniFlex operating at 15mV and 40mA. Approximately 10 mg of aged sample was
removed from the scintillation vial at each time point and scanned using the SmartLab
(40mV and 44mA). Each sample was scanned from 5 – 50° 2q at 2°/min, and 0.02° step
size in Bragg-Brentano mode with a Cu-Ka radiation source. Diffraction peaks were
indicative of sample crystallization. All INDME stability was acquired using the Smartlab
diffractometer.
5.2.5

Fourier Transform Infrared Spectroscopy
The hydrogen bonding of samples was studied using Fourier Transform Infrared

Spectroscopy (FTIR) with an Attenuated Total Reflectance (ATR) diamond crystal
attached. A Nicolet iS50 FTIR (Thermo Fisher Scientific, Waltham, MA) or Bruker Vertex
70 FTIR spectrometer (Bruker Corporation, Billerica, MA) was used for the analysis.
Powdered samples were placed on the diamond ATR crystal (single bounce, 42° angle of
incidence). Each sample was scanned 64 times from 4000 to 400 cm-1 with 4 cm-1
resolution. Experiments were repeated in triplicate with the mean spectra reported. An
ATR correction was applied to account for varying evanescent wave penetration as a
function of wavelength and a rubber band baseline correction was also applied. The
carbonyl peak intensity in each spectrum was normalized for comparison purposes.

5.3

Results
The purpose of this study was to investigate the effects of drug-polymer hydrogen

bonding on the physical stability of ASDs by comparing the crystallization onset times of
IND-PVP and INDME-PVP ASDs. ASDs were first prepared and characterized to ensure
that they were fully amorphous and consistent with prior studies of the identical ASDs (84,
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89, 154, 284). The ASDs were then stored around their glass transition temperature and
monitored for signs of crystallization using PXRD.
5.3.1

Initial Amorphous Solid Dispersions
All IND-PVP ASDs were analyzed to confirm that their formulation resulted in the

complete loss of crystallinity. All initial IND- and INDME-PVP ASDs were X-ray
amorphous as evidenced by the presence of broad amorphous halos and the lack of sharp
peaks in the PXRD diffractograms (Figure 5.2).

Figure 5.2. Initial powder diffraction patterns for (A) IND-PVP and (B) INDME-PVP
ASDs. Drug loading increases from 65% (top) to 100% (bottom).
Each initial sample was also analyzed using modulated DSC with a heat-cool-heat
cycle. The first heating cycle showed a single Tg, along with the absence of a melting
endotherm, indicating the melt-quench procedure created fully amorphous ASDs. Heating
to 200°C erased any thermal history attributed to the formulation process. The second
heating cycle Tg corresponds to the ‘ideal’ ASD and was used to assign storage
temperatures. Increasing drug content results in a linear decrease in the observed Tg from
the second heating scan (Figure 5.3).
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Figure 5.3. Observed and predicted (Gordon-Taylor equation) glass transition
temperatures for IND- and INDME-PVP ASDs. Tg values shown correspond to the second
heating cycle.
The Tg of IND dispersions decreases from 70.6°C in 65-35 ASDs to 44.2°C in pure
IND and is well predicted by the Gordon-Taylor equation. The Tg of INDME dispersions
decreases from 29.9°C to 6.5°C between 65% and 100% INDME and shows a large
negative deviation from the Gordon-Taylor equation. Deviations from the Gordon-Taylor
equation have previously been related to the presence of specific drug-polymer interactions
such as hydrogen bonds. However, specific interactions do not always result in deviations
nor does adherence to the Gordon-Taylor equation necessarily indicate the absence of
specific interactions (58, 75, 256, 296). Previous studies show extensive drug-polymer
hydrogen bonds are present in IND-PVP ASDs yet its Tg is well predicted by the GordonTaylor equation as IND-IND bonds are approximately the same strength as IND-PVP
bonds formed (84, 89, 126, 284). The presence and degree of specific drug-polymer
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interactions in INDME-PVP is not as well understood currently and may contribute to the
significant deviation from the Gordon-Taylor equation.
ATR-FTIR spectra were acquired for pure crystalline and amorphous drugs,
polymer, and initial ASDs to probe any specific interactions that may exist (Figure 5.4).
As mentioned above, extensive drug-polymer hydrogen bonding exists in IND-PVP ASDs
and the hydrogen bonding states associated with the carbonyl stretch of IND-containing
systems have been assigned previously (Figure 5.4A) (67, 84). Briefly, IND (carboxylic
acid)-PVP (amide) hydrogen bonds in ASDs replace the IND carboxylic acid dimers found
in g-IND (89).

206

Figure 5.4. The carbonyl region of ATR-FTIR spectra of initial (unaged) materials for (A)
IND and (B) INDME. Crystalline drug (black), amorphous drug (red), 80-20 ASD (blue),
and PVP K12 (gray).
Analogous FTIR peak assignments can be made in INDME systems based on its
similar chemical structure to IND (Figure 5.4B). Despite having no strong hydrogen bond
donor groups, weak CH-O intermolecular hydrogen bonds between the amide oxygen and

207

aromatic protons, as well as a Cl-O halogen bond with the carboxylic acid, are reported in
crystalline INDME (297). Presumably some degree of these weak interactions also exists
in amorphous INDME. No direct evidence of INDME-PVP specific interactions were
found, however weak intermolecular INDME interactions causing subtle spectral changes
are not easily detected using FTIR and may help to explain the deviation of INDME-PVP
ASDs from Tg predicted by the Gordon-Taylor equation.
IND-PVP and, to some extent, INDME-PVP ASDs have been studied previously
using solid-state nuclear magnetic resonance (SSNMR) spectroscopy. SSNMR confirmed
the presence of IND-PVP hydrogen bonds previously detected using DSC and FTIR and
was also used to quantify the relative populations of intermolecular hydrogen bonded
species as a function of drug loading (84, 89, 284). INDME showed no obvious signs of
hydrogen bonding with PVP via SSNMR although it has been studied in less detail than
IND (154). Additional SSNMR analysis may help to explain its large Tg deviations from
the Gordon-Taylor equation.
5.3.2

Stability Study
The effects of drug loading, storage temperature, and drug-polymer hydrogen

bonding on the physical stability of ASDs were investigated by comparing the
crystallization tendencies of IND and INDME as well as their dispersions with PVP. ASDs
were stored under identical conditions relative to their glass transition temperature to
isolate the effects of hydrogen bonding on crystallization onset time in two structurally
similar compounds.
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5.3.2.1 Storage Conditions
Samples were stored between T/Tg = 0.89 and T/Tg = 1.17 to directly compare IND
and INDME crystallization. Normalizing storage temperature to Tg allowed for the direct
comparison of compounds with widely varying Tg values (Figure 5.3). The effects of water
were minimized by storage over desiccant prior to testing for crystallization. Certain
samples were stored for longer periods of time to confirm whether crystallization trends in
the supercooled liquid continue at lower temperatures and/ or drug loadings.
Samples were assayed using PXRD at various time points starting at 30 minutes for
the highest drug-loadings or temperatures. Most samples were analyzed after one day and
then twice a week for two months after which the samples were analyzed weekly. After six
months, extended stability samples were scanned monthly.
IND diffraction patterns showed peaks consistent with g-IND (298). No other peaks
were present indicating all IND-PVP ASDs crystallized as the stable g-IND polymorph,
regardless of drug loading or storage temperature. Similarly, there is only one reported
INDME polymorph. All INDME diffraction peaks are consistent with the only reported
INDME crystal structure (297). This indicates consistency in crystallization of INDME
across the design space.
5.3.2.2 Crystallization Onset Time
The crystallization onset time (tc) is defined as the earliest time at which crystals
are detectable and was determined when peaks emerged in PXRD patterns. Figure 5.5
shows the onset of crystallization for ASDs stored at varying drug loadings and
temperatures.

209

Figure 5.5. Crystallization onset time detected by PXRD as a function of drug loading at
constant temperature for (A) IND-PVP and (B) INDME-PVP ASDs. Error bars correspond
to the difference between the last measurement and observed crystallization onset time.
The dotted lines at high temperatures and drug loadings indicate that crystallization was
observed at the earliest observation point (30 minutes).
The time for crystallization onset to occur decreased exponentially with drug
loading and storage temperature for both IND and INDME. Pure drugs crystallized in less
than a day at all storage temperatures. In fact, IND and INDME crystallized in less than 30
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minutes when stored in the supercooled liquid state above 70°C and 30°C, respectively. A
linear relationship was observed for the plot of log(tc) versus IND content for ASDs stored
where all drug-polymer concentrations studied were in the supercooled liquid state (≥
70°C). A similar linear relationship was observed for the plot of log(tc) versus drug INDME
content for ASDs stored where all drug-polymer concentrations studied were in the
supercooled liquid state (≥ 35°C). The slope of IND-PVP ASDs in Figure 5.5 was
generally greater than INDME-PVP ASDs indicating that PVP addition provided a greater
stabilizing effect against IND crystallization than INDME crystallization in most cases.
At lower temperatures (≤ 60°C) approaching Tg, IND crystallization is no longer
predicted by trends observed at higher temperatures (see Figure 5.6). The rate of IND
crystallization changes as a function of drug loading with crystallization occurring faster
than expected at low drug loadings based on trends at high drug loadings. The unexpected
change in tc is highlighted by samples having longer crystallization onset times at higher
temperatures which is the opposite of the observed trend above Tg. For example, 80-20
IND-PVP ASDs (Tg = 60.3°C) crystallized in 105 days at 60°C while the same dispersion
at 50°C (Tg – 10°C) crystallized in only 77 days. The changes in crystallization kinetics are
investigated further, including a discussion of their potential causes and implications.
5.3.2.3 Crystallization Near the Glass Transition Temperature
Figure 5.6 shows the crystallization onset time as a function of the scaled inverse
temperature, Tg/T. This accounts for the differences in Tg between IND- and INDMEASDs and allows for the direct comparison of molecular mobility in each system relative
to its Tg rather than storage temperature.
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Figure 5.6. Crystallization onset time as a function of the inverse temperature relative to
Tg for (A) IND-PVP and (B) INDME-PVP ASDs. Error bars correspond to the difference
between the last measurement and the observed crystallization onset time. The dotted lines
at high temperatures and drug loadings indicate that crystallization was observed at the
earliest observation point (30 minutes).
IND tc exponentially increases with decreasing temperature in the supercooled
liquid state but a negative deviation (beginning at approximately Tg/T = 0.97) from the
exponential trend is observed near Tg indicating crystallization occurs faster than expected
in the glassy state. The magnitude of the deviation is directly dependent on drug loading
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and allows Figure 5.6A to be further divided into three regions based on drug loading
(region I > 95% IND, 95% ≥ region II ≥ 80%, region III < 80%). In region I, tc decreases
near and slightly below Tg for 100-0, 99-1, and 98-2 IND-PVP ASDs. Region II still sees
a non-Arrhenius change in tc with temperature around Tg although the changes are less
drastic than in region I. Furthermore, significant overlap exists in this region across
multiple drug loadings as drug-polymer hydrogen bonding becomes increasingly important
for stabilizing the system. No IND crystallization was observed below Tg in region III. This
was consistent with trends observed in the supercooled liquid state when extrapolated into
the glassy state. This suggests that any crystallization observed below Tg during an
extended stability study can be predicted by observed tc above Tg and any deviations would
be expected to be minimal. For all concentrations of INDME, the log(tc) of INDME (Figure
5.6B) follows a linear relationship with Tg/T from the supercooled liquid into the glassy
state.
Figure 5.7 is similar to Figure 5.6 but shows the relationship between the natural
logarithm of the inverse tc and the scaled inverse temperature, Tg/T, at constant drug
loadings. The inverse of the crystallization onset time can be interpreted approximately as
the rate of crystallization (299, 300). Further, the isothermal crystallization activation
energy can be determined from the slope of the lines for Tg/T < 0.97.
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Figure 5.7. The rate of crystallization as a function of scaled inverse temperature for (A)
IND-PVP and (B) INDME-PVP ASDs. Error bars correspond to the difference between
the last measurement and the observed crystallization onset time. The dotted lines at high
temperatures and drug loadings indicate that crystallization was observed at the earliest
observation point (30 minutes).
Figure 5.7 shows the crystallization kinetics in the supercooled liquid (Tg/T < 1)
and glassy states (Tg/T > 1). The rates of pure drug crystallization of IND and INDME are
approximately the same above Tg and only varies near Tg for IND. The rate of
crystallization increases with increasing drug loading in both IND and INDME ASDs
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although this difference decreases at lower drug loadings (Figure 5.7A and B). In general,
the rate of crystallization decreases with temperature for IND and IND-PVP ASDs.
However, the same deviation seen in Figure 5.6A is also observed near Tg for IND systems.
Figure 5.7A can similarly be divided into the same three regions based on IND content.
The slope of the lines indicates the activation energy required for isothermal crystallization
of either IND or INDME in the presence of absence of PVP. The change in slope as Tg is
approached in Figure 5.7A may indicate a change in the rate-limiting step of crystallization
(54).
Figure 5.8 plots the activation energy of isothermal crystallization onset (∆Ea)
above Tg as a function of drug loading (measured from the slopes in Figures 5.7A and B)
for IND and INDME ASDs. Figure 5.8 also overlays the different forms of amorphous
IND that exist as a function of drug loading based on a previous study by Yuan et al. which
used solid-state NMR to quantify the different hydrogen bonding motifs that exist between
IND and PVP (89). It should be noted that Yuan et al. acquired the quantitative speciation
data at 20°C (well below Tg) and may not accurately reflect the species present at the
temperature range used to determine ∆Ea (above Tg). For comparison purposes, the data
points from Figure 11A in Yuan et al. (89) and this study are displayed in the same chart.
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Figure 5.8. Crystallization activation energy for IND and INDME in the presence of
varying amounts of PVP. The relative populations of IND species (determined by Yuan et
al. using SSNMR (89)) are also shown. Crystallization observed at the earliest time point
(30 minutes) was not included in activation energy calculations. Error bars correspond to
the difference between the activation energy determined used either the last measurement
prior to crystallization and the observed crystallization onset time.
∆Ea generally increases with increasing drug loading over the concentration range
investigated, reaching a maximum between 85% and 95% drug loading before decreasing
sharply towards pure drug. The ∆Ea of IND crystallization is 1.5- to 2.3-times greater than
INDME across all drug loadings. This corresponds to an average ∆Ea of 67 kJ/mol which
is well within the range of reported hydrogen bond strengths (83). ATR-FTIR provided no
evidence of INDME-PVP hydrogen bonding. However, extensive hydrogen bonding exists
in IND-PVP ASDs which was highlighted previously by Yuan et al. and is applied here to
provide insights into the physical stability of ASDs (89). It also appears that changing Ea
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also corresponds to changes in hydrogen bonded species. While the specific changes in
hydrogen bonded species shown in Figure 5.8 were determined below Tg, speciation still
likely changes with drug loading above Tg although the dimer is expected to dominate at
higher temperatures (89). At 70% IND, virtually all IND-IND dimers and free IND have
been eliminated. Interestingly, this drug loading also corresponds to the point at which
accelerating crystallization was no longer observed. Quantitative analysis via SSNMR is
currently underway to investigate the changes in hydrogen bonding above Tg. The
implications for changing hydrogen bond speciation and activation energy will be
discussed further in section 5.4.2.2.
5.3.2.4 Differences in IND and INDME Crystallization
Various molecular, physicochemical, and thermodynamic properties were explored
to explain the difference between IND and INDME crystallization kinetics near the glass
transition, particularly the unexplained increase in IND crystallization rate. First, DSC
measured enthalpic recovery to probe molecular mobility just below Tg. Data was fit to the
Kohlrausch-Williams-Watts equation however, at 40°C (IND) and 2.7°C (INDME),
molecular mobility was still too high to measure meaningful structural relaxation times
(110).
Next, the thermodynamic driving force for crystallization (i.e., the difference in
Gibbs free energy between the crystalline and amorphous state) was investigated. As
outlined in section 5.2.3.2, the Hoffman equation (Equation 5.1) used physical properties
of the pure drug to predict free energy differences (44). Figure 5.9A shows the free energy
change upon crystallization for IND and INDME in the supercooled liquid state. Similarly,
the configurational heat capacity was calculated from the difference in the amorphous heat
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capacities of both drugs and used to calculate configurational properties (Equations 5.2 –
5.5). Figure 5.9B shows the configurational enthalpy (Hconfig), entropy (Sconfig), and free
energy (Gconfig) as a reduced temperature, (T – Tg)/(Tm – Tg).

Figure 5.9. (A) Thermodynamic driving force for crystallization as a function of reduced
temperature as predicted by the Hoffman equation. (B) Configurational thermodynamic
properties as a function of reduced temperature. Configurational enthalpy is shown in
black; configuration entropy is in red; and configurational free energy is in blue.
Both the Hoffman equation (Figure 5.9A) and the configurational properties
(Figure 5.9B) predict the free energy change upon crystallization to be greater for IND at
all temperatures between Tg and Tm relative to INDME. While the absolute value of free
energy change was greater by configurational properties, the relative difference in free
energy change is the same. IND crystallization at Tg results in a 26.1% or 25.5% greater
free energy change (compared to INDME) when predicted by the Hoffman equation or
∆Gconfig, respectively. It is also noted from Figure 5.9B that Hconfig of IND and INDME is
nearly the same close to Tg while there is a greater relative difference in Sconfig. Therefore,
Sconfig is the main contributor to the difference in Gconfig between IND and INDME. While
it is interesting that the thermodynamic analysis above provides some evidence as to why
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IND may have a greater tendency to crystallize near Tg, it must be noted that both the
Hoffman equation and configurational properties apply only to the pure drugs and may not
necessarily be applicable in their respective ASDs.
Other properties, including glass forming ability (GFA), fragility, strength, nonisothermal Ea, and glass transition Ea, were measured and recorded in Table 5.1 to better
understand the differences in crystallization between IND and INDME. Baird et al.
previously described how to measure GFA, fragility parameter, strength parameter, and the
glass transition activation energy (40). The details of isothermal and nonisothermal
crystallization activation energy are found in references (131, 299, 301).
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Table 5.1. Comparison of physicochemical properties between indomethacin and
indomethacin methyl ester.
IND

INDME

Molecular Weight (g/mol)

357.79

371.82

Crystal Density (g/cm3)

1.37a

1.404b

Amorphous Density (g/cm3)

1.34

1.34c

Tg (°C)

44.3

6.5

Tm (°C)

160.0

91.9

TK (°C)

9

-65

∆Gconfig(Tg) (kJ/mol)

-7.5

-5.9

∆Hfus (kJ/mol)

38.6

33.2

∆Sfus (J/molK)

89.6

90.9

Glass Forming Ability

Class 3

Class 3

Fragility Parameter, m

58.25d

66

Strength Parameter, D

14.25d

12

Isothermal Cryst. Ea (kJ/mol)

123.2

68.5

Nonisothermal Cryst. Ea (kJ/mol)

N/A

135.9

Glass Transition Ea (kJ/mol)

356.25

351

Hydrogen Bond Donors/ Acceptors

1/5

0/6

Reference (302). bReference (297). cAssuming amorphous density is 5% less than
crystalline density. dReference (40).

a
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INDME is a slightly larger molecule that forms crystals 2.5% more dense than IND.
The estimated amorphous density of INDME is equal to that of IND. The thermodynamics
of crystallization are approximately equal between the two compounds with the heat of
fusion in IND being slightly higher than INDME. Both were class 3 (good) glass formers
based on Baird’s GFA classification system which also implies they will form stable ASDs
(40, 116). Similarly, both were moderately fragile liquids based on both their fragility and
strength parameters although INDME was slightly more fragile by both measures. As
shown in Figure 5.8, the isothermal crystallization activation energy is greater in IND than
INDME. The non-isothermal crystallization activation energy of INDME was
approximately twice that of its isothermal activation energy while no IND crystallization
was observed upon heating even at rates as slow as 0.5°C/min. Lastly, the glass transition
activation energy was approximately equal between IND and INDME although greater
values for IND have been reported in the literature (303).

5.4

Discussion
IND has been extensively studied in the literature, particularly as it pertains to ASD

formulations. Its structural analogue, INDME, has not been studied in nearly as much detail
and provides the opportunity to directly compare the effects of hydrogen bonding on
crystallization while minimizing differences in structure. The causes for markedly different
crystallization behavior around Tg are explored and the implications for formulating ASDs
are discussed.
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5.4.1

ASD Stability
IND and INDME display similar trends in crystallization above Tg however their

behavior becomes markedly different near and below Tg. Crystallization at a given
temperature, both nucleation and crystal growth, is a balance between thermodynamic
driving force and kinetic factors such as molecular mobility (46). Molecular mobility
encompasses the translational, rotational, and vibrational movement of molecules required
to locate other molecules and nucleate or integrate on to a growing crystal surface. While
all molecular mobility decreases with temperature, translational mobility is significantly
reduced below Tg relative to the supercooled liquid state. Conversely, the difference in free
energy between the amorphous and crystalline state represents the thermodynamic driving
force for crystallization and increases continuously below Tm. The crystallization rates of
both compounds shown in Figure 5.7 are directly compared in Figure 5.10. To make it
easier to read the plots, they are divided into high (Figure 5.10A) and low (Figure 5.10B)
drug loadings.
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Figure 5.10. Comparison of the rates of crystallization between IND- and INDME-PVP
ASDs as a function of scaled inverse temperature for (A) 95 – 100% (w/w) drug loading
and (B) 70 – 95% (w/w) drug loading. The ability of PVP to suppress IND crystallization
onset in ASDs relative to pure IND compared to the ability of PVP to suppress INDME
crystallization in ASDs relative to pure INDME is shown in (C) at constant drug loadings
and in (D) at constant temperatures.
The rate of crystallization, ln(1/tc), is approximately equal between IND and
INDME systems at temperatures far above Tg where molecular mobility is high. The rates
diverge as Tg is approached with INDME crystallizing faster than IND due to reduced
mobility and the increasing importance of IND-PVP hydrogen bonding (Fsigure 5.10A).
The temperature relative to Tg at which the rates diverge generally increases as drug loading
decreases. For example, 100-0 and 99-1 ASDs diverge at Tg/T = 0.95 while 98-2 and 95-5
diverge at Tg/T = 0.925 and 0.90, respectively. However, the difference in IND and INDME
crystallization rates is relatively small for most lower drug loadings (Figure 5.10B). This
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indicates that the degree to which IND is better stabilized by PVP increases towards Tg.
Additional PVP reduces the crystallization rate of IND at Tg while INDME crystallization
rate is approximately equal at Tg regardless of PVP content. Once in the glassy state, the
non-Arrhenius behavior of high drug loading IND-PVP ASDs causes faster crystallization
than INDME systems. While INDME-PVP ASDs generally crystallize faster than INDPVP ASDs of equivalent drug loadings above the Tg and IND-PVP ASDs crystallize faster
slightly below Tg, no conclusions can be made about the difference in crystallization rates
deeper into the glassy state as crystallization was not observed below Tg/T > 1.03.
The ability of PVP to stabilize amorphous drug in an ASD relative to pure drug is
compared between IND and INDME in Figures 5.10C and D. The relative stability of IND
or INDME in the presence of PVP is a complex relationship that is dependent on both
temperature and drug loading. At high drug loadings, PVP generally stabilizes IND better
than INDME although the effect is temperature dependent. Specifically, all IND ASDs
were better stabilized by PVP at Tg while the difference in relative stabilization diminishes
at higher temperatures. It is important to note here the difference in crystallization rates
near Tg. On an absolute scale, INDME-PVP ASDs crystallize faster than IND-PVP ASDs
slightly above and at Tg. However, despite the acceleration in IND crystallization near Tg,
IND-PVP ASDs are better stabilized relative to 100% IND when compared to the relative
stability of INDME-PVP ASDs and 100% INDME.
Figure 5.10D shows that PVP better stabilizes INDME relative to IND at high
temperatures where intermolecular hydrogen bond strengths are weaker. It also shows the
drug loading at which hydrogen bonding becomes the primary stabilizing mechanism at
different temperatures. Near Tg, drug-polymer hydrogen bonding becomes more important
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for stabilizing the amorphous drug as the molecules possess less translational mobility. As
polymer content increases, the degree to which lowering the storage temperature improves
stability also generally increases. The data points at 70-30 clearly show how the ability to
form extensive intermolecular hydrogen bonds improves stability at different temperatures.
The importance of drug-polymer hydrogen bonds in stabilizing an amorphous drug
generally increases near Tg (aside from 90-10, vide infra). A reduction in drug loading near
Tg is more effective in stabilizing a drug when hydrogen bonds are present whereas the
effect is more similar regardless of whether hydrogen bonds exist or not at higher
temperatures. For example, if drug loading decreases from 90% to 80% at Tg/T=1, an INDPVP ASD sees a disproportional increase in stability compared to the same INDME-PVP
ASD. The same change in drug loading at Tg/T=0.925 does little to affect the relative
stability between the two ASDs where INDME is still better stabilized than IND.
As shown in Figure 5.10D, in the drug loading range around 90%, IND and INDME
seem to have comparable normalized crystallization onset times whereas both above and
below this range, the normalized crystallization onset time for INDME is faster than IND.
While the exact reason is unclear, Yuan et al. showed that there are multiple different
species present (IND-IND carboxylic acid dimer, chain, free, IND carboxylic acid-PVP
amide/ IND carboxylic acid-IND amide) and that these species interconvert around Tg at
this concentration (vide infra) (89).
The effects of phase separation must also be considered. The lack of extensive drugpolymer hydrogen bonding in INDME-PVP ASDs likely causes phase separation in those
ASDs. In fact, phase separation was previously observed in 90-10 INDME-PVP ASDs but
not in 70-30 ASDs (154). Samples in this study were prepared in a similar fashion so phase
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separation likely begins somewhere between 70% and 90% INDME and is at least present
for all drug loadings of 90% INDME or more. The stabilizing effect of PVP is diminished
in domains containing disproportionately high drug levels and leads to the faster
crystallization of INDME at most temperatures above Tg.
5.4.1.1 Thermodynamics
Typical thermodynamic values do not explain the difference in crystallization
tendency between IND and INDME. The heat of fusion (∆Hfus) is related to the energy
required to break the crystalline lattice is slightly greater for IND and agrees very well with
the enthalpy of IND dimerization reported by Yuan et al. (89). Similarly, the entropy of
fusion (∆Sfus) is related to the difference in molecular ordering between the crystal and
liquid and is similar between the two compounds. Since ∆Hfus and ∆Sfus were
approximately equal between IND and INDME, the difference in their thermodynamic
stability lies in the heat capacity difference at Tg. This is reflected through their
configurational properties.
Configurational free energy and the Hoffman equation show that IND
crystallization is more favorable than INDME at all temperatures relative to Tg. Therefore,
IND would be expected to crystallize faster than INDME. This was generally not the case
as INDME crystallized faster than IND in most cases, particularly in the supercooled liquid
state where extensive hydrogen bonding exists between IND and PVP. Slight differences
are observed between the thermodynamic properties of IND and INDME (Figure 5.9B and
Table 5.1) which may contribute to the differences in crystallization. The slight differences
in ∆Hfus are reflected in the Hoffman equation while there is minimal difference in Hconfig
near Tg.
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The large difference in Sconfig between IND and INDME is the main reason for
differences in thermodynamic driving force. Sconfig represents the difference between the
number of molecular configurations that exist in the amorphous state and the well-defined
configuration of a crystalline phase (56, 57). Therefore, less constricted molecules which
are able to exist in a number of configurations in the supercooled liquid state typically have
greater Sconfig values and are less likely to be in a preferrable orientation for crystallization
(57). The effect of hydrogen bonding on configurational entropy has not been directly
studied. Presumably, the lack of intermolecular hydrogen bonding or specific interactions
will increase the number of possible amorphous orientations and increase Sconfig. We
assume that the strongly hydrogen bonded network in amorphous IND decreases the
number of possible configurations relative to INDME which contains no or weak
interactions thus explaining the larger Sconfig for INDME. Further, the presence of polymer
will likely hinder crystallization through stabilizing drug-polymer interactions or dilution
effects (57). As Zhou et al. point out, the polymer may increase the effective
configurational entropy by keeping the drug in a configuration very different from the
crystalline phase (57).
5.4.1.2 Kinetics
Locking the drug into configurations unfavorable for crystallization can
alternatively be viewed similarly to reducing the molecular mobility of the drug. Polymers
typically used in ASDs have a Tg significantly higher than the Tg of the drug and act as
antiplasticizers by increasing the Tg of the mixture. Increasing amounts of PVP increased
the Tg of IND and INDME ASDs. Drugs stored at an equivalent temperature relative to Tg
can be approximated as having the same level of molecular mobility (57). However, IND
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and INDME exhibited different crystallization behavior with INDME often crystallizing
prior to IND relative to Tg. Clearly, antiplasticization alone cannot explain the difference
in crystallization behavior. Extensive IND-PVP hydrogen bonding helps stabilize the
amorphous state relative to INDME-PVP ASDs (84). Figure 5.10 demonstrates the impact
of additional stabilization by hydrogen bonding where increasing PVP content decreases
the crystallization rate at Tg due to hydrogen bonding between the IND carboxylic acid and
PVP amide. Conversely, the lack of specific INDME-PVP interactions results in
crystallization being governed by temperature relative to Tg. Increasing the PVP content
from 10 – 30% has nearly no effect on the INDME crystallization rate near Tg whereas
increasing PVP content from 10 – 30% dramatically changed the IND crystallization rate
near Tg.
Molecular mobility is highly temperature dependent and is difficult to compare
between molecular systems for a single temperature unless done relative to the glass
transition where molecular mobility is approximately the same (structural relaxation, τ ~
100 s) (57). Measuring structural relaxation times at Tg/T = 1.014 (40°C and 2.7°C for IND
and INDME, respectively) yielded inconclusive results as mobility was still relatively high
so close to Tg.
Fragility relates the relative change in local structure or mobility with decreasing
temperature near Tg (304). Both the strength (D) and fragility parameters (m) classified
IND and INDME as moderately fragile although IND could be considered slightly more
fragile than INDME. Being more fragile than INDME, IND was expected to display a
larger glass transition activation energy (∆ETg), or, the energy required for structural
relaxation to occur (305). A small difference was observed but it is unlikely that such a
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small increase in activation energy for IND relative to INDME can account for the drastic
changes in crystallization.
The strength parameter, D, represents the rate at which an ideal glass loses
molecular mobility with decreasing temperature. Compounds with higher D values lose
molecular mobility slowly and results in higher mobility for a longer amount of time (57).
Zhou et al. demonstrated that this is also true after aging and, therefore, also applies to real
structurally relaxed glasses (57). Whereas IND had a greater D value than INDME, it was
expected to have a greater likelihood of crystallization at a specific Tg/T. In addition, the
INDME was farther from its Kauzmann or “zero mobility” temperature (TK) relative to
IND when stored at its Tg. Both D and Tg/TK suggest that IND possessed greater molecular
mobility near and below Tg relative to INDME. However, it is unclear whether these small
differences can explain the large difference in crystallization behavior. The implications of
differences in other properties measured for IND and INDME are discussed further in
section 5.4.2.2.
5.4.1.3 Drug-in-Polymer Solubility
Crystallization in an ASD is also dependent on the concentration of drug dispersed
within the polymer matrix relative to its crystalline solubility. Aside from highly potent
APIs, most pharmaceutically relevant drug loadings will be supersaturated and
thermodynamically unstable. Therefore, most drug products must be kinetically stabilized
through storage below Tg to help delay crystallization. Figure 5.11 shows the IND-PVP
solubility phase diagram overlaid with the results of IND crystallization as well as a similar
plot for INDME-PVP.
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Figure 5.11. Solubility phase diagram overlaid with the experimental design space for (A)
IND-PVP ASDs and the time at which crystallization was observed. The IND solubility
line was constructed based on reference (46). (SSR = Supersaturation ratio.) (B)
Experimental design space for INDME-PVP ASDs and the time at which crystallization
was observed. The initial data points used to construct the INDME solubility and SSR
curves are shown only as an estimate.
Figure 5.11A displays the effects of thermodynamics, kinetics, and solubility on
crystallization onset time. All samples were supersaturated with respect to IND-PVP
solubility and therefore were thermodynamically unstable. Approximately one quarter of
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samples were kinetically stabilized by storage below Tg however not all glassy samples
remained amorphous. In fact, some 100-0, 99-1, and 98-2 IND-PVP ASDs stored below
Tg crystallized in less than a month highlighting that drug loading dominates the
crystallization process at those conditions.
Indomethacin crystallization appears to follow an approximately sigmoidal pattern
as a function of time with respect to temperature and drug loading. At high IND loadings
or a combination of high temperatures and IND loadings, IND crystallizes fastest, but lower
IND contents at high temperature, IND crystallizes more slowly. However, both IND-PVP
solubility and Tg must also be considered to better describe IND crystallization. As the
supersaturation level increases, crystallization not only occurs above Tg (70% drug loading,
SSR ~ 2), but also below Tg (90% drug loading, SSR > 10). The difference in solubility
along the Tg line alone greatly increases the thermodynamic driving force for
crystallization. In addition, Tg seems to become more important in inhibiting crystallization
at lower drug loadings due to reduced levels of supersaturation. For example, 99-1 INDPVP crystallized at 40°C (Tg/T = 1.01, SSR = 142) in less than a day while 75-25 INDPVP at 60°C (Tg/T= 1.01, SSR = 3.5) remained amorphous for over nine months. Still,
solubility alone does not fully explain why some IND samples crystallize faster below Tg
than above Tg as large differences in stability still exist near even in the glassy state. For
instance, 75-25 IND-PVP ASDs at 50°C did not crystallize in over 9 months while 80-20
IND-PVP ASDs at the same temperature crystallized within three months. This indicates
that Tg may not necessarily be the best indicator to use for predicting stability.
In contrast to IND, Figure 5.11B shows INDME follows an approximately linear
crystallization pattern with respect to time and drug loading. A combination of high storage
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temperature and drug loading results in the fastest crystallization. Research to more
accurately determine the INDME-PVP solubility is currently underway. The estimated
solubility of INDME in PVP is shown but is only an approximation due to extremely slow
crystal growth kinetics preventing crystallization from reaching equilibrium over
reasonable experimental timescales.
As expected, INDME is less soluble in PVP than IND at all temperatures (e.g., 30%
versus 40% w/w at 25°C). The lack of hydrogen bonding between INDME and PVP was
expected to decrease solubility and stability. However, INDME’s increased stability
relative to IND near Tg may indicate a non-obvious decoupling between supersaturation
and stability in the absence of hydrogen bonding. Indeed, similar results have been found
in the literature. Fenofibrate has very low solubility in copovidone, neither of which have
hydrogen bond donating groups, yet fenofibrate-copovidone ASDs exhibit exceptional
kinetic stability, remaining amorphous over 15 years at ambient conditions (306)
5.4.2

Diffusionless Crystallization
The rate of crystallization was expected to decrease continuously through the glass

transition as a reduction in molecular mobility creates conditions less favorable for
nucleation and crystal growth. Crystallization rates of INDME-containing systems
exhibited Arrhenius behavior but IND and IND-PVP ASDs of high drug loadings were
markedly non-Arrhenius to the point that crystallization was observed to occur faster than
expected near and slightly below Tg. Despite slowing kinetics near Tg, certain organic
systems have shown an acceleration in crystal growth rate near and slightly below Tg. Up
to this point, this has only been observed in 12 organic molecular liquids or ASDs with 1
– 2% polymers present (50, 54, 55, 150, 267, 307, 308). This acceleration in crystal growth
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rate has been attributed to a switch from diffusion-controlled to diffusionless/ glass-crystal
(GC) crystal growth. Here, the rate of nucleation and/ or crystal growth is no longer limited
by IND diffusivity (i.e., the rate at which amorphous IND molecules migrate to the nucleus
or crystal surface). Many theories have been previously proposed to account for this
anomalous behavior whereby the crystal growth rate increases up to 4 orders of magnitude
near the Tg compared to the expected behavior extrapolated from above the Tg (52, 54, 55,
293, 309, 310). Briefly, homogeneous nucleation-based crystallization assumes that
diffusionless crystal growth occurs by the coalescence of homogeneous crystal nuclei onto
an existing crystal surface at a rate determined by β-relaxation (52). Alternatively, a
tension-induced interfacial mobility process proposes that the density difference between
phases at the glass-crystal interface creates tension which provides free volume for
molecules near the growing crystal front to have enhanced molecular mobility needed for
rapid crystal growth (293, 310, 311). The tension-induced model was further refined to be
a surfaced-facilitated transformation in which it is proposed that the interfacial tension is
continually relieved through the creation of voids or fractures (55). The creation of new
surfaces allows for surface crystal growth which is much faster than bulk crystal growth
including bulk diffusionless IND crystal growth (312). It was also proposed that the
molecular motions responsible for diffusionless crystal growth are native to the local glassy
state rather than a-relaxation or bulk-liquid diffusion (54). Rotational and vibrational
motions effectively allow for the growth of certain crystal structures due to a favorable
orientation in the liquid state near the crystal interface rather than relatively larger
rearrangements such as diffusion.
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5.4.2.1 Structural Considerations
Larger molecules with a greater number of rotatable bonds are typically better glass
formers due to the specific conformations required for crystallization (40). Interestingly,
IND is the largest molecule for which diffusionless crystal growth has been observed (308).
In addition, it is observed to occur at the greatest degree of supercooling and proceed at the
slowest rate indicating that sufficient molecular mobility must exist relatively far into the
glassy state.
Diffusionless crystal growth has been shown to occur more often in molecules with
more isotropic crystal structures (54). This was rationalized by the nearest neighbors being
at approximately the same distance (i.e., similar to the liquid state) and suggests
diffusionless crystal growth is more likely if molecular packing is sufficiently similar
between the liquid state and the crystalline state (313). Indeed, the structure of g-IND is
isotropic and similar to the short-range ordering in the amorphous state where carboxylic
acid dimers dominate (89, 314, 315). While only g-IND was observed in this study,
diffusionless crystal growth was observed previously in g-IND and a-IND (48).
5.4.2.2 Activation Energy and Hydrogen Bonding Speciation
Activation energy is expected to increase with additional PVP present as the
polymer can inhibit nucleation and crystal growth. Only the crystallization onset time was
monitored in this study, so the question remains as to whether the observed activation
energy represents that of nucleation or crystal growth. Woldt determined the activation
energies of nucleation and crystal growth based on differences in the isothermal and nonisothermal crystallization activation energies (316). Non-isothermal crystallization (even
when heating amorphous IND at rates as slow as 0.5°C/min) was not observed in IND or
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IND-PVP implying that the activation energy was much greater than the isothermal
activation energy observed from crystallization onset times. Conversely, INDME
isothermal and non-isothermal activation energies were approximately equal. This suggests
a difference in nucleation mechanism between the two compounds and may be related to
the slow initial growth of nuclei to an observable size (131, 317). Further, the measured
activation energy in this study for 90-10 IND-PVP was almost identical to the viscous flow
activation energy (i.e., crystal growth) of a 90-10 IND-PVP ASD by Tian et al. (318).
Therefore, it is likely that the measured activation energies in this study are reflective of
the initial growth process (from nucleation to a crystal of an observable size) in IND and
INDME where a larger energy barrier must be overcome for the initial growth of g-IND
crystals. While informative, this still does not explain the acceleration in IND
crystallization near Tg, so it is likely that the nucleation process is largely involved in the
diffusionless crystallization phenomenon.
Figure 5.8 showed that the measured activation energies overlaid with hydrogen
bonding arrangements in amorphous IND change as a function of PVP content (89). The
introduction of PVP inhibits nucleation and crystal growth through the formation of drugpolymer hydrogen bonds and reduces the molecular mobility of IND. The isothermal IND
crystallization activation energy increases as a result. The activation energy of INDME
also follows a similar trend with increasing PVP content despite the lack of any significant
hydrogen bonding. However, as previously mentioned, the Tg of INDME-PVP ASDs
significantly deviates from the predictions of the Gordon-Taylor equation which likely
indicates the presence of some drug-polymer interactions or lack of drug-drug interactions.
This is likely a halogen interaction and would not be as energetically favorable as IND-
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PVP hydrogen bonding. Therefore, the magnitude of the difference in activation energy
measured corresponds to the energy required to break IND-IND or IND-PVP hydrogen
bonds prior to recrystallization and agrees well with hydrogen bonding energy values
reported in the literature (83). Conversely, the greater thermodynamic driving force for gIND crystallization is due to the formation of hydrogen bonds in IND-IND cyclic
carboxylic acid dimers. The enthalpy and entropy of fusion measured in this study are
almost exactly equal and opposite of the standard enthalpy and entropy of dimerization
reported by Yuan et al (89). Therefore, the energies measured in this study directly reflect
the effects of hydrogen bonding. Drug-polymer hydrogen bonds in ASDs increase the
activation energy of isothermal crystallization but do not seem to impact how activation
energy changes with increasing polymer content.
The hydrogen bond speciation of IND as a function of PVP concentration shown in
Figure 5.8 is determined by thermodynamics for a specific temperature. The speciation
data in Figure 5.8 was acquired at 20°C which is significantly below IND’s Tg and the
range of IND storage conditions. The relative proportions of hydrogen bonded species will
likely be skewed towards more IND-IND dimers in the supercooled liquid state.
The presence of drug-polymer hydrogen bonding (rather than the relative
proportion of each species) seems to affect the isothermal activation energy. Despite
similar changes in isothermal activation energy as a function of PVP content, similar
hydrogen bonded species are not expected to exist in INDME due to replacing the
carboxylic acid of IND with an ester. Any hydrogen bonded or intermolecular species
existing in INDME are likely much different than those of IND. Rather, it is the changes
in molecular mobility accompanying the addition of PVP which is expected to impact the
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activation energy. In the case of IND near the Tg, similar hydrogen bonded species in the
amorphous and crystalline states are proposed to contribute to diffusionless crystallization.
The IND acid-PVP amide hydrogen bonds stabilize amorphous IND as they replace
the IND-IND carboxylic acid dimers and also reduce the translational mobility of the
dimers remaining. Cyclic IND dimers exist in both amorphous and crystalline g-IND and
may presumably act as nucleation sites when mobility is reduced in the presence of PVP
or at temperatures near Tg. The maximum in activation energy is likely explained as a
balance between reducing concentrations of IND dimers and a reduction in molecular
mobility which can allow for diffusion away from the crystal nucleus. Even at reduced
diffusional mobilities, dimers may still possess rotational and vibrational modes of motion
required to incorporate onto a growing crystalline nucleus. Eventually nearly all IND
dimers have been replaced by IND-PVP hydrogen bonds such that a critical nucleus is less
likely to form, and crystallization becomes more difficult as hydrogen bonds must be
broken prior to crystallization. This occurs at 30% PVP which is also the concentration
below which no diffusionless crystallization was observed. This agrees well with the
observation that diffusionless crystal growth occurs in molecules with similar liquid and
crystalline structures.
The contribution of hydrogen bonding can be further explored by considering its
temperature dependence. Increased thermal energy weakens hydrogen bonds at high
temperatures so the fraction of dimers in the amorphous state is expected to increase at
lower temperatures (89). Yuan et al. showed this was the case where, below Tg, the fraction
of dimers increases dramatically with decreasing temperature compared to the slope above
Tg (89). They attribute the deviation from the supercooled liquid trend occurring below Tg
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to the increased free energy of the non-equilibrium glass. The increased number of dimers
in the glassy state serves as the building blocks for crystallization to g-IND and likely
contribute to increased accelerated crystallization onset near and slightly below Tg.
For the above arguments to hold, the molecular mobility of IND near Tg must be
considered in greater detail. Two-dimensional (2D) exchange solid-state NMR
spectroscopy (SSNMR) was previously used to investigate the local mobility of pure
amorphous IND and IND-PVP ASDs (154). Cross peaks near and slightly below the Tg in
samples indicated IND systems have sufficient translational mobility required for exchange
to occur during the experimental mixing time. In particular, cross peaks in pure amorphous
IND at 50°C (Tg = 46°C) indicated amorphous IND was able to continually break cyclic
dimer (dimer) hydrogen bonds and form carboxylic acid-amide (complex) hydrogen bonds
(and vice versa) as the Tg is approached (154). Furthermore, cross peaks were observed in
90-10 IND-PVP ASDs (Tg = 53°C) at 50°C. At 60°C the same cross peaks were observed
with greater intensity indicating dimers and complexes continually break and form near Tg
in the presence of PVP. Comparable results were obtained at 60°C and 70°C for 80-20
IND-PVP ASDs (Tg = 64°C). Remarkably similar results were obtained in this study for
crystallization onset where tc deviated from the expected exponential relationship for a
given drug loading near the Tg for some samples (Figure 5.6A). No deviations from the tc
trends in 70-30 ASDs indicated the diffusionless crystallization mode was not active.
Similarly, no cross peaks were observed at 70°C or 80°C for 70-30 IND-PVP ASDs (Tg =
73°C) (154). 30% PVP disrupts and replaces nearly all dimers with IND (carboxylic acid)PVP (amide) hydrogen bonds (89). This confirms that the diffusionless crystal growth and
crystallization mode accessed near the Tg in certain systems is influenced by the local
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mobility and the ability to break and form hydrogen bonds. Cross peaks in other polymeric
systems have also been associated with other modes of molecular mobility including βrelaxation (319). This is particularly relevant in the glassy state where diffusional arelaxations slow dramatically and may explain why diffusionless crystal growth and its
enhanced crystal growth rate is observed in some amorphous drugs where sufficient
translational or other molecular mobility exists near the Tg. It may also help to explain why
this phenomenon had previously not been observed above 2% polymer content. In the
presence of polymer, crystal growth rate not only depends on the movement of drug
molecules to the crystal interface (drug diffusivity, Ddrug) but is also dependent on the
diffusivity of the polymer (Dpolymer) away from the growing crystal interface. Dpolymer
decreases faster than Ddrug with decreasing temperatures such that the system again
becomes diffusion controlled and diffusionless crystal growth ceases (267). At higher
polymer concentrations, the polymer suppresses the nucleation and/ or crystal growth rate
such that diffusionless crystallization is not observed on experimental timescales typically
used with microscopy. Therefore, crystallization onset must be observed over long periods
of time rather than measuring crystal growth rate to observe diffusionless crystallization as
it manifests as a decrease in tc from expected trends above Tg.
Ultimately, it is proposed that a combination of factors explain the difference in
IND and INDME crystallization and the observation of diffusionless crystallization in IND.
Most importantly, the presence of dimers in the amorphous and crystalline state serves as
nucleation sites. Hydrogen bond formation drives the greater thermodynamic driving force
for crystallization to g-IND despite a greater activation energy barrier. These observations
highlight the importance of b-relaxations to diffusionless crystallization and agree most
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closely with the explanations of Musumeci et al. (52, 308). Specifically, diffusionless
crystallization in a solid-state process which is disrupted by greater levels of translational
mobility above Tg and inhibition of b-relaxations deeper into the glassy state. At higher
temperatures, molecules may diffuse away from the crystal interface prior to incorporation
whereas structural reorientation required is too great at temperatures far below Tg or
significant polymer contents to occur solely through local mobility (308). Other strongly
hydrogen bonded systems, especially those with similar speciation in the crystalline and
amorphous phases, are likely to exhibit the same phenomenon despite it being difficult to
observe under typical stability conditions.
5.4.3

Formulation Implications
Amorphous drug products should always be stored below Tg to minimize the

likelihood of crystallization. Storage of amorphous drugs or ASDs more than 50°C below
the Tg is generally agreed to prevent crystallization on pharmaceutically relevant timescales
(284, 320). Despite an extremely high thermodynamic driving force for crystallization,
storage that far in the glassy state effectively eliminates the translational molecular motions
typically associated with crystallization. However, some molecules, including
indomethacin, still possess sufficient molecular mobility in the form of b-relaxations to
induce nucleation and crystal growth (79, 283). Besides, storage at such low temperatures
may not always be feasible for low-Tg drugs or due to a lack of cold chain. Therefore, the
storage of amorphous formulations near Tg is not uncommon.
An acceleration in drug crystallization onset time near Tg for an ASD with
pharmaceutically relevant concentrations of polymer present has been shown for the first
time. Crystallization presumably adversely affects bioavailability and/ or indicates a failed
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stability study and is observed orders of magnitude faster than expected just below Tg. This
clearly shows that IND stability in the supercooled liquid state cannot be extrapolated into
the glassy state. The changes in crystallization trends can occur over small temperature
ranges and may be missed or insufficiently characterized with standard stability studies.
Future stability studies should be designed to account for the possibility of these drastic
changes near Tg by storing additional samples near Tg.
While IND and 11 other molecules have exhibited diffusionless crystal growth, to
the best of our knowledge, only IND has also shown the acceleration in crystallization
onset. From a stability perspective, the diffusionless crystallization observed is more
detrimental to the physical stability of an ASD assuming that the presence of crystallization
adversely affects bioavailability. However, similarities are likely to exist between the two
phenomena and diffusionless crystallization may also be present in the other molecules.
Pure amorphous drug candidates which exhibit diffusionless crystal growth may therefore
indicate that stability studies of the corresponding ASD should be designed with special
attention paid to crystallization kinetics near Tg.

5.5

Conclusions
Indomethacin is more mobile than indomethacin methyl ester, has a greater

thermodynamic driving force for crystallization, and a greater crystallization activation
energy for all drug loadings and storage temperatures but is better stabilized by PVP above
Tg due to extensive hydrogen bonding in both the crystalline and amorphous state.
Amorphous solid dispersions of IND and INDME, which lacks hydrogen bond donors,
show markedly different crystallization tendencies. Crystallization onset above Tg in both
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drugs follows an exponential dependence on drug loading. While this trend can predict
INDME crystallization in the glassy state, IND-PVP ASDs crystallize faster than expected
near and below Tg. This was attributed to diffusionless crystallization and, to the best of
the authors knowledge, was the first time this was observed in ASDs with pharmaceutically
relevant polymer contents.
The occurrence of diffusionless crystallization was further investigated and found
to be driven by hydrogen bonding and molecular mobility. IND-IND hydrogen bonded
dimers exist in both the amorphous state and g-IND. Decreasing mobility near Tg and in
the presence of PVP restrict IND dimer mobility which eventually serve as nuclei for
accelerated crystallization. At 30% PVP, IND dimers are nearly absent and corresponds to
the point at which diffusionless crystallization is no longer observed.
While the results here help to explain the occurrence of diffusionless crystallization
in indomethacin, other systems exhibiting diffusionless crystal growth have not been
studied as extensively. Additional comprehensive stability studies would be useful in
identifying whether the same phenomenon can be observed in the crystallization onset
times of other systems. Similarly, additional studies on other compounds are needed to
determine whether the changes in hydrogen bonding and activation energy observed here
are also found in other fast crystallizing systems. To this end, a data mining or extended
stability study of all GC compounds may be fruitful.

Copyright © Travis Wayne Jarrells 2022
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CHAPTER 6: SUMMARY AND FUTURE DIRECTIONS
6.1

Summary
Amorphous solid dispersions (ASDs) have become a leading formulation approach

to improve the bioavailability of many poorly soluble drugs. Their emergence in the
pharmaceutical industry has been driven by drug discovery and combinatorial chemistry
techniques that produce highly target-specific but poorly water-soluble drug candidates.
These poorly soluble drug candidates now comprise a significant fraction of pipeline
molecules and marketed products. However, the main drawback hindering the widespread
commercialization of ASDs is their inherently poor physical stability and propensity to
crystallize. Crystallization can occur during formulation, storage, or during dissolution if
the amorphous drug is not adequately stabilized within the polymer matrix. While
crystallization is generally detrimental to dissolution rate and solubility, the degree to
which bioavailability is affected depends on the amount and quality of the crystals formed.
Polymers used in ASDs usually stabilize the amorphous API in at least one of three
ways: (1) through specific drug-polymer interactions including hydrogen bonding, (2)
through a reduction in the molecular mobility of the API molecules (i.e., antiplasticization),
and (3) by diluting the concentration of drug molecules or acting as a physical barrier to
nucleation and crystallization. Among others, the mechanism(s) by which a polymer
stabilizes an amorphous drug is dependent on the drug-polymer combination, drug
concentration, preparation technique, and other environmental factors such as storage
temperature and relative humidity. General guidelines exist for improving the long-term
physical stability of an amorphous formulation including storage at temperatures as far
below Tg as possible, drug loadings below the drug-polymer solubility, and minimizing
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exposure to elevated relative humidity. However, each of the suggestions mentioned above
are not always feasible and each ASD must be adequately characterized to ensure stability
over the shelf life of the drug product.
Advanced analytical methods are needed to sufficiently characterize amorphous
formulations both from a research and regulatory standpoint. A molecular-level
understanding drug-polymer interactions is often needed to help rationally formulate ASDs
which remain stable over their shelf life and remain bioequivalent to their unaged drug
product. This means that the analytical method used should be able to identify, qualitatively
analyze, and quantify aspects of the formulation that are critical to its stability and
performance. This information may also be applied to better predict the stability of ASDs
and/ or compare generic and innovator products during generic drug development. To this
end, solid-state nuclear magnetic resonance (SSNMR) spectroscopy has been used
extensively to investigate pharmaceutical solids and better understand their interactions in
the amorphous state on a molecular level. This dissertation focused on using SSNMR, as
well as other analytical techniques, to better characterize the structure and composition of
amorphous formulations, their physical stability, and their broad applications to drug
development.
In addition to small molecules, larger molecules including some polymers have also
been used as active pharmaceutical ingredients. Recently, advances in polymerization
chemistry and the desire to minimize adverse side effects associated with poor ligandreceptor specificity has led to the development of more polymeric APIs. The increased
complexity of polymeric APIs compared to small molecules leads to their classification as
non-biological complex drugs (NBCDs). NBCDs are more difficult to structurally
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characterize which leads to difficulties demonstrating API sameness during generic drug
development. Chapter 3 focused on developing a SSNMR method for the quantitation of
the three block copolymer units present in patiromer (Veltassaâ). Poor aqueous solubility
prevented quantitative analysis with typical solution-based techniques. A new peak
integration method which accounted for cross polarization dynamics and spinning
sidebands was successful in quantifying the carboxylate (m-block), aromatic (n-block), and
aliphatic (p-block) blocks in patiromer. It was found that the average lot of patiromer
contained 90.9 ± 0.4%, 7.6 ± 0.3%, and 1.5 ± 0.4% m-, n-, and p-blocks, respectively.
These values agreed well with reported values on the package insert (m = 91%, n+p = 9%)
and also provided the specific proportions of n- and p-blocks present. The FDA is actively
pursuing the quantitation method in Chapter 3 for the development of a generic form of
patiromer.
More often, however, characterization of amorphous pharmaceuticals is applied to
amorphous solid dispersions. Various methods exist to detect and, in some cases, quantify
crystallinity in ASDs. Chapter 4 compares DSC, PXRD, and SSNMR for their ability to
quantify crystallinity in nifedipine-PVP ASDs which were annealed in-situ in the DSC or
ex-situ in an oven. Equivalent levels of crystallinity were observed in DSC- or ovenannealed samples. Using the resulting Tg from DSC measurements is commonly used to
quantify crystallinity and typically yields accurate data but is limited at high drug loadings.
The DSC heat of dissolution method was found to grossly underestimate crystallinity due
to changing crystal quality at different annealing temperatures. Conversely, PXRD and
SSNMR were both found to provide accurate measurements of crystallinity in ASDs with
both SSNMR methods (peak deconvolution and two-component 1H T1 relaxation time
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measurements) yielding similar results. Since PXRD and SSNMR each provided accurate
measures of crystallinity, they were also applied, for the first time, to measure drug-inpolymer solubility and are particularly useful for systems that are difficult to measure with
DSC.
While Chapter 4 focuses mostly on characterizing the thermodynamic stability of
ASDs, Chapter 5 investigates the difference in crystallization kinetics of two structurally
similar drugs, indomethacin (IND) and indomethacin methyl ester (INDME), dispersed in
PVP solid dispersions. The lack of hydrogen bonding in INDME compared to IND resulted
in markedly different crystallization onset times in their respective ASDs. IND was better
stabilized by PVP above Tg but showed an unexpected acceleration in crystallization rate
near and slightly below Tg. This was attributed to diffusionless crystal growth and found
to be the first occurrence of the phenomena at pharmaceutically relevant polymer
concentrations. Drug-polymer hydrogen bonds are typically assumed to improve
amorphous stability but are likely a contributor to the instability of IND near its Tg. The
results of Chapter 5 highlight the need to extensive stability studies in ASDs, especially
near the glass transition temperature.
Most of the work performed in this dissertation was done in the absence (or
minimal) moisture. However, solvents and other sources of moisture are commonly
encountered

during

formulation,

manufacturing,

and

storage

of

amorphous

pharmaceuticals. For example, multiple solvents are often used to dissolve a drug and
polymer during spray drying which must then be sufficiently removed during the drying
process. Additionally, formulated drug products encounter moisture during storage at or
exposure to ambient relative humidity. Appendix A began to investigate the effects
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atmospheric moisture and mixed spray drying solvents have on the physical properties
(glass transition temperature and diffusivity) of pharmaceutical polymers using dynamic
vapor sorption. Both polymers, PVPVA and HPMCAS, were significantly plasticized by
water and acetone although the degree to which Tg was reduced was independent of the
identity of the solvent. Rather, the total mass of solvent absorbed was found to control the
plasticization indicating that most of the absorbed mass was loosely bound or does not
interact with the polymer. The rate of solvent diffusion out of the polymer during drying
was dependent on the polymer-solvent combination as well as the difference in initial and
final solvent activities. The results of Appendix A may be useful in helping to model the
spray drying process.

6.2

Future Directions
Chapters 3, 4, 5, and Appendix A investigated a wide variety of issues and

developed methods to better characterize amorphous pharmaceutics. However, the due to
the immense complexity of amorphous solids, not all aspects of physical stability were
explored. This left many questions unanswered and led to the development of new
questions along the way. In particular, it would be useful, and necessary, to further validate
some of the proposed methods through the investigation of other amorphous systems. For
example, SSNMR and PXRD should be compared with DSC crystallinity results in other
drug-polymer systems with known drug-polymer solubilities prior to their application to
systems which are difficult or impossible to measure with DSC. This may include ASDs
with cellulose-based polymers (e.g., HPMCAS) or drugs crystallizing to multiple
polymorphs. Furthermore, the SSNMR T1 relaxation time quantitation method from
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Chapter 4 holds great potential for differentiating between residual and process-induced
crystallinity.
It is also desirable to quantify how hydrogen bonding affects ASD stability through
drug-in-polymer solubility measurements. Even though the methods to quantify
crystallinity in Chapter 4 greatly expand the number of systems in which drug-polymer
solubility can be determined, further method development is needed to determine solubility
in systems with extremely slow crystal growth kinetics. For example, while IND-PVP
solubility is easy to measure, the Tg of annealed INDME-PVP ASDs was poorly resolved
and crystallinity did not appear to reach equilibrium even after five days. Although the
PXRD and SSNMR method demonstrated in Chapter 4 can quantify crystallinity using
measures other than Tg, they both require large amounts of sample and do not address the
fact that the time required to reach equilibrium is the rate-limiting step. Development of
new methods to rapidly attain equilibrium or reduce the sample volume required would be
especially useful, particularly for material-limited samples such as in the early stages of
drug development.
Diffusionless crystallization is a particularly interesting research area due to the
extremely low number of molecules in which it has been observed. A better understanding
of the causes of this mode of crystallization may be improved through a data mining
approach to see whether common trends can be identified across systems in which diffusion
crystal growth is active. A further investigation into the effects of hydrogen bonding on
crystallization near Tg and diffusionless crystallization is also warranted. In particular,
combining the stability study from Chapter 5 with the work of Yuan et al. (89) to quantify
hydrogen bonded species that exist in other ASDs would shed light as to how hydrogen
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bonds change and confer stability at different storage conditions. This may be used to more
definitively connect the changes in hydrogen bonding to diffusionless crystallization. In
addition, it would be especially interesting to use SSNMR to quantitatively monitor any
changes in hydrogen bonding that may occur as a function of preparation method or during
structural relaxation.
Lastly, Karl Fischer titration, solution-state NMR, and solid-state NMR were all
unsuccessful in quantifying the relative amounts of water and acetone present in dual
solvent systems. Accurate quantitation of all spray drying solvents is necessary to develop
a reliable model of particle drying or attributing changes in Tg to relative sorbate content.
Additional analytical methods should be explored to develop a quantitative method.
Headspace gas chromatography has been successful for the quantitation of six volatile
organic impurities in an API and may also be useful in polymers or ASDs (321). Similarly,
tandem techniques including TGA-FTIR or TGA-mass spectrometry may provide viable
options for solvent quantitation once it desorbs during heating. A natural next step would
be the investigation of additional polymers and/ or different solvent mixtures to see the
observed trends in plasticization are solvent-dependent or occur in all systems. Finally,
absorption and desorption experiments should be repeated on ASDs which better represent
a spray dried dispersion.

Copyright © Travis Wayne Jarrells 2022
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APPENDIX A:

INVESTIGATING CO-SORPTION BEHAVIOR OF WATER

AND ACETONE IN PHARMACEUTICALLY RELEVANT POLYMERS:
ISOTHERMS, DIFFUSIVITY, AND PLASTICIZATION
A.1 Introduction
Water is typically assumed to be detrimental to the chemical and physical stability
of amorphous pharmaceuticals yet an amorphous drug product may be exposed to water
and/ or other solvents along the pharmaceutical supply chain such as during formulation,
manufacturing, or storage (322, 323). Spray drying is a commonly used unit operation for
the formulation of poorly soluble drugs as the drug can be made amorphous to improve its
aqueous solubility. However, this comes with the risk of recrystallization as the amorphous
drug is inherently unstable. Often, the drug is formulated with a polymer with the goal of
creating an amorphous solid dispersion (i.e., spray dried dispersion (SSD)) which
maintains a greater aqueous solubility relative to the crystalline drug but is more stable
than pure amorphous drug (33).
Spray drying first involves selecting a suitable solvent or co-solvent mixture to
dissolve the API and excipients. Droplets containing API and excipient are then formed as
the solution is sprayed into a low humidity chamber at elevated temperatures. As a spraydried droplet undergoes the particle formation process, moisture conditions change rapidly
while the particle temperature converges to the dryer's outlet temperature (324).
To maintain the solubility advantage of the amorphous phase, the drug must remain
fully amorphous during all stages of manufacturing (e.g., spray drying) and during storage.
However, the physical stability and other physicochemical properties of a spray dried
amorphous drug product are affected by residual water or other residual solvents after
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drying. Water and other small molecular liquids are strong plasticizers and increase the
molecular mobility of the system. This is observed as a reduction in the glass transition
temperature (Tg) with increasing solvent content (325). The increased molecular mobility
at lower Tgs is related to amorphous instability and crystallization (5).
Elevated solvent contents are typically a result of absorption or residual solvent
remaining after the spray drying process. In spray dried dispersions (SSDs) or amorphous
solid dispersions (ASDs), significant water absorption by exposure to elevated relative
humidity can cause phase separation and/ or crystallization (67). During spray drying, the
solvent content and the Tg of the drying droplet continually change during the particle
formation process. It is nearly impossible to remove all solvent during the primary drying
stage and the rate is in part determined by the diffusivity of each spray drying solvent out
of the drying droplet (326). Acceptable final solvent contents are determined by desired
product properties and solvent-specific ICH Q3C guidelines (327). Insufficient evaporation
during primary drying can result in the presence of residual solvents in a SSD with similar
effects on stability to those seen from absorption. In fact, as little as 1% residual water was
shown to create drug rich regions in itraconazole-HPMC SSDs (328). Residual solvents
can further spur crystallization or chemical degradation reactions including hydrolysis
(323). Other moisture-induced changes may include opacification and hydrate or solvate
formation (323, 329).
The rise in the number of poorly soluble drug candidates and the resulting research
interest in amorphous formulations has led to many amorphous products produced via
spray drying. Therefore, the spray drying process and the resulting products must be
adequately characterized to ensure consistent product performance and solid-state stability.
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From a process development standpoint, understanding material properties during the
drying process (i.e., relevant solvent content, Tg, diffusivity, etc.) would be useful in
developing a model of the process or a design space. Similarly, a better understanding of
the kinetics of solvent uptake in ASDs and their effects on physicochemical properties
would be useful for designing systems more resistant to moisture-induced instabilities.
Polymers typically make up the largest fraction of an ASD and are more hygroscopic than
the API component (67). Therefore, by first studying the effects of mixed solvents on only
a polymer (in the absence of drug), it provides a simplified system where the component
most affected by exposure to moisture can be investigated without any complicating effects
of a drug.
In this chapter, the moisture uptake, drying, and diffusivity behavior in the presence
of two processing solvents is shown for two polymers commonly used in ASDs
manufactured by spray drying. HF-grade hydroxypropylmethylcellulose acetate succinate
(HPMCAS−HF) and polyvinylpyrrolidone-co-vinyl acetate (PVPVA) (Figure A.1) are
equilibrated with water and acetone vapors to simulate the spray drying process and a
simplified SSD. Solvent absorption and desorption were analyzed using dynamic vapor
sorption isotherms and diffusivity analysis. Thermal analysis was performed to investigate
the plasticizing effects of co-sorption solvent systems of water and acetone using
differential scanning calorimetry. Various analytical techniques were used during initial
attempts to quantify the relative amount of each sorbed solvent. We report that both
PVPVA and HPMCAS are significantly plasticized by water and acetone although the
magnitude of Tg reduction is dependent on the total solvent uptake rather than the identity
of the solvent. The diffusivity and plasticizing ability of a solvent depends on the polymer
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and its density. Initial diffusivity out of HPMCAS during desorption is independent of the
difference in solvent activity (thermodynamic driving force) but the relative diffusivity of
acetone compared to water increases with solvent activity in PVPVA. Attempts to quantify
the relative proportions of water and acetone absorbed into each polymer using Karl
Fischer titration, solution-state nuclear magnetic resonance (NMR) spectroscopy, or solidstate NMR were unsuccessful.

Figure A.1. Chemical structures of polyvinylpyrrolidone-co-vinyl acetate (PVPVA) and
hydroxypropylmethylcellulose acetate succinate (HPMCAS).

A.2 Materials and Methods
HPMCAS-HF (lot 9023040) was purchased from Shin-Etsu (Tokyo, Japan) and
PVPVA (lot MKCL5134) was purchased from Sigma (St. Louis, MO). Each polymer was
dried at least 18 hours at 25°C under vacuum and stored in desiccators over Drierite (0%
RH) prior to use. HPLC-grade acetone was purchased from VWR International (Radnor,
PA) and Milli-Q water was obtained in house via a Millipore Milli-Pak 40 Q-Pod
(Burlington, MA).
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A.2.1 Dynamic Vapor Sorption
All isotherms were generated on a dynamic vapor sorption (DVS) Resolution
(Surface Measurement Systems, Allentown, PA). Unless otherwise noted, all samples were
packed into a T-zero aluminum differential scanning calorimetry (DSC) pan using 20 – 25
mg of polymer such that the surface was approximately planar. Extreme care was taken
such that no polymer was present on the lip, side, or bottom of the pan. The sample and
pan were then placed on a sample holder and suspended from a hang-down wire in the
sample compartment at 25°C. Total dry nitrogen gas flow rates of 200 sccm were used for
all experiments (200 sccm through the water or acetone compartments for single solvent
measurements, and a combination totaling 200 sccm through the water and acetone
compartments for dual solvent measurements). Unless otherwise noted, the first stage of
all DVS experiments began with a 5 hour drying period at 0% RH.
A.2.1.1 Isotherm Generation
Samples were exposed to step changes in relative humidity or partial pressure from
0 – 90% and back to 0% in 10% increments. The sample was exposed to a given solvent
activity until its change in mass with respect to time (DMDT) was less than 0.002%/min
for 10 minutes at which point the sample was assumed to be in equilibrium.
A.2.1.2 Diffusivity
Diffusion coefficients were measured using the same DVS Resolution system as
mentioned previously. Polymer samples were packed into T-Zero DSC pans at a known
thickness. The flat surface of the polymer was approximated as a thin film for one-sided
diffusion. Some samples were prepared by melt casting to minimize the void fraction
present in the polymer. Packed DSC pans were melted on a hot plate (approximately 5
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minutes at 180°C) then transferred to the DVS. The melt cast film was dried at 25°C and
0% RH for 2 hours and the initial mass and film thickness were then recorded.
The packed or melt cast films were then exposed to various relative humidities or
partial pressures for diffusivity measurements. Each sample was stepped from 0% RH to
10% RH to 0% RH to 20% RH and so on up to 50% RH before returning to 0% RH. The
same sample was used for all diffusivity measurements unless hysteresis was observed at
0% RH. The rate of uptake was measured in each step and fitted to the following equation
(A.1) where Mt is the amount adsorbed at time, t; M∞ is the amount adsorbed at
thermodynamic equilibrium; l is the film thickness; and D is the diffusion constant.
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The equation is applied over the range Mt/M∞ < 0.4 and D is calculated as the initial
diffusivity for each RH step change.
A.2.2 Differential Scanning Calorimetry
Uptake at a given relative humidity, partial pressure, or combination of two solvents
was accomplished by exposing dry samples to the desired % RH or % P/Po via a single
step and allowed to equilibrate for 18 hours. Equilibrated samples were then removed from
the DVS Resolution and immediately sealed using a Tzero hermetic lid then transferred to
a Q2000 DSC (TA Instruments, New Castle, DE) for scanning to determine the Tg.
Standard (non-modulated) DSC with no pinhole was used to better capture the sample’s
environment from the DVS. Samples were equilibrated at 20°C before heating at 10°C/min
to 150°C. Samples were held at 150°C for 5 minutes before cooling at 1°C/min to 0°C. The
samples remained at 0°C for 5 minutes before reheating at 10°C/min back to 150°C. The
cooling scan was performed at a sufficiently slow rate to allow all desorbed solvent to
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reabsorb into the polymer and effectively erase its thermal history. The final heating scan
is performed quickly enough to capture the Tg of the plasticized system such that the
heating rate is greater than the rate of desorption. Reported Tg values were determined from
the midpoint of the glass transition step-change in the resulting heat flow curves.
Theoretical Tg values were calculated via the Gordon-Taylor and Fox equations, as
shown by Equation A.2 and A.3, respectively.
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Tg,1 and Tg,2 are the glass transition temperature of polymer and sorbate,
respectively. X1 and X2 are the weight fractions of polymer and sorbate, respectively, and
K is the fitting constant.
A.2.3 Sorbate Quantitation
The total amount of sorbate in each equilibrated polymer sample was determined
as the change in mass from DVS measurements in single solvent experiments. However,
the relative amounts of each sorbate present were not easily measured so various analytical
techniques were used in an attempt to quantify absorbed water and acetone in dual sorption
experiments.
A.2.3.1 Solid-state Nuclear Magnetic Resonance Spectroscopy
1

H and

13

C solid-state nuclear magnetic resonance (SSNMR) spectroscopy with

magic angle spinning (MAS) was acquired on a Bruker NEO Spectrometer (Bruker,
Billerica, MA) operating at a 1H resonant frequency of 399.49 MHz and 13C frequency of
100.46 MHz. Approximately 50mg of powdered polymer samples (equilibrated using DVS
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procedure described above) were quickly packed into 4mm zirconia rotors and sealed with
teflon end caps. A Revolution NMR HX probe (Revolution NMR, Fort Collins, CO) spun
the sample at the magic angle at speeds of 10 – 13 kHz while at 18.5°C.

13

C spectra were

acquired with a 1.5 ms contact time for cross polarization (CP), approximately 50 ms
acquisition time, and sample-dependent pulse delay. 1H/13C 1D and 2D SSNMR spectra
were acquired using a 2.5 µs 1H-90° pulse and 100 kHz 1H decoupling with SPINAL64. A
dried polymer sample was used as a standard. Samples equilibrated in the presence of only
water or acetone were also used as a reference to identify the location of sorbate peaks.
Ideally, the relative amounts of water and acetone present in dual-solvent samples can be
determined by integration of the respective water and acetone peaks in the 1H-SSNMR
spectra.
A.2.3.2 Solution-state Nuclear Magnetic Resonance Spectroscopy
1
1

H NMR were performed on a Bruker DRX500-2 spectrometer with a 499.87 MHz

H resonance frequency. 64 scans with a 1 s pulse delay, each containing 16384 acquisition

points, were collected for each sample. Dried or equilibrated polymer samples were
dissolved in d4-methanol to form 10 mg/mL solutions. Additional dried polymer solutions
were spiked with varying amounts of water or acetone for comparison with the equilibrated
samples.
A.2.3.3 Karl Fischer Titration
Equilibrated samples were analyzed for water content using Karl Fischer titration
(KFT). A C20S coulometric KF titrator (Mettler Toledo, Columbus, OH) was used to
dissolve 2 – 10 mg of polymer in Karl Fischer reagent. Residual water content was
determined from the KFT analysis of samples dried under vacuum and then in the DVS at
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0% RH for 5 hours. The acetone content in equilibrated samples was calculated as the
difference between the total uptake in the DVS and the water content measured by KFT
after correcting for residual water.

A.3 Results
A.3.1 Isotherm Analysis
Water and acetone sorption and desorption isotherms were obtained for dried
polymer systems. The single component isotherms are shown in Figure A.2. Sorption and
desorption isotherms for both polymers were acquired for up to 90% RH or P/Po prior to
Tg analysis in the DSC.

Figure A.2. Full cycle isotherms for dried PVPVA or HPMCAS-HF exposed to water or
acetone at 25°C. (A) PVPVA-water, (B) PVPVA-acetone, (C) HPMCAS-water, and (D)
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HPMCAS-acetone. Blue = uptake; red = desorption. The insert in (C) shows the negative
hysteresis at low % RH.
The isotherm shapes for water uptake are similar between PVPVA and HPMCAS
although PVPVA absorbs approximately four-times as much water as HPMCAS at 90%
RH. Each appears to contain a small amount of type II isotherm at low partial pressures
then follows a reversible type III isotherm and are similar to PVPVA and HPMCAS
reported in the literature at 25°C (330). Desorption also follows similar trends in each
polymer as positive hysteresis is observed. The difference arises below 30% RH where
HPMCAS loses residual water which was tightly bound prior to absorption. Acetone
sorption in PVPVA and HPMCAS is approximately linear up to 30% and 70% P/Po,
respectively, at which point rapid solvent uptake is observed. In this case, total acetone
uptake at 90% P/Po is approximately equal between the polymers. No hysteresis is initially
observed for acetone systems upon desorption. However, below 70% and 80%
respectively, PVPVA and HPMCAS exhibit positive hysteresis which remains even at dry
conditions. PVPVA contains ca. 8% acetone after drying while HPMCAS contains ca. 4%
acetone.
A.3.2 Plasticization
The glass transition temperature is a critical parameter which can indicate the
stability of amorphous systems and is very sensitive to absorbed species. Therefore, the Tg
of HPMCAS and PVPVA equilibrated in the presence of water, acetone, or both was
measured to determine how the presence of moisture affects Tg. Figure A.3 plots the
changes in adsorbent uptake and glass transition temperature as a function of partial
pressure in pure solvent systems.
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Figure A.3. Change in mass and glass transition temperature as a function of solvent
activity. (A) PVPVA-water, (B) PVPVA-acetone, (C) HPMCAS-water, and (D)
HPMCAS-acetone. Note the difference in the scale of the dm axis for (C).
Exposure to increasing activities of solvent causes an increase in sorbate uptake
equal to that seen in Figure A.2. Similarly, the increasing solvent content causes an
approximately linear decrease Tg in all systems studied. Water and acetone both have an
extremely low Tg (-136°C and ca. -176°C, respectively) and are much smaller molecules
relative to polymers (331). Therefore, both solvents act as plasticizers, with increasing
amounts absorbed into the polymer causing an approximately linear decrease in Tg and
increasing the molecular mobility of the polymer.
The change in mass due to solvent uptake and the corresponding change in Tg varies
between each polymer-solvent system. For example, when held constant at 40% RH or
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P/Po, 7.2% water reduces the Tg of PVPVA from 105°C to 59°C while 2% water reduces
the Tg of HPMCAS from 117°C to 100°C. Similarly, approximately 10% acetone uptake
decreases the Tg of both polymers by 60°. Similar results were observed in the literature
for spray dried HPMCAS systems (125).
Figure A.4 shows the Tg as a function of water content predicted by the GordonTaylor and Fox equations.

Figure A.4. Observed and predicted glass transition temperature as a function of solvent
content for (A) PVPVA-water, (B) PVPVA-acetone, (C) HPMCAS-water, and (D)
HPMCAS-acetone. Observed (black circles), the Gordon-Taylor equation (solid line), and
the Fox equation (dashed line).
Figure A.4 shows that the ad-/absorbed solvent plasticizes the polymer and reduces
the glass transition temperature. As mentioned in Figure A.3, the degree to which Tg is
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reduced varies between different polymer-solvent systems. Figure A.4 also shows the
predicted Tg when calculated with either the Gordon-Taylor or Fox equation. Most systems
are relatively well predicted by the Fox equation although less so for HPMCAS (Figure
A.4C and A.4D). Interestingly, the Gordon-Taylor equation underestimates the Tg in all
systems except for HPMCAS-water which is the only system which is overestimated by
the Fox equation.
Differences between the observed and predicted Tg values can potentially indicate
some degree of interactions between the polymer and solvent. The Gordon-Taylor equation
is based on volume additivity and assumes that the mixture components are non-interacting
(76). A positive deviation from predicted values can indicate the presence of polymersolvent interactions which are energetically more favorable than the sum of any polymerpolymer or solvent-solvent interactions that may exist. Both PVPVA and HPMCAS form
hydrogen bonds with absorbed water molecules but only PVPVA has measured Tg values
greater than Gordon-Taylor predictions (332, 333). The Tg of HPMCAS was difficult to
measure due to its extensive sidechain substitution. In theory, each sidechain inherently
has varying levels of molecular mobility due to the different functional groups present
which are then further affected to varying degrees by the presence of moisture. Therefore,
individual sidechain mobility will contribute in varying amounts to the structural changes
near Tg. Nonetheless, the Tg of HPMCAS equilibrated at elevated relative humidities is
well predicted by the Gordon-Taylor equation. Acetone and PVPVA each lack hydrogen
bond donor groups and are well predicted by the Fox equation but still show positive
deviations from the Gordon-Taylor equation. Conversely, Tg is underestimated by the
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Gordon-Taylor equation for HPMCAS-acetone systems possibly due to the interaction of
acetone with the hydroxyl and/ or carboxylic acid side chains of HPMCAS.
The relative plasticizing effects of water and acetone were also compared based on
Figure A.4. The slope of Tg versus solvent content indicates the magnitude to which a given
amount of solvent plasticizes the polymer. Acetone reduces the glass transition temperature
of both PVPVA and HPMCAS by approximately 6.5°C (6.8% and 6.3%, respectively) for
every one percent of solvent absorbed. Water varies in the extent to which the polymer is
plasticized. In good agreement with values reported in the literature, the Tg of PVPVA is
reduced by 6.8°C for every one percent water uptake (332). An equivalent water uptake of
1% plasticizes HPMCAS to a greater extent as Tg is reduced by 7.5°C.
To this point, only single-solvent systems have been considered. However, mixed
solvent systems are often used during spray drying to solubilize all solid components.
Therefore, the combined plasticizing effect of water and acetone was also investigated to
better represent a real spray drying solution. Figure A.5 shows the reduction in Tg when
PVPVA and HPMCAS are exposed to mixed solvent systems with constant partial
pressures of acetone.
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Figure A.5. Glass transition temperature as a function of relative humidity with a constant
background partial pressure of acetone for (A) PVPVA and (B) HPMCAS-HF.
(Background acetone partial pressure: black = 0%, red = 10%, blue = 20%, gray = 30%,
purple = 40%.)
The black line (0% P/Po acetone) shows the same reduction in Tg with relative
humidity as that shown in Figure A.3A and A.3B. The greater water absorption at an
equivalent relative humidity in PVPVA compared to HPMCAS is also evident in Figure
A.5 based the slopes of the lines. This difference has implications relating to spray dried
product stability. Exposure of a PVPVA-containing product to a particular relative
humidity is more susceptible to moisture uptake relative to a HPMCAS-containing product
at the same humidity. The introduction of a background partial pressure of acetone causes
a roughly linear reduction in Tg for a constant relative humidity. For example, for every
10% P/Po, the Tg of PVPVA or HPMCAS is reduced by approximately 10°C or 14°C,
respectively.
The effect of total solvent content on the glass transition temperature is shown in
Figure A.6.
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Figure A.6. Glass transition temperature as a function of total solvent uptake for single
and mixed solvent systems. (A) PVPVA. (B) HPMCAS-HF. (Acetone partial pressure:
black = 0%, red = 10%, blue = 20%, gray = 30%, purple = 40%.)
The glass transition temperature of both PVPVA (Figure A.6A) and HPMCAS
(Figure A.6B) decreases linearly with the total solvent content regardless of the solvent
combination used to equilibrate the polymer. Presumably, the linear change in Tg is
independent of the relative amounts of each solvent present (see section A.4.4). The
difference in overlap in partial pressure data is also observed in Figure A.6. PVPVA shows
significant overlap between samples equilibrated with varying background partial
pressures of acetone while HPMCAS shows a continual reduction in Tg with increasing
acetone background. The difference is due to the relative uptake of each solvent. PVPVA
absorbed comparable amounts of water and acetone at all solvent activities while
HPMCAS absorbed significantly more water relative to acetone. Any water uptake in
HPMCAS, even at 40% RH, was overcome by acetone absorption, even at as little as 10%
P/Po. This is further illustrated by the difference in the slopes of Figure A.5A and A.5B.
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A.3.3 Sorbate Quantitation
The DVS used in this study provided the total mass change during sorption but did
not quantify the relative amounts of sorbate present in dual sorption experiments. Various
analytical methods were used in an attempt to quantify each sorbate present in an
equilibrated sample however none were successful. The results are included here for
informational purposes only.
First, Karl Fischer titration (KFT) was used to measure the water content. In theory,
the difference between the total uptake (measured using DVS) and water content (from
KFT) should yield the mass of acetone in the sample. The entire equilibrated sample was
placed in the electrolysis cell. Dry samples were first analyzed by KFT to determine the
initial residual water content. The average PVPVA residual water content (0.181%) was
used to correct for residual water in other equilibrated samples.
Preliminary samples equilibrated only in the presence of water (up to 90% RH)
were used to compare measured water content using the DVS or KFT. Samples equilibrated
at low relative humidity showed equivalent water contents when analyzed by either DVS
or KFT. However, PVPVA samples equilibrated above 60% or 70% RH changed from a
loose dry powder into a sticky gel due to absorbing enough water to plasticize the system
into the supercooled liquid state. The sample did not fully dissolve into the Karl Fischer
solution. Water content measured with KFT plateaued above 60% RH and became
significantly less than values measured with DVS.
Nonetheless, PVPVA test samples equilibrated in the presence of water and acetone
at 10% RH and 10% P/Po or 30%/30% were first analyzed. The relative amounts of water
and acetone absorbed in each sample are shown in Table A.1.
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Table A.1. Relative uptake of water and acetone in PVPVA dual solvent experiments as
measured by Karl Fischer titration.
Total Mass Uptake
(%)

Water (%)

Acetone (%)

10% RH, 10% P/Po

3.028

77.05

22.95

30% RH, 30% P/Po

11.037

22.41

77.59

The relative uptake of water and acetone varies as a function of total solvent activity
in equilibrated PVPVA samples. At low solvent activities (10%/10%), nearly three-times
as much water is absorbed compared to acetone. This is not surprising considering that 2.5times as much water absorbed at 10% RH compared to 10% P/Po acetone in single solvent
experiments. It is interesting to note that a greater total solvent uptake is observed in the
dual solvent experiment compared to adding together the single component data. One may
hypothesize that the presence of acetone causes extra swelling of the polymer to allow
additional water uptake. Indeed, this was seen previously during water and acetone
absorption into polyvinyl alcohol (334).
At higher total solvent activities (30%/30%), acetone appears to absorb to a greater
extent than water. This would indicate that acetone out-competes water at higher solvent
activities. However, this is unlikely as the relative affinity of either sorbate should not
significantly change with uptake. A more likely explanation is the incomplete dissolution
of the equilibrated PVPVA in the Karl Fischer solution. The 30%/30% PVPVA sample
changed into a viscous gel similar to the water-equilibrated samples above 60% RH.
Presumably, a significant amount of water (and acetone) remained in the undissolved
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PVPVA which was unaccounted for by the KFT calculation and led to the underestimation
of water/ overestimation of acetone. As many samples exhibited a similar change in
morphology at high solvent activities, Karl Fischer titration was not seen as a viable
quantitative technique at least within the scope of this experiment.
Solution-state nuclear magnetic resonance (NMR) spectroscopy was explored as an
alternative quantitative analytical technique. Deuterated methanol (CD3OD) was found to
adequately solubilize both PVPVA and HPMCAS. Dried polymer samples spiked with the
equivalent of 1% solvent uptake were analyzed using 1H NMR (Figure A.7).

Figure A.7. Initial 1H NMR spectra for quantitative analysis. All samples were dissolved
at 10-15 mg/ml in methanol-d4. (A) Dried HPMCAS-HF, (B) PVPVA with 10% acetone,
(C) PVPVA with 10% water, and (D) dried PVPVA. (Percentage refers to uptake in the
polymer prior to dissolving in the NMR solvent.
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The water peak (4.9 ppm) was well resolved although significant amounts of
residual water were also present and must be corrected for. The acetone peak (2.15 ppm)
did overlap slightly with peaks in both polymer spectra which makes deconvolution and
accurate quantitation more difficult. At the time of writing, NMR is still being explored as
a quantitative analytical technique. For the purposes of this experiment, the biggest
challenge facing its implementation is finding a suitable NMR solvent (solubilizes all
components and has a well-resolved residual solvent peak). Furthermore, the solvent
selected will be system dependent as the polymer (and drug, for SSDs) and each solvent
will all have different chemical shifts.
Lastly, solid-state NMR (SSNMR) was used for quantifying water and acetone as
well as to provide additional molecular-level information into the state of the sorbate in the
polymer. One-dimensional and two-dimensional 1H and 13C spectra were acquired for each
polymer before and after exposure to solvents. Figures A.8 and A.9 show 1H and

13

C

SSNMR spectra for PVPVA, respectively. 1H and 13C spectra are shown for HPMCAS in
Figures A.10 and A.11, respectively.
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Figure A.8. 1H SSNMR spectra of PVPVA after drying or exposure to mixed solvents.

Figure A.9. 13C SSNMR spectra of PVPVA after drying or exposure to mixed solvents.
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Figure A.10. 1H SSNMR spectra of HPMCAS-HF after drying or exposure to mixed
solvents.
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Figure A.11.

13

C SSNMR spectra of HPMCAS-HF after drying or exposure to mixed

solvents.
1

H SSNMR peaks in both dried polymers are very broad due to 1H-1H homonuclear

dipolar coupling. Peak shape changed with solvent absorption. PVPVA exposed to 10%
RH and 75% P/Po acetone developed two peaks. The smaller peak at 4 ppm is attributed to
water while the larger peak at 2.5 ppm is attributed to greater acetone uptake. The
underlying PVPVA peak is still very broad and difficult to deconvolute. Similar results are
found for HPMCAS however the water peak at 4 ppm does not appear indicating either
that water is highly mobile or that very little was absorbed into the polymer. In addition,
there are many hydroxyl groups in HPMCAS sidechains which would have similar
chemical shifts to water.

13

C SSNMR showed a sharp peak at 32 ppm in HPMCAS
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attributed to acetone. A similar peak was also found in PVPVA although a resonance also
appears at the same chemical shift in the dry polymer. Water was not detected using 13C
SSNMR.
To improve the resolution of the 1H spectra, DUMBO (decoupling using mindboggling optimization) was applied to reduce 1H-1H coupling and achieve more solutionlike spectra. Figures A.12, A.13 and A.14 show the 2D spectra of various equilibrated
polymers using DUMBO. The abscissa shows the original 1H spectra while the ordinate
shows the results of enhanced decoupling.
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Figure A.12. 1H-1H homonuclear 2D spectrum of PVPVA equilibrated at 10% RH and
75% P/Po acetone acquired using DUMBO.
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Figure A.13. 1H-1H homonuclear 2D spectrum of HPMCAS-HF equilibrated at 20% RH
and 20% P/Po acetone acquired using DUMBO.
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Figure A.14. 1H-1H homonuclear 2D spectrum of HPMCAS-HF equilibrated at 10% RH
and 75% P/Po acetone acquired using DUMBO.
The resolution of the 1H DUMBO spectra is improved but the 1H peaks are still too
broad for quantitative purposes. At this point, further experiments are needed to identify
the peaks present, including the creation of a calibration curve at a series of relative
humidities and partial pressures. Faster MAS speeds would also help to reduce linewidths
and improve resolution.
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A.3.4 Diffusivity
The initial rate at which solvents moved into or out of the polymers were measured
as diffusion coefficients or diffusivity. Respectively, Figures A.15 and A.16 plot the
diffusivity of water vapor into and out of PVPVA or HPMCAS at varying relative
humidities. Samples of varying density or morphology (packed versus melt cast) were
analyzed to represent changes in particle density that occur throughout the spray drying
process or variations in the particle morphology of the final product (326). All absorption
diffusion experiments started at 0% RH or P/Po and all desorption diffusion experiments
ended at 0%. For absorption experiments, the x-axis represents the size of the step change
or the final activity that the sample was equilibrated. For desorption experiments, the xaxis represents the activity the sample was initially equilibrated at prior to a step change to
0% RH or P/Po.

Figure A.15. Initial diffusivity during absorption of water into a polymer at varying
activities and different morphologies.
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Figure A.16. Desorption diffusivity of water out of PVPVA or HPMCAS with varying
particle morphologies.
Diffusivity of water into HPMCAS occurs at twice the rate of water into PVPVA
and is constant across the relative humidity range observed. Melt quenched samples contain
less void space and are denser than the packed samples. The diffusivity of water in both
polymers decreases by nearly two orders of magnitude in the in melt-quenched samples
relative to the packed samples. The difference in diffusivity between PVPVA and
HPMCAS decreases as relative humidity increases. The initial diffusivity of water uptake
at 50% RH in each polymer is approximately the same.
Water diffusivity during desorption out of the polymer shows similar results to
absorption. Diffusion out of HPMCAS is greater than PVPVA diffusivity for packed and
melt-quenched samples. Again, this difference is approximately constant in packed
samples but decreases at high relative humidity in melt-quenched samples.
Under normal circumstances, samples will only be dissolved in acetone and no
acetone vapor will be absorbed in a spray dried product. Therefore, the diffusivity of
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acetone during desorption was also investigated to better understand the difference between
water and organic solvent removal during spray drying. Figure A.17 shows the desorption
diffusivity of water or acetone in either polymer as well as the acetone/ water relative
diffusivity.

Figure A.17. Desorption diffusivity of solvent in polymer at varying activities. The relative
diffusivity of acetone compared to water in each polymer is also shown.
The diffusivity of acetone is greater than the diffusivity of water out of PVPVA
while the two solvents diffuse out of HPMCAS at approximately the same rate. The water
desorption diffusivity shown in Figure A.17 is the same as in Figure A.16. Water and
acetone diffusion out of HPMCAS appears to be independent of the change in activity (i.e.,
desorption driving force). On the other hand, acetone diffusion out of PVPVA increases
with increasing driving force while water diffusion remains approximately constant.
Therefore, the relative rate of diffusivity (Dacetone/Dwater) decreases with decreasing solvent
activity. Practically, this means that, while acetone is removed from PVPVA at a greater
rate during the entire drying process, its rate of removal will slow as the particle dries. The
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majority of acetone is removed rapidly, creating a drying particle with increased water
content relative to the initial feed solution concentration.

A.4 Discussion
Water or various organic solvents may be found in a drug substance or drug product
as a result of processing/ manufacturing or exposure to environmental humidity. In each
case, the presence of solvent may have unintended consequences relating to the stability of
a pharmaceutical formulation. Dynamic vapor sorption is an important analytical technique
as it can investigate how materials both respond to exposure to elevated levels of water or
organic solvents as well as how solvents are removed during drying. The latter of which
allows DVS to be used as an approximation of solvent removal during spray drying.
A.4.1 Water and Acetone Uptake
Water uptake is of particular interest since nearly all pharmaceutical systems are
exposed to environmental humidity. The greatest benefit to acetone absorption is the
creation of systems with acetone contents representing various timepoints in the spray
drying process. Type III isotherms indicate that water is adsorbed in a multilayer fashion.
However, the small amount of type II isotherm at low partial pressures may suggest that
water forms or begins to form an incomplete monolayer in each polymer prior to multiple
adsorbate layers forming (335). The increase from linear acetone uptake above a polymerspecific solvent activity may indicate a shift to multilayer absorption at higher partial
pressures. Since water and acetone are two commonly used spray drying solvents, their
dual solvent absorption experiments allow the creation of systems with mixed solvent
contents and material properties similar to various time points during spray drying.
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A.4.2 Drying and Desorption
PVPVA and HPMCAS retain a greater moisture content after drying than their
initial moisture content prior to ad-/ absorption and may be problematic from a product
drying/ residual solvent standpoint (see section A.4.3.2). A positive hysteresis loop
(Figures A.2A, A.2B, and A.2D) indicates that pores exist in the polymer adsorbents and
absorption into the interior of the dried polymer is likely regardless of the adsorbent and
adsorbate present. Incomplete drying or exposure to elevated humidity during either
production or storage may result in elevated solvent content despite a return to the previous
equilibrium conditions. Negative hysteresis at low relative humidity (e.g., water desorption
from HPMCAS) can indicate that a phase change has occurred and water which was
initially tightly bound is now free to leave during drying. In either case, hysteresis may
affect product properties, as the solvent content after spray drying may not necessarily
match the solvent content after exposure to elevated humidity conditions. This further
complicates the adequate characterization of amorphous products produced by unit
operations utilizing solvents including spray drying. Therefore, the spray drying process
must be well characterized to control drug product uniformity especially as the presence of
residual solvents must be controlled from both a regulatory and product stability standpoint
(327).
A.4.3 Application to Amorphous Product Stability
The stability of a spray dried product is dependent on a variety of factors including
the kinetics of solvent uptake or desorption, as well as plasticization from increased solvent
content. Therefore, the stability must be considered both during and after drying where the
SSD may be exposed to environmental stresses. For the purposes of this chapter, the

281

discussion focus will be limited to the movement of moisture into/ out of polymeric
systems and their effect on the glass transition temperature.
A.4.3.1 Stability During Spray Drying
Desorption studies are most applicable to approximate the solvent removal process
during spray drying. The rate of solvent removal was found to be dependent on the solventpolymer combination, and, for acetone out of PVPVA, also dependent on the difference
between the initial and final solvent content. In spray dried systems, the rate of solvent
removal has been shown previously to affect the final particle morphology and dissolution
performance (336, 337). In addition to the drying rate, the solubility, feed solution
concentration, and inlet/ outlet temperatures also affect the morphology of the spray dried
product (326). Therefore, a thorough investigation of desorption during dynamic vapor
sorption may be used to gain insights into the spray drying process and how diffusivity and
Tg can affect stability during and after drying.
Most drugs manufactured by spray drying are poorly water soluble. For a
multicomponent system, such as an amorphous solid dispersion, an organic solvent or
mixed solvent system is often needed to fully solubilize the drug and polymer. These
solvents are then rapidly removed during the primary drying to form an intimately mixed
drug-polymer amorphous solid dispersion. However, variable solvent removal rates have
also been shown to affect the product homogeneity in ASDs produced from a single solvent
(338). One could hypothesize then, that the disproportionate removal of the organic solvent
and water observed for PVPVA (Figure A.17), especially early in the drying process, may
cause changes to the physicochemical properties of the final SSD. In the least, spray dried
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systems with relatively slow water diffusivity may result in a product with high residual
water content.
Changes in the mixed solvent composition relative to the feed solution composition
can also affect the miscibility and/ or solubility of the dissolved solids. The solvent(s)
comprising a feed solution should maximize solute-solvent interactions and fully solubilize
solid components. In the case of a polymer, a good solvent would result in polymer
swelling which helps stabilize an amorphous drug in a SSD (339). Therefore, a change in
solvent composition during drying can affect solvent quality which may be detrimental to
final SSD product quality and performance (337, 339). Furthermore, rapid changes to the
solvent composition and solids concentration can potentially cause the system to pass
through phase envelopes leading to phase separation and/ or crystallization (326, 340).
Since the organic solvent is added mainly to solubilize the drug, its removal prior to/ at a
faster rate than water may be particularly problematic concerning moisture-induced phase
separation and crystallization.
The changing solvent content during spray drying also affects the physical
properties of the drying droplet including the glass transition temperature. Therefore, the
Tg may also be used to understand changes occurring within a drying droplet during spray
drying. Typical spray drying solvents, including water and acetone, plasticize the system
and their presence can significantly affect the physical stability of a SSD. Changes in Tg
indicate changes to the relative mobility of the system and can provide information
regarding the likelihood of phase separation or crystallization occurring as the particle
dries.
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From a mobility standpoint, the initial stages of primary drying represent the
greatest chance for crystallization as the solvent content is highest and the drug/ polymer
is significantly plasticized. The polymer is likely in the supercooled liquid state as the Tg
may be reduced below the drying temperature. However, the concentration of the dissolved
solids is also low during the early stages of primary drying and less likely to crystallize.
The concentration of dissolved solids increases and eventually can become supersaturated
with the removal of solvent through additional drying. This increases the likelihood for
crystallization despite an increase in Tg. This is especially concerning given that the relative
rates of solvent removal may vary due to differences in water and acetone diffusivity. For
example, acetone desorption diffuses out of PVPVA faster than water which creates an
excess of water remaining in the droplet at the later stages of drying. Again, since most
drugs being spray dried are poorly water soluble, the increase in relative water content will
further increase the supersaturation in the remaining mixed solvent and may complicate
their formulation as an ASD using spray drying. Therefore, the relative rates of solvent
diffusion out of a drying droplet must be considered during spray drying if they are
significantly different.
It cannot be overlooked that the diffusivity values measured in this study were for
single component systems. While the diffusivities measured in this study agree well with
values reported in the literature, it is possible that the presence of one solvent changes the
diffusivity of the other (326). For example, increasing proportions of acetone in polyvinyl
alcohol decreases the diffusivity of water (334). Again, this underscores the need for a
quantitative method so that the diffusivity of each solvent in the presence of another can
be more accurately measured to account for cosolvent effects.
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A.4.3.2 Residual Solvent & Stability During Storage
Spray drying conditions and the resulting material properties (e.g., particle size,
morphology, and residual solvent content) ultimately affect the downstream processability,
physical stability, and shelf life of the spray dried material (326, 340-342). The amount of
residual solvent should be minimized as they can catalyze both physical and chemical
degradation reactions. Chemically, residual water can often cause hydrolysis in a sample
whereas physically, residual solvents can cause polymorphic transformations, aggregation,
or crystallization, etc. (343). As far as amorphous stability is concerned, solvents with a
large plasticizing ability, especially those which are difficult to remove during primary or
secondary drying, are of the greatest concern to product stability.
In addition to the physical stability implications resulting from residual solvent
content, toxicity resulting from residual solvents must also be considered. Therefore, the
concentration of residual solvent must be controlled to limit unintended side effects to the
patient. The allowable solvent concentration is specific to each individual solvent and is
explicitly outlined by the International Conference of Harmonization’s Q3C guidelines
(327).
While the residual solvent content after spray drying affects physical stability, the
impact of the storage conditions on stability must also be considered. Exposure to elevated
temperature or humidity conditions will affect the water content of the spray dried material.
The temperature, pressure, and solvent activity determine the equilibrium sorbate content
of a polymer-solvent combination, but the diffusivity affects the rate at which the solvent
moves into or out of the polymer to reach equilibrium. Nearly all excipients, drug
substances, and formulated drug products will all uptake some amount of water when
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exposed to environmental relative humidity either through adsorption to the surface and/
or absorption and diffusion into the bulk. The rate of absorption is strongly material
dependent. In the case of polymeric excipients, differences in water absorption diffusivity
may be partially explained by each polymer’s affinity for water. The greater number of
hydrophilic groups in HPMCAS would explain the greater initial diffusivity of water
compared to PVPVA. However, PVPVA is more hygroscopic and forms a greater number
of strong hydrogen bonds between its carbonyl groups and water compared to weaker
hydrogen bond formation in HPMCAS which results in its increased equilibrium water
content (344, 345). When considering the shelf life of a SSD, the use of polymeric
excipients which absorb large amounts of water should be balanced against the polymer’s
ability to stabilize the drug against crystallization in the presence of moisture and other
product properties such as viscosity. For example, the additional stability imparted by the
hygroscopic polymer PVP in ASDs was shown to outweigh the instability of increased
moisture uptake (67, 130). However, this cannot be assumed for all drug-polymer
combinations and should be investigated for each ASD.
The water absorbed into an amorphous solid will plasticize the material (observed
as a reduction in Tg) and may increase the likelihood of crystallization. Polymers which
absorb greater amounts of water or are plasticized to a greater extent by a constant amount
of water may be at greater risk of moisture-induced instability. For a given water content,
HPMCAS is slightly more plasticized by water (7.5°C/%) than PVPVA (6.8°C/%). Despite
the difference, the relative effect of plasticization on stability in these two polymers
exposed to environmental humidity conditions is expected to be minimal, especially as
PVPVA absorbs much more water than HPMCAS across all humidities tested. PVPVA is
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more hygroscopic than HPMCAS although its diffusivity is lower which means that,
despite its greater water uptake, it will absorb environmental water slower over the range
of relative humidity conditions studied. Practically, this means that the greater rate of
absorption in HPMCAS may pose a greater stability risk to HPMCAS-containing SSDs
when exposed for a short period of time. However, exposure of PVPVA-containing SSDs
to elevated humidities for longer amounts of time may be at a greater risk of phase
separation or crystallization. Further studies are required to investigate how the stabilizing
ability of the polymer changes in the presence of moisture to determine the true risk of
moisture-induced instability in ASDs.
A.4.4 Effects Dual Solvent Sorption on the Glass Transition Temperature
The effect of absorbed water on the glass transition temperature has been
extensively studied and well characterized in the literature (126, 325, 346, 347). However,
spray drying often exposes drugs and/ or polymers to multiple solvents, each of which can
plasticize the system, yet the effect of multiple solvents on Tg has not been studied in much
detail. DVS in tandem with DSC allowed for the determination of Tg across a variety of
mixed solvent partial pressures.
Increasing amounts of a single solvent absorbed into each polymer caused a linear
decrease in Tg where the magnitude of the reduction in Tg was dependent on polymersolvent combination (see Figure A.6). Previous studies indicated the extent to which Tg
changes at a constant solvent content may be related to differences in solvent-polymer
interaction (332). Therefore, it is particularly surprising that the Tg values measured after
equilibration in the presence of two solvents all condense to a master curve in each system
regardless of the combination of solvents. In other words, Tg is dependent on the total
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solvent uptake rather than the identity of the solvent for the two polymer-water-acetone
systems studied. This suggests that the solvent molecules are non-interacting or weakly
bound to the polymers such that the change in Tg is dependent on the Tg of the solvent.
However, this does not appear to be the case. The Tg of water and acetone are significantly
different (-136°C versus -176°C, respectively) and they have been shown previously to
have varying extents and strengths of hydrogen bonding with each polymer (331-333).
This finding also has implications relating to developing a model for the spray
drying process. Since the Tg seems to depend on the total solvent content rather than the
relative amounts of each solvent, only the total moisture content is needed to determine the
extent of plasticization at any point in the drying process. This value is easily accessible,
especially towards the later stages of drying. Nonetheless, to truly model the drying droplet,
the relative amounts of each solvent are needed and underscores the need for the
development of an analytical technique to do so. Section A.4.5 discusses the need and
challenges of quantitation in greater detail.
A.4.5 Relative Solvent Quantitation
Quantifying the relative amount of each absorbed solvent proved to be difficult
even when using a variety of analytical techniques including DSC, DVS, KFT, SSNMR
and solution-state NMR. However, it is necessary to be able to quantify each solvent to
develop a model to better predict the changes in solvent content during spray drying. It was
shown in sections A.3.2 and A.4.4 that the change in Tg with solvent content depends on
the total solvent content rather than the relative amounts of water and acetone. This would
make predicting Tg much easier however, this cannot be assumed to be true for all systems
without the further analysis of additional polymer-mixed solvent systems. In addition, the
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results of single isotherm experiments for water and acetone cannot necessarily be assumed
to be additive. For example, even for single solvents, Crowley and Zografi showed that
water absorption was not additive in ASDs based on drug and polymer single component
isotherms (348). The differences were attributed to differences in the amount of available
hydrogen bonding sites between the pure components and water versus the ASD and water.
Similarly, differences in each solvent’s affinity for a polymer are reflected through
differences in their individual isotherms. This explains why total solvent uptake in dual
solvent isotherms does not equal the sum of individual water and acetone uptake
experiments. This is all relevant information which must be considered when developing a
predictive model.
While the analytical techniques discussed in this chapter were unsuccessful in
quantifying the relative amounts of water and acetone, there is a clear need for further
research. Tandem or chromatographic techniques such as thermogravimetric analysis-mass
spectrometry (TGA-MS) or headspace gas chromatography (HSGC), respectively, are
likely next steps to attempt quantification. Indeed, HSGC has recently been used to
quantify up to six volatile organic compounds in an API (321). A similar approach may
also be useful for polymers or ASDs with the ultimate goal of combining known solvent
contents, glass transition temperatures, and diffusivity values to characterize the spray
drying process.

A.5 Conclusion
Appendix A investigated the absorption and desorption of water and acetone in
PVPVA and HPMCAS and their effects on the glass transition temperature and diffusivity.
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Sorption experiments were performed using dynamic vapor sorption while the extent of
plasticization caused by the presence of solvents was determined using differential
scanning calorimetry. PVPVA and HPMCAS, both commonly used during spray drying,
behaved very differently when exposed to water and/ or acetone. Water absorption was
used to approximate the effects environmental humidity during storage. Similarly,
exposure of polymers to varying combinations of partial pressures of water and acetone
was used to approximate the spray drying process where a drying particle has varying
solvent contents at different points in the drying process.
Despite their different glass transition temperature’s, a given amount of water and
acetone plasticize each polymer to a similar extent. In addition, the reduction in Tg was
dependent on the total amount of absorbed solvent content rather than the identity of the
solvent. This is particularly surprising based on the differences in solvent Tg, molecular
size, and hydrogen bonding ability. This implies that the sorbed solvent is loosely bound
with the polymer and was confirmed using solid-state NMR. Although the solution- and
solid-state NMR techniques used in Appendix A were unsuccessful in quantifying the
relative amounts of solvent in a polymer, it was shown that the total solvent uptake may be
useful in predicting plasticization (i.e., Tg) in the equilibrated polymer.
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